<SEC-DOCUMENT>0001193805-24-000551.txt : 20240423
<SEC-HEADER>0001193805-24-000551.hdr.sgml : 20240423
<ACCEPTANCE-DATETIME>20240423164840
ACCESSION NUMBER:		0001193805-24-000551
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20240611
FILED AS OF DATE:		20240423
DATE AS OF CHANGE:		20240423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		24865460

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>e663535_def14a-immunic.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-indent: 0.25in; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: black 1pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><I><BR> UNITED STATES SECURITIES AND EXCHANGE COMMISSION<BR> Washington, D.C. 20549</I></FONT></P>
                                                                            <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>SCHEDULE 14A</B></FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE<BR> SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )</B></FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant &#9746;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant &#9744;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Preliminary Proxy Statement</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9746;<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Definitive Proxy Statement</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Definitive Additional Materials&#9;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
    Soliciting Material Pursuant to &sect;240.14a-12</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 18pt"><B>IMMUNIC, INC</B>.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">(Name of Registrant as Specified In Its Charter)</FONT></P>
                                                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
                                                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Payment of Filing Fee (Check the appropriate box):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;
</FONT>No fee required.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt">Title of each class of securities to which transaction applies:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Aggregate number of securities to which transaction applies:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11<BR>
(set forth the amount on which the filing fee is calculated and state how it was determined):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Proposed maximum aggregate value of transaction:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Total fee paid:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#9744; &#8239;&#8239;Fee paid
previously with preliminary materials.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in">&#9744; &#8239;&#8239;Check box if any part of
    the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
    previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amount Previously Paid:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form, Schedule or Registration Statement No.:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Filing Party:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Date Filed:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 102px; width: 331px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1200 Avenue of the Americas, Suite 200<BR>
New York, New York 10036<BR>
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To our Stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are pleased to invite you to attend the annual meeting of stockholders
of Immunic, Inc. (&ldquo;Immunic&rdquo; or the &ldquo;Company&rdquo;), to be held on June 11, 2024 at 9:00 a.m. Eastern time, virtually
via the Internet at https://web.lumiconnect.com/276702602. The annual stockholders meeting will be a completely virtual meeting and will
be conducted exclusively by webcast on the Internet. No physical meeting will be held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details regarding how to attend the annual meeting and the business
to be conducted at the annual meeting are more fully described in the accompanying notice of annual meeting of stockholders and proxy
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your vote is important. Regardless of whether you plan to attend the
annual meeting, it is important that your shares be represented and voted at the annual meeting, and we hope you will vote as soon as
possible. You may vote by proxy over the Internet or by telephone by following the instructions on the proxy card or voting instruction
card. Voting over the Internet or by telephone, written proxy or voting instruction card will ensure your representation at the annual
meeting regardless of whether you attend the annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you for your ongoing support of, and continued interest in, Immunic,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><I>/s/ Dr. Daniel Vitt</I></FONT></TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><I>/s/ Dr. Duane Nash</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Dr. Daniel Vitt<BR>
Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Dr. Duane Nash<BR>
Executive Chairman of the Board of Directors</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York<BR>
April 23, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">ii</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 12pt">1</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND ANNUAL MEETING</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">2</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">9</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">PROPOSAL NUMBER 1 ELECTION OF CLASS I DIRECTORS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">20</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">PROPOSAL NUMBER 2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">21</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">PROPOSAL NUMBER 3 TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING THE COMPANY&rsquo;S NAMED EXECUTIVE OFFICER COMPENSATION</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">23</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">REPORT OF THE AUDIT COMMITTEE</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">25</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">EXECUTIVE OFFICERS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">26</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">EXECUTIVE COMPENSATION</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">28</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">RELATED PERSON TRANSACTIONS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">40</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">SECURITY OWNERSHIP</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">41</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">OTHER MATTERS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">44</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">PROPOSALS OF STOCKHOLDERS FOR 2025 ANNUAL MEETING</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">45</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">THE BOARD OF DIRECTORS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">46</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">iii</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IMMUNIC, INC.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1200 Avenue of the Americas, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">NOTICE OF ANNUAL MEETING
OF STOCKHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="2" CELLPADDING="2" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%"><FONT STYLE="font-size: 10pt"><B>Time and Date</B></FONT></TD>
    <TD STYLE="width: 84%"><FONT STYLE="font-size: 10pt">9:00 a.m. Eastern time, on June 11, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Place</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Virtually via the Internet at https://web.lumiconnect.com/276702602. No physical meeting will be held.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Items of Business</B></FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in">(1) To elect Dr. Daniel Vitt and
Dr. Duane Nash as Class I Directors to serve until our 2027 annual meeting of stockholders and until their successors are duly elected
and qualified.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in">(2) To ratify the appointment of
Baker Tilly US, LLP (&ldquo;Baker Tilly&rdquo;) as our independent registered public accounting firm for the fiscal year ending December
31, 2024.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in">(3) To approve, by non-binding
advisory vote, the resolution approving named executive officer compensation.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in">(4) To transact other business
that may properly come before the annual meeting.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Adjournments and Postponements</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Any action on the items of business described above may be considered at the annual meeting at the time and on the date specified above or at any time and date to which the annual meeting may be properly adjourned or postponed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Record Date</B></FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 22, 2024</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Only stockholders of record of our common stock as of the close of
    business on April 22, 2024 are entitled to notice of and to vote at the annual meeting.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Meeting Admission</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">You are invited to attend the annual meeting if you are a stockholder of record or a beneficial owner of shares of our common stock, in each case, as of the close of business on April 22, 2024. If you are a stockholder of record, you must use your 16-digit control number included on your notice, on your proxy card or on the instructions that accompanied your proxy materials, to enter the annual meeting. If you are not a stockholder of record but hold shares as a beneficial owner in &ldquo;street name,&rdquo; you may be required to provide proof of beneficial ownership, such as your most recent account statement as of the record date, a copy of the voting instruction form provided by your broker, bank, trustee, or nominee, or other similar evidence of ownership. If you do not comply with the procedures outlined above, you will not be admitted to the virtual annual meeting.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Voting</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Your vote is very important</B>. You may vote by proxy over the Internet or by telephone by following the instructions on the proxy card or voting instruction card. For specific instructions on how to vote your shares, please refer to the section entitled <I>Questions and Answers About the Proxy Materials and Annual Meeting</I> beginning on page 1 of the accompanying proxy statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By order of the Board of Directors,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>/s/ Dr. Daniel Vitt</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Daniel Vitt<BR>
Chief Executive Officer<BR>
New York, New York<BR>
April 23, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMUNIC, INC</B>.<BR>
<B>PROXY STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For the 2024 Annual Meeting of Stockholders to be held on June 11,
2024</B>. The information provided in the &ldquo;Questions and Answers&rdquo; format below is for your convenience only and is merely
a summary of the information contained in this proxy statement. You should read the entire proxy statement carefully.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">QUESTIONS AND ANSWERS<BR>
ABOUT THE PROXY MATERIALS AND ANNUAL MEETING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Why am I receiving these materials?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proxy statement and the enclosed form of proxy are furnished in
connection with the solicitation of proxies by our board of directors for use at the 2024 annual meeting of stockholders of Immunic, Inc.,
a Delaware corporation, and any postponements or adjournments thereof. The annual meeting will be held on June 11, 2024 at 9:00 a.m. Eastern
time, virtually via the Internet at https://web.lumiconnect.com/276702602. No physical meeting will be held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stockholders are invited to attend the annual meeting and are requested
to vote on the items of business described in this proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">What am I voting on?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You are being asked to vote on three proposals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the election of Dr. Daniel Vitt and Dr. Duane Nash as Class I Directors to hold office until our 2027 annual meeting of stockholders
and until their successors are duly elected and qualified;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the ratification of the appointment of Baker Tilly as our independent registered public accounting firm for our fiscal year ending
December 31, 2024; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the approval, by non-binding advisory vote, of the resolution approving named executive officer compensation (the &ldquo;Say on Pay
Proposal&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">What if other matters are properly brought before
the annual meeting?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the date of this proxy statement, we are not aware of any other
matters that will be presented for consideration at the annual meeting. If any other matters are properly brought before the annual meeting,
the persons named as proxies will be authorized to vote or otherwise act on those matters in accordance with their judgment. If for any
reason Dr. Daniel Vitt and Dr. Duane Nash are not available as candidates for director, the persons named as proxy holders will vote your
proxy for such other candidates as may be nominated by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">How does the board of directors recommend that
I vote?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors recommends that you vote your shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;<B>FOR</B>&rdquo; the election of Dr. Daniel Vitt and Dr. Duane Nash;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;<B>FOR</B>&rdquo; the ratification of the appointment of Baker Tilly as our independent registered public accounting firm for
our fiscal year ending December 31, 2024; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>&ldquo;FOR&rdquo; </B>the Say on Pay Proposal.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Who may vote at the annual meeting?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Only stockholders of record as of the close of business on April 22,
2024, the record date, are entitled to vote at the annual meeting. As of the record date, there were 90,079,016 shares of our common stock
issued and outstanding, held by 52 holders of record. We do not have cumulative voting rights for the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Stockholder of Record</I>: <I>Shares Registered in Your Name</I>.
If, at the close of business on the record date for the annual meeting, your shares were registered directly in your name with our transfer
agent, Equiniti Trust Company, LLC, then you are a stockholder of record. As a stockholder of record, you have the right to grant your
voting proxy directly to the individuals listed on the proxy card or to vote electronically at the annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Beneficial Owner: Shares Registered in the Name of a Broker, Bank,
or Other Nominee</I>. If, at the close of business on the record date for the annual meeting, your shares were held, not in your name,
but rather in an account at a brokerage firm, bank, or other nominee, then you are the beneficial owner of shares held in &ldquo;street
name&rdquo; and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered
the stockholder of record for purposes of voting at the annual meeting. As a beneficial owner, you have the right to direct your broker,
bank or other nominee regarding how to vote the shares in your account by following the voting instructions your broker, bank or other
nominee provides. You are also invited to attend the annual meeting. However, since you are not the stockholder of record, you may not
vote your shares electronically at the annual meeting unless you obtain a valid proxy from your broker, bank or other nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">How can I attend the annual meeting?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may attend the annual meeting online, including to vote and/or
submit questions during the meeting, by logging in at https://web.lumiconnect.com/276702602. The virtual annual meeting will begin at
approximately 9:00 a.m. Eastern time, with log-in beginning at approximately 8:45 a.m. on June 11, 2024. To participate in the virtual
annual meeting, you will need the 16-digit control number included on your notice, on your proxy card or on the instructions that accompanied
your proxy materials. Shares held in your name as the stockholder of record may be voted electronically during the annual meeting. Shares
for which you are the beneficial owner but not the stockholder of record may also be voted electronically during the annual meeting. However,
even if you plan to attend the virtual annual meeting, the Company recommends that you vote your shares in advance, so that your vote
will be counted if you later decide not to attend the annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">How can I vote my shares?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Stockholder of Record: Shares Registered
in Your Name</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">If you are a stockholder of record, you
may vote in one of the following ways:</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>You may vote electronically at the annual meeting</B>. See above in &ldquo;<I>How can I attend the annual meeting</I>?&rdquo;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>You may vote by telephone</B>. To vote over the telephone, dial toll-free 1 (800) 776-9437 or 1-718-921-8500 from foreign countries
using a touch-tone telephone and follow the recorded instructions. Have your proxy card in <I>hand</I> when you call. You will be asked
to provide the company number and control number from your proxy card. Telephone voting is available 24 hours a day, 7 days a week, until
11:59 p.m. Eastern time, on June 10, 2024.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>You may vote via the Internet</B>. To vote via the Internet, go to www.voteproxy.com to <I>complete</I> an electronic proxy card.
Have your proxy card in hand when you visit the website. You will be asked to provide the company number and control number from your
proxy card. Internet voting is available 24 hours a day, 7 days a week, until 11:59 p.m. Eastern time, on June 10, 2024.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Beneficial Owner: Shares Registered in the Name of a Broker,
Bank or Other Nominee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are a <I>beneficial</I> owner of shares held of record by a
broker, bank or other nominee, you will receive voting instructions from your broker, bank or other nominee. You must follow the voting
instructions provided by your broker, bank or other nominee in order to instruct your broker, bank or other nominee on how to vote your
shares. Beneficial owners of shares should generally be able to vote by returning the voting instruction card, by telephone or via the
Internet. However, the availability of telephone or Internet voting will depend on the voting process of your broker, bank, or other nominee.
As discussed above, if you are a beneficial owner, you may not vote your shares electronically at the annual meeting unless you obtain
a legal proxy from your broker, bank or other nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Can I change my vote or revoke my proxy?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stockholder of Record: Shares Registered in Your Name.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are a stockholder of record, you can change your vote or revoke
your proxy at any time before the annual meeting by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>entering a new vote by Internet or telephone (until the applicable deadline for each method as set forth above);&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>returning a later-dated proxy card (which automatically revokes the earlier proxy);&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>providing a written notice of revocation to our corporate secretary at Immunic, Inc., 1200 Avenue of the Americas, Suite 200, New
York, New York 10036, Attn: Corporate Secretary; or&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>attending the annual meeting and voting electronically. Attendance at the annual meeting will not cause your previously granted proxy
to be revoked unless you specifically so request.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Beneficial Owner: Shares Registered in the Name of a Broker,
Bank or Other Nominee.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are the beneficial owner of your shares, you must contact the
broker, bank or other nominee holding your shares and follow their instructions to change your vote or revoke your proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Do any of the proposals entitle me to a dissenter&rsquo;s
right of appraisal?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our stockholders are not entitled to dissenters&rsquo; rights in connection
with any of the proposals to be voted on at the annual meeting. Furthermore, we do not intend to independently provide our stockholders
with any such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">What is the effect of giving a proxy?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proxies are solicited by, and on behalf of, our board of directors.
The persons named in the proxy, Glenn Whaley, our Chief Financial Officer, and Inderpal Singh, our General Counsel, have been designated
as proxies for the annual meeting by our board of directors. When proxies are properly dated, executed and returned, the shares represented
by such proxies will be voted at the annual meeting in accordance with the instruction of the stockholder. If no specific instructions
are given, however, the shares will be voted in accordance with the recommendations of our board of directors as described above and,
if any other matters are properly brought before the annual meeting, the shares will be voted in accordance with the proxies&rsquo; judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">How many votes do I have?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On each matter to be voted upon at the annual meeting, each stockholder
will be entitled to one vote for each share of our common stock held by them on the record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">What is the quorum requirement for the annual
meeting?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A quorum is the minimum number of shares required to be present or
represented at the annual meeting for the meeting to be properly held under our bylaws and Delaware law. Holders of a majority of the
voting power of our outstanding common stock entitled to vote at the annual meeting must be present in person or represented by proxy
for us to hold and transact business at the annual meeting. On the record date, there were 90,079,016 shares outstanding and entitled to
vote. Thus, the holders of at least 45,039,509 shares that must be present in person or represented by proxy at the annual meeting to have a quorum, i.e., the number of holders of more
than half of the voting power of outstanding common stock entitled to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abstentions, &ldquo;WITHHOLD&rdquo; votes, and &ldquo;broker non-votes&rdquo;
(as explained below) are counted as present and entitled to vote for purposes of determining a quorum. If there is no quorum, the meeting
may be adjourned to another date by the chairman of the meeting or the holders of a majority of the voting power present in person or
represented by proxy at the annual meeting and entitled to vote thereat.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">What are broker non-votes?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Broker non-votes occur when a beneficial owner of shares held in &ldquo;street
name&rdquo; does not give instructions to the broker holding the shares as to how to vote on matters deemed &ldquo;non-routine.&rdquo;
There is at least one &ldquo;routine&rdquo; matter to be voted upon at the meeting relating to the ratification of Baker Tilly as our
independent auditors for the year ending December 31, 2024. Generally, if shares are held in &ldquo;street name,&rdquo; the beneficial
owner of the shares is entitled to give voting instructions to the broker holding the shares. If the beneficial owner does not provide
voting instructions, the broker can still vote the shares with respect to matters that are considered to be &ldquo;routine,&rdquo; but
not with respect to &ldquo;non-routine,&rdquo; matters. In the event that a broker votes shares on the &ldquo;routine&rdquo; matters,
but does not vote shares on the &ldquo;non-routine&rdquo; matters, those shares will be treated as broker non-votes with respect to the
&ldquo;non-routine&rdquo; proposals. Accordingly, if you own shares through a nominee, such as a broker or bank, please be sure to instruct
your nominee how to vote to ensure that your vote is counted on each of the proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">What matters are considered &ldquo;routine&rdquo;
and &ldquo;non-routine&rdquo;?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ratification of the appointment of Baker Tilly as our independent
registered public accounting firm for our fiscal year ending December 31, 2024 (Proposal No. 2) is considered routine under applicable
federal securities rules. All other proposals are considered &ldquo;non-routine&rdquo; under applicable federal securities rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">What are the effects of abstentions and broker
non-votes?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An abstention represents a stockholder&rsquo;s affirmative choice to
decline to vote on a proposal. If a stockholder indicates on its proxy card that it wishes to abstain from voting its shares, or if a
broker, bank or other nominee holding its customers&rsquo; shares of record causes abstentions to be recorded for shares, these shares
will be considered present and entitled to vote at the annual meeting. As a result, abstentions will be counted for purposes of determining
the presence or absence of a quorum and will also count as votes against a proposal in cases where approval of the proposal requires the
affirmative vote of a majority of the shares present in person or represented by proxy and entitled to vote at the annual meeting (Proposals
No. 2 and No. 3). However, because the outcome of Proposal No. 1 (election of a director) will be determined by a plurality vote, abstentions
will have no impact on the outcome of such proposal as long as a quorum exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Broker non-votes will be counted for purposes of calculating whether
a quorum is present at the annual meeting, but will not be counted for purposes of determining the number of votes cast. Therefore, a
broker non-vote will make a quorum more readily attainable but will not otherwise affect the outcome of the vote on any proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">What is the voting requirement to approve each
of the proposals?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Proposal No. 1: Election of Class I Directors</I></B>. The election
of each of Dr. Daniel Vitt and Dr. Duane Nash requires a plurality of the votes cast by the holders of shares present in person or represented
by proxy at the annual meeting and entitled to vote on the election of directors. This means that if Dr. Daniel Vitt and Dr. Duane Nash
each receives a single vote, they will be elected as Class I Directors. You may vote &ldquo;FOR&rdquo; or &ldquo;WITHHOLD&rdquo; for Dr.
Daniel Vitt and Dr. Duane Nash. Because the outcome of this proposal will be determined by a plurality vote, shares voted &ldquo;WITHHOLD&rdquo;
will not prevent Dr. Daniel Vitt and Dr. Duane Nash from being elected as directors. Shares voted &ldquo;WITHHOLD&rdquo; will count towards
the quorum requirement for the annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Proposal No. 2: Ratification of Appointment of Baker Tilly</I></B>.
The ratification of the appointment of Baker Tilly requires the affirmative vote of a majority of the shares present in person or represented
by proxy at the annual meeting and entitled to vote thereon to be approved. You may vote &ldquo;FOR,&rdquo; &ldquo;AGAINST,&rdquo; or
&ldquo;ABSTAIN&rdquo; on this proposal. Abstentions will count towards the quorum requirement for the annual meeting and will have the
same effect as a vote against the proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Proposal No. 3: Approval, by non-binding advisory vote, of the
Say on Pay Proposal.</I></B> The approval, on an advisory basis, of the Say on Pay Proposal requires the affirmative vote of a majority
of the shares present in person or represented by proxy at the annual meeting and entitled to vote thereon to be approved. You may vote
&ldquo;FOR,&rdquo; &ldquo;AGAINST,&rdquo; or &ldquo;ABSTAIN&rdquo; on this proposal. Abstentions will count towards the quorum requirement
for the annual meeting and will have the same effect as a vote against the proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Who will count the votes?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A representative of Equiniti Trust Company, LLC will tabulate the votes
and act as inspector of elections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">What if I do not specify how my shares are to
be voted or fail to provide timely directions to my broker, bank or other nominee?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stockholder of Record: Shares Registered in Your Name</I>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are a stockholder of record and you submit a proxy but you do
not provide voting instructions, your shares will be voted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;<B>FOR</B>&rdquo; the election of Dr. Daniel Vitt and Dr. Duane Nash;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;<B>FOR</B>&rdquo; the ratification of the appointment of Baker Tilly as our independent registered public accounting firm for
our fiscal year ending December 31, 2024; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;<B>FOR</B>&rdquo; the Say on Pay Proposal.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, if any other matters are properly brought before the annual
meeting, the persons named as proxies will be authorized to vote or otherwise act on those matters in accordance with their judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Beneficial Owner: Shares Registered in the Name of a Broker,
Bank or Other Nominee</I>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brokers, banks and other nominees holding shares of common stock in
&ldquo;street name&rdquo; for customers are generally required to vote such shares in the manner directed by their customers. In the absence
of timely directions, your broker, bank or other nominee will have discretion to vote your shares on the sole &ldquo;routine&rdquo; matter
- Proposal No. 2 relating to ratifying the appointment of Baker Tilly. Absent direction from you, however, your broker, bank or other
nominee will not have the discretion to vote on Proposal No. 1 relating to the election of a director or on Proposal No. 3 relating to
approval of &ldquo;Say on Pay.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">How can I contact Immunic&rsquo;s transfer agent?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may contact our transfer agent by writing to Equiniti Trust Company,
LLC, 6201 15th Avenue, Brooklyn, New York 11219. You may also contact our transfer agent via email at help@astfinancial.com or by telephone
at 1 (800) 937-5449.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">How are proxies solicited for the annual meeting,
and who is paying for such solicitation?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This year we are furnishing our proxy materials to our stockholders
primarily via &ldquo;Notice and Access&rdquo; delivery pursuant to Securities and Exchange Commission (&ldquo;SEC&rdquo;) rules. On or
about April 23, 2024, we mailed,   to our stockholders a &ldquo;Notice Regarding the Availability of Proxy Materials&rdquo; (the
&ldquo;Notice&rdquo;) containing instructions on how to access the proxy materials via the Internet. Utilizing this method of proxy delivery
expedites receipt of proxy materials by our stockholders, reduces the cost of producing and mailing the full set of proxy materials and
helps us contribute to sustainable practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you receive a Notice by mail, you will not receive a printed copy
of the proxy materials in the mail. Instead, the Notice instructs you on how to access the proxy materials and vote over the Internet.
If you received a Notice by mail and would like to receive paper copies of our proxy materials in the mail, you may follow the instructions
in the Notice for making this request. The Notice also contains instructions on how you may request to receive an electronic copy of our
proxy materials by email or phone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors is soliciting proxies for use at the annual
meeting by means of the proxy materials. We will bear the entire cost of proxy solicitation. The original solicitation of proxies may
be supplemented by solicitation by telephone, electronic communication, or other means by our directors, officers or employees. No additional
compensation will be paid to these individuals for any such services, although we may reimburse such individuals for their reasonable
out-of-pocket expenses in connection with such solicitation. We do not plan to retain a proxy solicitor to assist in the solicitation
of proxies. If you choose to access the proxy materials and/or vote over the Internet, you are responsible for any Internet access charges
you may incur. If you choose to vote by telephone, you are responsible for any telephone charges you may incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Where can I find the voting results of the annual
meeting?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will announce preliminary voting results at the annual meeting.
We will also disclose voting results on a Current Report on Form 8-K filed with the SEC within four business days after the annual meeting.
If final voting results are not available to us in time to file a Current Report on Form 8-K within four business days after the annual
meeting, we will file a Current Report on Form 8-K to publish preliminary results and, within four business days after final results are
known, file an additional Current Report on Form 8-K to publish the final results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">What does it mean if I receive more than one
set of Notices?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you receive more than one set of Notices, your shares may be registered
in more than one name and/or are registered in different accounts. Please follow the voting instructions on each Notice to ensure that
all of your shares are voted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>I share an address with another stockholder, and we received only
one printed copy of the proxy materials. How may I obtain an additional copy of the proxy materials?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have adopted an SEC-approved procedure called &ldquo;householding,&rdquo;
under which we can deliver a single copy of the proxy materials to multiple stockholders who share the same address unless we receive
contrary instructions from one or more of the stockholders. This procedure reduces our printing and mailing costs. Upon written or oral
request, we will undertake to promptly deliver a separate copy of the proxy materials to any stockholder at a shared address. To receive
a separate copy, or, if you are receiving multiple copies, to request that we only send a single copy of next year&rsquo;s proxy materials,
you may contact us as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Immunic, Inc.<BR>
Attention: Investor Relations<BR>
1200 Avenue of the Americas, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, New York 10036<BR>
(858) 673-6840</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stockholders who hold shares in &ldquo;street name&rdquo; may contact
their brokerage firm, bank, broker-dealer or other nominee to request information about householding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Is there a list of stockholders entitled to
vote at the annual meeting?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The names of stockholders of record entitled to vote at the annual
meeting will be available at the annual meeting and from our corporate secretary for ten days prior to the meeting for any purpose germane
to the meeting, between the hours of 9:00 a.m. and 4:30 p.m. Eastern time, at our corporate headquarters located at 1200 Avenue of the
Americas, Suite 200, New York, New York 10036.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">When are stockholder proposals due for next
year&rsquo;s annual meeting?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please see the section entitled &ldquo;<I>Proposals of Stockholders
for 2025 Annual Meeting</I>&rdquo; in this proxy statement for more information regarding the deadlines for the submission of stockholder
proposals for our 2025 annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">BOARD OF DIRECTORS AND CORPORATE
GOVERNANCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Composition of the Board</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors (&ldquo;board&rdquo;) is currently composed
of seven members. Two of our current directors, Dr. Vitt and Dr. Neermann, began their service in April 2019 in connection with the stock-for-stock
exchange transaction between the Company (then known as Vital Therapies, Inc.) and Immunic AG (the &ldquo;Exchange Transaction&rdquo;).
Five of the seven directors that currently comprise our board are &ldquo;independent directors&rdquo; within the meaning of such term
as set forth in the listing standards of the Nasdaq Stock Market, LLC (&ldquo;Nasdaq&rdquo;). Our board is divided into three staggered
classes of directors. At each annual meeting of stockholders, a class of directors will be elected for a term of three years to succeed
the class of directors whose terms are then expiring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the names, ages, and certain other information
for each director with a term expiring at the annual meeting (who is also a nominee for election as a director at the annual meeting)
and for each of the continuing members of our board. All information is as of April 23, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 23%; border-bottom: black 1pt solid">Name</TD>
    <TD STYLE="width: 5%; border-bottom: black 1pt solid">Class</TD>
    <TD STYLE="width: 6%; border-bottom: black 1pt solid">Age</TD>
    <TD STYLE="width: 29%; border-bottom: black 1pt solid">Position</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid">Director <BR>
Since</TD>
    <TD STYLE="width: 11%; border-bottom: black 1pt solid">Current <BR>
Term <BR>
Expires</TD>
    <TD STYLE="width: 16%; border-bottom: black 1pt solid">Expiration of <BR>
Term for Which <BR>
Nominated</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><I>Nominees for Director</I></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Dr. Daniel Vitt</TD>
    <TD>I</TD>
    <TD>55</TD>
    <TD>Director, Chief Executive Officer, President</TD>
    <TD>2019</TD>
    <TD>2024</TD>
    <TD>2027</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>Dr. Duane Nash</TD>
    <TD>I</TD>
    <TD>53</TD>
    <TD>Executive Chairman of the Board</TD>
    <TD>2019</TD>
    <TD>2024</TD>
    <TD>2027</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><I>Continuing Directors</I></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: Transparent">
    <TD>Dr. J&ouml;rg Neermann</TD>
    <TD>II</TD>
    <TD>57</TD>
    <TD>Director</TD>
    <TD>2019</TD>
    <TD>2025</TD>
    <TD>&mdash;</TD></TR>
  <TR STYLE="background-color: #CCECFF">
    <TD STYLE="vertical-align: top">Ms. Tamar Howson</TD>
    <TD STYLE="vertical-align: top">II</TD>
    <TD STYLE="vertical-align: top">75</TD>
    <TD STYLE="vertical-align: top">Director</TD>
    <TD STYLE="vertical-align: top">2019</TD>
    <TD STYLE="vertical-align: top">2025</TD>
    <TD STYLE="vertical-align: bottom">&mdash;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: Transparent">
    <TD>Mr. Barclay Phillips</TD>
    <TD>II</TD>
    <TD>61</TD>
    <TD>Lead Independent Director</TD>
    <TD>2019</TD>
    <TD>2025</TD>
    <TD>&mdash;</TD></TR>
  <TR STYLE="background-color: #B6DDE8">
    <TD STYLE="vertical-align: top">Ms. Maria T&ouml;rns&eacute;n </TD>
    <TD STYLE="vertical-align: top">III</TD>
    <TD STYLE="vertical-align: top">45</TD>
    <TD STYLE="vertical-align: top">Director</TD>
    <TD STYLE="vertical-align: top">2022</TD>
    <TD STYLE="vertical-align: top">2026</TD>
    <TD STYLE="vertical-align: bottom">&mdash;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>Dr. Richard Rudick</TD>
    <TD>III</TD>
    <TD>73</TD>
    <TD>Director</TD>
    <TD>2023</TD>
    <TD>2026</TD>
    <TD>&mdash;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nominees for Director </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dr. Daniel Vitt</B>. Dr. Vitt is our Chief Executive Officer and
a member of the board, positions he has held since April 2019. From January 2017 to 2022, he was also managing director of Immunic Research
GmbH in Halle (Saale), our Germany subsidiary. He joined Immunic in January 2017 from 4SC AG, a publicly listed stock company based in
Martinsried, Germany, which he co-founded in 1997. At 4SC, he served as Chief Scientific Officer and Chief Development Officer. In addition,
from December 2011 to November 2017, Dr. Vitt served as managing director of 4SC Discovery GmbH, a German limited liability company. As
a member of the executive board of 4SC, he was responsible for all research and development activities at 4SC group including four clinical
stage products. Dr. Vitt currently serves as managing director for Listrax UG, a German limited liability company, and Brauhaus Germering
GmbH, a German limited liability company. He is also a director of Immunic Australia Pty Ltd., an Australian limited liability company.
Dr. Vitt studied chemistry in Siegen and W&uuml;rzburg, Germany from 1989 to 1994 and graduated from the University of W&uuml;rzburg.
During his doctoral studies, he focused on the molecular design of small molecule therapeutics. In 1998, he received his Ph.D. from the
Institute of Organic Chemistry at the University of W&uuml;rzburg. We believe that Dr. Vitt&rsquo;s extensive senior management experience
in the life sciences industry, including as the Company&rsquo;s Chief Executive Officer, qualify him to serve as a member of our board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dr. Duane Nash</B>. Dr. Nash has been a member of the Board since
January 2019 and has served as Chairman of the board of directors since April 2019, and as Executive Chairman since April 2020. Dr. Nash
joined the Company in 2012, prior to the Exchange Transaction and has held various leadership roles in the Company, including Medical
Director, Executive Vice President, Chief Business Officer, President, and Chief Executive Officer, a position he held until April 2019.
Prior to joining the Company, Dr. Nash held various positions at Wedbush PacGrow Life Sciences, an investment bank, where he was employed
from March 2009 to March 2012, serving most recently as Senior Vice President in Equity Research. Before that, he was a research analyst
at Pacific Growth Equities, an investment bank, from April 2008 through March 2009, which was subsequently acquired by Wedbush Securities,
Inc. Dr. Nash also practiced as an attorney from November 2002 to February 2008, most recently at the law firm of Davis Polk &amp; Wardell,
where he focused on intellectual property litigation and corporate matters. Dr. Nash has served on the board of directors of public and
private companies in the pharmaceutical space since 2012. Dr. Nash earned a B.A. in biology from Williams College, an M.D. from Dartmouth
Medical School, a J.D. from the University of California, Berkeley, and an M.B.A. from the University of Oxford. Dr. Nash completed his
internship in general surgery at the University of California at San Francisco. We believe that Dr. Nash&rsquo;s expertise and experience
as a director and his service in various executive capacities for the Company, along with his extensive experience as an executive, research
analyst and attorney, qualify him to serve as a member of our board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Continuing Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dr. J&ouml;rg Neermann</B>. Dr. Neermann has been a member of the
Board since April 2019. He most recently served as the CEO of the privately held German biotech company, Curexsys GmbH from May 2021 until
September 2022. Prior to this until the end of 2020, Dr. Neermann worked for Life Sciences Partners (&ldquo;LSP&rdquo;) and was the managing
director of LSP Services Deutschland GmbH, which provides management services for LSP V Co&ouml;peratieve U.A., one of the Company&rsquo;s
stockholders. He joined LSP in January 2007 and left the company in early 2021. Dr. Neermann&rsquo;s prime focus and responsibility within
LSP was to invest in unlisted securities. Prior to joining LSP, Dr. Neermann was the managing director of Deutsche Venture Capital, a
venture capital and private equity division of Deutsche Bank, where he ran its healthcare investment franchise. Previously, he worked
at Atlas Ventures in Germany where he also invested in the healthcare sector. Dr. Neermann has a strong scientific background and hands-on
finance and investment expertise and has served on the boards of numerous European biotech and life science companies. From September
2011 until June 2023, Dr. Neermann served as a non-executive director at Vivoryon N.V., a German biotech company that went public on Euronext
Amsterdam in 2014, which is active in the development of novel, disease-modifying therapeutics against Alzheimer&rsquo;s disease. Currently,
Dr. Neermann serves as a non-executive director at Idea AG, a private German company. Dr. Neermann was previously a supervisory board
member of ViCentra B.V., a Dutch limited liability company, and Eyesense GmbH, a German limited liability company, until January 2021,
Ventaleon GmbH, a German limited liability company, until December 2020, and Kuros AG, a Swiss-headquartered company, until May 2017.
Dr. Neermann was also a board member of Imcyse S.A., a Belgian limited liability company, until January 2021. Currently, he is owner and
managing director of Betula29 GmbH, a German limited liability company. Dr. Neermann studied biotechnology at the Technical University
of Brunswick, Germany, and MIT in Cambridge, USA, and holds a Master&rsquo;s degree and a Ph.D. in biotechnology from the Technical University
in Brunswick, Germany. He also studied economics at the Technical University in Brunswick, Germany, and Harvard Business School. We believe
that Dr. Neermann is qualified to serve on our board due to his scientific background and extensive experience as an investor in the biotechnology
and healthcare industries, which enable him to contribute important insights to our board on strategic leadership and drug commercialization
matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tamar Howson</B>. Ms. Howson has been a member of the Board since
October 2019. Ms. Howson has served as an Independent Director at MEI Pharma, Inc. since September 2019, and Cue Biopharma, Inc. since
September 2020. She previously served as an Independent Director at Organovo Holdings, Inc. from June 2013 until September 2019, Enzymotec
until December 2017, ContraVir until October 2018 and Scientus Pharma until December 2019. From January 2009 until December 2011, Ms.
Howson worked as a Senior Advisor on the transaction team at JSB-Partners, providing business development support to life sciences companies.
Before that, she served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals, Inc. Prior to her role
at Lexicon Pharmaceuticals, Inc, Ms. Howson was Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb Company,
responsible for worldwide oversight and management of the identification, evaluation and negotiation of mergers and acquisitions, licensing
and other external alliance activities. Additionally, Ms. Howson spent nearly a decade at SmithKline Beecham, where she served as Senior
Vice President and Director, Business Development and managed the company&rsquo;s USD 100 million venture capital fund, SR One. We believe
that Ms. Howson&rsquo;s extensive experience in corporate and business development in the biotechnology and pharmaceutical industries
qualify her to serve as a member of our board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Barclay Phillips</B>. Mr. Phillips has been a member of the Board
since November 2019. Mr. Phillips is currently the Chief Operating Officer and Chief Financial Officer of Ribometrix, Inc., a discovery
stage biotechnology company developing RNA-targeted small molecule therapeutics and managing member of Domantle Consulting LLC, a business
strategy consulting firm for biotechnology companies. From 2008 to May 2019, Mr. Phillips served as the Chief Financial Officer for three
separate Nasdaq listed, development stage biotechnology companies; G1 Therapeutics, Inc. (GTHX), Novavax (NVAX) and Micromet (acquired
by Amgen in 2012 for $1.2B). In addition to carrying the CFO role, Mr. Phillips also held the title of SVP Corporate Development at G1
Therapeutics. During his tenure as CFO, Mr. Phillips was responsible for all finance and accounting functions, financing strategy (successfully
raising over $1.4B), Wall Street and investor relations, public relations and corporate strategy and corporate development. Prior to his
CFO experience, Mr. Phillips had extensive experience in life science venture investing and public market investing, serving for 9 years
as the Managing Director of Vector Fund Management, a late-stage life sciences venture capital fund with over $250 million in committed
capital and approximately 30 venture investments in biotechnology, medical technology and healthcare services companies. In addition,
Mr. Phillips was Biotechnology Analyst and Director of Venture Investments for INVESCO Funds group, a no-load mutual fund family with
a healthcare sector fund franchise totaling over $3.5 billion in assets under management. Mr. Phillips has served on the boards of several
public and private companies, including roles as Audit Chair and Chair of the Nominating and Corporate Governance committees. He received
a Bachelor of Arts degree in economics from the University of Colorado at Boulder. We believe that Mr. Phillips&rsquo; significant expertise
in the areas of financing strategy, capital markets, and business development for multiple, Nasdaq-listed life science companies qualify
him to serve as a member of our board and lead independent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Maria T&ouml;rns&eacute;n</B>. Ms. T&ouml;rns&eacute;n joined the
Board in July 2022. Currently, Ms. T&ouml;rns&eacute;n serves as President (North America) of Calliditas Therapeutics AB. Ms. T&ouml;rns&eacute;n
served as Chief Commercial Officer at Passage Bio from July 2021 until December 2022, where she was responsible for leading and building
out the company&rsquo;s commercial organization and strategy, including determining product positioning and paths to commercialization.
From 2019 to 2021, Ms. T&ouml;rns&eacute;n served as Senior Vice President and General Manager of Sarepta Therapeutics&rsquo; U.S. Commercial
organization, including market access, trade &amp; distribution, reimbursement, sales, patient services and marketing. From 2017 to 2019,
she was Vice President, Global Therapeutic Area Head of rare neurological, metabolic and endocrine diseases at Sanofi Genzyme, where she
managed a $1.6 B portfolio with five marketed and three pipeline products, and was commercial lead on multiple alliances. From 2011 to
2017, Ms. T&ouml;rns&eacute;n held advancing commercialization roles in the endocrine and rare diseases groups at Shire, rising to the
role of Vice President, Head of Endocrine Rare Disease Sales, U.S. Commercial. Earlier in her career, she gained experience in global
marketing and as a Product Specialist at Merck KGaA and Eli Lilly, respectively. Ms. T&ouml;rns&eacute;n earned a Master of Science (MSc)
in International Business Administration from Lund University, Sweden. We believe that Ms. T&ouml;rns&eacute;n&rsquo;s extensive experience
in product commercialization, organization and strategy qualify her to serve on our board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dr. Richard Rudick. </B>Dr. Rudick joined the Board in April 2023.
Dr. Rudick has served since January 2023 as the President and CEO of Astoria Biologica, a private biotechnology company developing novel
therapies for multiple sclerosis. Previously, Dr. Rudick served as the Vice President of Development Science at Biogen, Inc., a biotechnology
company which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, from May 2014
until September 2020. Dr. Rudick also served as a staff neurologist and director of the Mellen Center for the Cleveland Clinic from January
1987 until May 2014. Dr. Rudick holds an M.D. from Case Western Reserve University School of Medicine. We believe that Dr. Rudick&lsquo;s
extensive leadership in clinical research and development experience of multiple sclerosis treatments qualify him to serve on our board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The listing rules of Nasdaq require us to maintain a board comprised
of a majority of independent directors, as determined affirmatively by our board. In addition, the Nasdaq listing rules require that,
subject to specified exceptions, each member of our audit, compensation and nominating and governance committees must be independent.
Audit committee members and compensation committee members must also satisfy the independence criteria set forth in Rule 10A-3 and Rule
10C-1, respectively, under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). Under the Nasdaq listing
rules, a director will only qualify as an &ldquo;independent director&rdquo; if, in the opinion of our board, the director does not have
a relationship that would interfere with the exercise of independent judgment in carrying out his or her responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board has undertaken a review of the independence of our directors
and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent
judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning his
or her background, employment and affiliations, including family relationships, our board has determined that none of Ms. Howson, Dr.
Neermann, Mr. Phillips, Ms. T&ouml;rns&eacute;n and Dr. Rudick, representing five of our seven directors, has a relationship that would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each is an &ldquo;independent
director&rdquo; as that term is defined under the Nasdaq listing rules. Dr. Nash and Dr. Vitt are not currently considered independent
directors because of their positions as our Executive Chairman and Chief Executive Officer, respectively. Mr. Phillips is our lead independent
director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In making these determinations, our board considered the relationships
that each non-employee director has with us and all other facts and circumstances our board deemed relevant in determining their independence,
including consulting relationships, family relationships and the beneficial ownership of our capital stock by each non-employee director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board Leadership Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board is currently chaired by Dr. Nash. Our board believes that
the Company and its stockholders are currently best served by this leadership structure. As Executive Chairman, Dr. Nash promotes unified
leadership and direction for our board and management and provides the critical leadership necessary for carrying out our strategic initiatives.
Dr. Nash, together with our board&rsquo;s strong committee system and independent directors, allows our board to maintain effective oversight
of our business operations, including independent oversight of our financial statements, executive compensation, selection of director
candidates, and corporate governance programs. We believe our current board leadership structure enhances the board&rsquo;s ability to
effectively carry out its roles and responsibilities on behalf of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, Mr. Phillips serves as our lead independent director.
As the lead independent director, Mr. Phillips is responsible for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>presiding at all meetings of the Board at which the Chairperson is not present, including any executive sessions of the independent
Directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>calling meetings of the independent Directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>serving as an advisor to the CEO and the Chairperson, as well as a non-exclusive liaison between the Chairperson and the independent
Directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>proposing items to the Chairperson and CEO for inclusion in agendas for meetings of the Board when the Lead Independent Director determines
it is appropriate or necessary;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>being available, when appropriate, for consultation and direct communication with shareholders; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fulfilling such other responsibilities and carrying out such special projects as the Board may from time to time request.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board Diversity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each of the categories listed in the below table has the meaning as
it is used in Nasdaq Rule 5605(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD COLSPAN="9" STYLE="border-bottom: black 1pt solid; text-align: center"><B>Board Diversity Matrix</B></TD></TR>
  <TR STYLE="background-color: #F2F2F2">
    <TD STYLE="vertical-align: top"><B>Board Size</B>:</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 7%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 7%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>Total Number of Directors</TD>
    <TD>&nbsp;</TD>
    <TD>7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: #F2F2F2">
    <TD STYLE="vertical-align: top"><B>Gende</B>r:</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><B>Male</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><B>Female</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><B>Non-Binary</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><B>Gender Undisclosed</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>5</TD>
    <TD>&nbsp;</TD>
    <TD>2</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: #F2F2F2">
    <TD STYLE="white-space: nowrap; vertical-align: top"><B>Number of directors who identify in any of the categories below</B>:</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>African American or Black</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>Alaskan Native or American Indian</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>Asian</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>Hispanic or Latinx</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>Native Hawaiian or Pacific Islander</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>White</TD>
    <TD>&nbsp;</TD>
    <TD>5</TD>
    <TD>&nbsp;</TD>
    <TD>2</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&mdash;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid">Two or more races or ethnicities</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&mdash;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&mdash;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&mdash;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&mdash;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>LGBTQ+</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7">&mdash;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>Undisclosed</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7">&mdash;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Of our seven (7) current directors, two (approximately 29%) identify
as having at least one diversity characteristic (i.e. female, non-binary, LGBTQ+ and/or race or ethnicity other than white).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Role of Board in Risk Oversight Process</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board has an active role, as a whole and also at the committee
level, in overseeing risk management. Our board is responsible for general oversight and regular review of risk management, including
financial, strategic, and operational risks. The compensation committee is responsible for overseeing the management of risks relating
to our executive compensation plans and arrangements, and whether our compensation policies and programs have the potential to encourage
excessive risk taking. The audit committee is responsible for overseeing the management of risks relating to accounting matters and financial
reporting. The nominating and governance committee is responsible for overseeing our corporate governance practices and the management
of risks associated with board independence and potential conflicts of interest. Although each committee is responsible for evaluating
and overseeing the management of certain risks, the entire board is regularly informed through discussions from committee members about
such risks. The board believes its leadership structure is consistent with and supports the administration of its risk oversight function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Board Meetings and Committees</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During our fiscal year ended December 31, 2023, our board held seven
meetings (including regularly scheduled and special meetings), and each director attended at least 75% of the aggregate of (i) the total
number of meetings of our board held during the period for which he or she has been a director and (ii) the total number of meetings held
by all committees of our board on which he or she served during the periods that he or she served.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board has established an audit committee, a compensation committee,
and a nominating and governance committee. The composition and responsibilities of each of the committees of our board are described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Audit Committee</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee members currently consist of Mr. Phillips, Ms.
T&ouml;rns&eacute;n and Dr. Neermann. Mr. Phillips serves as the chairman. Each of the members of our audit committee is an independent
director under the Nasdaq listing rules, satisfies the additional independence criteria for audit committee members and satisfies the
requirements for financial literacy under the Nasdaq listing rules and Rule 10A-3 of the Exchange Act, as applicable. Our board has also
determined that Mr. Phillips and Ms. T&ouml;rns&eacute;n each qualify as an audit committee financial expert within the meaning of the
applicable rules and regulations of the SEC and satisfy the financial sophistication requirements of the Nasdaq listing rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee oversees our corporate accounting and financial
reporting processes and the audit and review of our financial statements and assists our board in monitoring our financial systems and
financial compliance. Among other responsibilities, our audit committee also:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>has the sole authority to engage, appoint and oversee the work of our independent auditors;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>approves the hiring, discharging and compensation of our independent auditors as well as the compensation of any other accountants
or auditors engaged by us in connection with the preparation of financial statements;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pre-approve all auditing services and related terms and non-audit services to be provided to us by our independent auditors and any
other accounts or auditors engaged by us in connection with the preparation of financial statements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>evaluates, at least annually, the qualifications, independence and performance of the independent auditors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reviews our financial statements and our critical accounting policies and estimates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>assists our board in monitoring and reviewing the adequacy and effectiveness of our internal accounting and financial controls as
well as our internal control policies and procedures on a regular basis;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reviews our policies with respect to financial risk assessment and financial risk management;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reviews and monitors our policies and procedures relating to related person transactions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reviews, in consultation with our independent auditors, our annual audit plan and scope of audit activities, monitoring such annual
audit plan&rsquo;s progress and reviewing and approving the scope and staffing of such plan; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>discusses and, as appropriate, reviews with management and our independent auditors our annual and quarterly financial statements
and annual and quarterly reports on Forms 10-K and 10-Q, among other matters.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee operates under a written charter approved by our
board and that satisfies the applicable rules and regulations of the SEC and the listing requirements of Nasdaq. The charter is available
on the corporate governance section of our website, which is located at http://ir.imux.com. Our audit committee held four meetings during
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Compensation Committee</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The members of our compensation committee are Ms. Howson, Ms. T&ouml;rns&eacute;n
and Dr. Rudick. Ms. Howson is currently the chair of our compensation committee. Our board has determined that each member of our compensation
committee is an independent director under the current rules of Nasdaq, satisfies the additional independence criteria for compensation
committee members under Rule 10C-1 and the Nasdaq listing rules, is a &ldquo;non-employee director&rdquo; within the meaning of Rule 16b-3
under the Exchange Act, and is an &ldquo;outside director&rdquo; for purposes of Section 162(m) of the Internal Revenue Code of 1986,
as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee oversees our corporate compensation programs.
The compensation committee also:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>assists our board in providing oversight of our compensation policies, plans and benefits programs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reviews and recommends for board approval corporate goals and objectives relevant to the compensation of our Chief Executive Officer,
our Section 16 executive officers and all other direct reports to the Chief Executive Officer who have material responsibilities within
the Company (collectively referred to as the &ldquo;Designated Employees&rdquo;);&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>evaluates the performance of our Chief Executive Officer and Designated Employees in light of established goals and objectives;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>recommends compensation of our Chief Executive Officer and Designated Employees based on its evaluations;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reviews and makes recommendations to our board with respect to the salary, benefit plans, compensation policies and programs for the
Chief Executive Officer and Designated Employees;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reviews and discusses with management the compensation disclosures required by SEC rules;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>engages a compensation consultant, legal counsel or other external advisors to advise on executive compensation and assess the independence
of executive officers in accordance with Nasdaq listing rules;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>evaluates whether any compensation consultant, legal counsel or other external advisor has a conflict of interest in accordance with
the SEC rules; and&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>prepares the annual compensation committee report required by SEC rules.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee operates under a written charter approved
by our board which satisfies the applicable rules and regulations of the SEC and the listing requirements of Nasdaq. The charter is available
on our website at http://ir.imux.com. Our compensation committee held five meetings during 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Nominating and Governance Committee</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The members of our nominating and governance committee are Dr. Neermann,
Mr. Phillips and Dr. Rudick. Dr. Neermann is the chairman of our nominating and governance committee. Our board has determined that each
member of our nominating and governance committee is independent under the Nasdaq listing rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our nominating and governance committee oversees and assists our board
in reviewing and recommending nominees for election as directors. Among other responsibilities, the nominating and governance committee
also:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>evaluates and makes recommendations regarding the organization and governance of our board and its committees;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>assesses the performance of members of our board and makes recommendations regarding committee and chair assignments;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>recommends desired qualifications for board membership and conducts searches for potential members of our board;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fulfills our board&rsquo;s oversight responsibility with respect to our cybersecurity policies, overseeing our risk management with
respect to cybersecurity, reviewing our adoption and implementation of systems, controls and procedures designed to prevent, detect and
respond to cyber-attacks or security breaches involving us, and reviewing our cybersecurity insurance requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>periodically reviews our policy with respect to the United States Foreign Corrupt Practices Act;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>monitors the compliance of our senior officers with our Code of Business Conduct and Ethics; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reviews and makes recommendations with regard to our corporate governance guidelines.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our nominating and governance committee operates under a written charter
approved by our board which satisfies the applicable rules and regulations of the SEC and the listing requirements of Nasdaq. The charter
is available on our website at http://ir.imux.com. Our nominating and governance committee held three meetings during 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Compensation Committee Interlocks and Insider
Participation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None of the current or past members of our compensation committee is
or has been an officer or employee of the Company. None of our executive officers currently serves, or in the past year has served, as
a member of the compensation committee (or other board committee performing equivalent functions or, in the absence of any such committee,
the entire board) or director of any entity that has one or more executive officers serving on our compensation committee or our board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Considerations in Evaluating Director Nominees</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In its evaluation of director candidates, including the member or members
of the board eligible for reelection, our nominating and governance committee will consider the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The current size and composition of our board and the needs of the board and its respective committees;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Factors such as character, integrity, judgment, diversity of experience, independence, area of expertise, corporate experience, length
of service, potential conflicts of interest, other commitments, and the like. Our nominating and governance committee evaluates these
factors, among others, and does not assign any particular weighting or priority to any of these factors; and&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Other factors that our nominating and governance committee may consider appropriate.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The nominating and governance committee also focuses on issues of diversity,
such as diversity in experience, international perspective, background, expertise, skills, age, gender, and ethnicity. The nominating
and governance committee does not have a formal policy with respect to diversity; however, our board and the nominating and governance
committee believe that it is essential that members of our board represent diverse viewpoints. Any nominee for a position on the board
must satisfy the following minimum qualifications:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The highest levels of personal and professional ethics and integrity;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Proven achievement and competence in the nominee&rsquo;s field and the ability to exercise sound business judgment;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Skills that are complementary to those of the existing board;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The ability to assist and support management and make significant contributions to the Company&rsquo;s success; and&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>An understanding of the fiduciary responsibilities required of a member of the board and the commitment of time and energy necessary
to diligently carry out those responsibilities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If our nominating and governance committee determines that an additional
or replacement director is required, the committee may take such measures as it considers appropriate in connection with its evaluation
of a director candidate, including candidate interviews, inquiry of the person or persons making the recommendation or nomination, engagement
of an outside search firm to gather additional information, or reliance on the knowledge of the members of the committee, board or management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After completing its review and evaluation of director candidates,
our nominating and governance committee recommends to our full board the director nominee. Our nominating and governance committee has
discretion to decide which individuals to recommend for nomination as directors and our board has the final authority in determining the
selection of director candidates for nomination to our board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Requirements for Stockholder Recommendations
of a Candidate to our Board</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is the policy of our nominating and governance committee to consider
recommendations for candidates to our board from our stockholders. A stockholder that wishes to recommend a candidate for consideration
by the committee as a potential candidate for director must direct the recommendation in writing to Immunic, Inc., 1200 Avenue of the
Americas, Suite 200, New York, New York 10036, Attention: Corporate Secretary, and must include the candidate&rsquo;s name, home and business
contact information, detailed biographical data, relevant qualifications, a signed letter from the candidate confirming willingness to
serve, information regarding any relationships between us and the candidate and evidence of the recommending stockholder&rsquo;s ownership
of our stock. Such recommendation must also include a statement from the recommending stockholder in support of the candidate, particularly
within the context of the criteria for board membership, including character, integrity, judgment, diversity of experience, independence,
area of expertise, corporate experience, potential conflicts of interest, other commitments and personal references. Further details are
set forth below in &ldquo;<I>Proposals of Stockholders for 2025 Annual Meeting</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our nominating and governance committee will consider the recommendation
but will not be obligated to take any further action with respect to the recommendation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Communications with the Board of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In cases where stockholders or other interested parties wish to communicate
directly with our non-management directors, messages can be sent to Immunic, Inc., Attention: Corporate Secretary, 1200 Avenue of the
Americas, Suite 200, New York, New York 10036. Our corporate secretary monitors these communications and will provide a summary of all
received messages to the board at each regularly scheduled meeting of the board. Our board generally meets on a quarterly basis. Where
the nature of a communication warrants, our corporate secretary may determine, in his judgment, to obtain the more immediate attention
of the appropriate committee of the board, non-management directors, independent advisors or our management, as our corporate secretary
considers appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our corporate secretary may decide in the exercise of his or her judgment
whether a response to any stockholder or interested party communication is necessary. This procedure for stockholder and other interested
party communications with the non-management directors is administered by our nominating and governance committee. This procedure does
not apply to (i) communications to non-management directors from our officers or directors who are stockholders or (ii) stockholder proposals
submitted pursuant to Rule 14a-8 under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Director Attendance at Annual Meetings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not have a formal policy regarding attendance by members of our
board at annual meetings of stockholders. We encourage, but do not require, directors to attend. All of our board members serving at the
time of our 2023 annual meeting attended our 2023 annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Code of Business Conduct and Ethics</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board has adopted a written code of business conduct and ethics
that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal
accounting officer and controller, or persons performing similar functions. A copy of the code of business conduct and ethics is available
on the corporate governance section of our website, which is located at http://ir.imux.com. If we make any substantive amendments to,
or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment
or waiver on our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Employee, Officer and Director Hedging</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board has adopted a written insider trading policy applicable to
all directors, officers and employees. Subject individuals are prohibited from engaging in transactions in publicly-traded options, such
as puts and calls, and other derivative securities with respect to the Company&rsquo;s securities, including any hedging or similar transaction
designed to decrease the risks associated with holding Company securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Director Compensation Policy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under our outside director compensation policy effective January 1,
2023, all non-employee directors are entitled to receive the following cash compensation for their services:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each non-employee director receives an annual base retainer of $40,000 except that the non-executive Chairman of the Board receives
an annual base retainer of $67,500;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in addition to the annual base retainer, the chairman of our audit committee receives an annual fee of $20,000 and other members of
our audit committee receive an annual fee of $10,000;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in addition to the annual base retainer, the chairman of our nominating and governance committee receives an annual fee of $10,000
and other members of our nominating and governance committee receive an annual fee of $5,000; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in addition to the annual base retainer, the chairman of our compensation committee receives an annual fee of $15,000 and other members
of our compensation committee receive an annual fee of $7,500.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All cash payments to non-employee directors are paid quarterly in arrears.
We also reimburse our directors for their reasonable expenses incurred in connection with attending board and committee meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The&nbsp;lead&nbsp;independent&nbsp;director&nbsp;is also be entitled
to receive an annual cash retainer of $10,000 paid quarterly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Equity Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to cash compensation, our non-employee directors are also
entitled to equity awards under our outside director compensation policy. Each new non-employee director who first joins us is granted
an initial award of a non-statutory stock option to purchase 20,000 shares of Company common stock, which increased to 32,000 for 2023.
In addition, on the date of each annual meeting of stockholders, each non-employee director who has been a non-employee director for 6
months or more on the date of the annual meeting is granted an annual award of a non-statutory stock option to purchase 10,000 shares
of Company common stock, which increased to 16,000 for 2023. The initial award vests in 36 monthly installments subject to the director&rsquo;s
continued service with the Company. The annual award vests in 12 monthly installments subject to the director&rsquo;s continued service
with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Director Compensation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee retained Aon Hewitt to provide recommendations
on non-employee director compensation based on an analysis of market data compiled from comparable companies in the biotechnology industry.
The following table summarizes compensation paid to our non-employee directors during or with respect to the fiscal year ended December
31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Fees Earned or <BR>Paid in Cash <BR>($)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Option</P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Awards</P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">($)<SUP>(1)</SUP></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">All Other <BR>Compensation <BR>($)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Total <BR>($)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-size: 10pt; text-align: left">Maria T&ouml;rns&eacute;n</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">55,290</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">24,378</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">79,668</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Tamar Howson</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">51,594</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,378</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75,972</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Dr. J&ouml;rg Neermann</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">58,576</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,378</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">82,954</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Dr. Vincent Ossipow<SUP>(2)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,417</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,417</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Barclay Phillips</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">74,783</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,378</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">99,161</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Dr. Richard Rudick</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">29,794</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">65,904</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">95,698</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD>The amounts in the &ldquo;Option Awards&rdquo; column reflect
the aggregate grant date fair value of stock options granted during the calendar year computed in accordance with the provisions of Accounting
Standards Codification (&ldquo;ASC 718&rdquo;) Compensation &ndash; Stock Compensation. The assumptions that we used to calculate these
amounts are discussed in Note 7 to our financial statements appearing at the end of our Annual Report on Form 10-K for the year ended
December 31, 2023. These amounts do not reflect the actual economic value that will be realized by the director upon the vesting of the
stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.<BR></TD>
</TR></TABLE>

<P></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD>Dr. Ossipow served out the rest of his term until June 28, 2023
and did not stand for re-election at the 2023 annual meeting.<BR></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL NUMBER 1<BR>
ELECTION OF CLASS I DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors is currently composed of eight directors and
is divided into three staggered classes of directors. At the annual meeting, two Class I Directors will be elected to our board of directors
by the holders of our common stock. Each Class I Director&rsquo;s term continues until our 2027 annual meeting and the election and qualification
of his or her successor, or such director&rsquo;s earlier death, resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Nominees for Director</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our nominating and governance committee recommended for nomination
and our board of directors nominated Dr. Daniel Vitt and Dr. Duane Nash for election as Class I Directors at the annual meeting. If elected,
they will serve as Class I Directors until the 2027 annual meeting and until their respective successors are duly elected and qualified.
For more information concerning Dr. Daniel Vitt and Dr. Duane Nash, please see the section entitled &ldquo;<I>Board of Directors and Corporate
Governance</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Daniel Vitt and Dr. Duane Nash have agreed to serve if elected,
and management has no reason to believe that they will be unavailable to serve. In the event that any of them is unable or declines to
serve as a director at the time of the annual meeting, proxies will be voted for any nominees who may be proposed by the nominating and
governance committee and designated by the present board of directors to fill the vacancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Required Vote</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Class I Directors elected to the board of directors will be elected
by a plurality of the votes cast by the holders of shares present in person or represented by proxy and entitled to vote on the election
of directors. In other words, if Dr. Daniel Vitt or Dr. Duane Nash receives a single &ldquo;FOR&rdquo; vote, he will be elected as Class
I Director. Shares represented by executed proxies will be voted, if authority to do so is not expressly withheld, for the election of
Dr. Daniel Vitt and Dr. Duane Nash. Broker non-votes will have no effect on this proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Board Recommendation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our board of directors recommends a vote &ldquo;FOR&rdquo; the election
to the board of directors of Dr. Daniel Vitt and Dr. Duane Nash as Class I Directors</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL NUMBER 2<BR>
RATIFICATION OF APPOINTMENT OF INDEPENDENT<BR>
REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee has appointed Baker Tilly US, LLP (&ldquo;Baker
Tilly&rdquo;) as the independent registered public accounting firm to audit our consolidated financial statements for the year ending
December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding such appointment and even if our stockholders ratify
such appointment, our audit committee, in its discretion, may appoint another independent registered public accounting firm at any time
during the year if it believes that such a change would be in the best interests of the Company and its stockholders. Our audit committee
is submitting the appointment of Baker Tilly to our stockholders because we value our stockholders&rsquo; views on such appointment and
as a matter of good corporate governance. If the appointment is not ratified by our stockholders, our audit committee may consider appointing
another independent registered public accounting firm. A representative of Baker Tilly is expected to attend the annual meeting, where
he or she will be available to respond to appropriate questions and, if he or she desires, to make a statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fees Paid to the Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following
table represents aggregate fees for services provided to us by Baker Tilly, our principal accountant. All fees below were pre-approved
by the audit committee</FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Fiscal Year</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023<BR>
($)</B></FONT></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022<BR>
($)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Audit Fees <SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">319,236</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">283,180</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Audit-related Fees<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">142,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">122,500</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Tax Fees</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">All Other Fees</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Total Fees</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">461,236</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">405,680</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P>(1) Includes professional services rendered for the audit of the Company&rsquo;s annual financial statements and review of financial
statements included in Forms 10-Q, or services normally provided in connection with statutory and regulatory filings (i.e., attest services
required by Section 404 of the Sarbanes-Oxley Act), including out-of-pocket expenses. <BR>
(2) Audit-related fees represent fees for services relating to comfort letters and registration statement filings.&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Auditor Independence</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2023, there were no other professional services provided by Baker
Tilly that would have required our audit committee to consider their compatibility with maintaining the independence of Baker Tilly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Pre-Approval Policy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee&rsquo;s policy is to pre-approve all audit and
permissible non-audit services provided by the independent accountants. These services may include audit services, audit-related services,
tax services and other services. Our audit committee generally pre-approves particular services or categories of services on a case-by-case
basis. The independent registered public accounting firm and management are required to periodically report to our audit committee regarding
the extent of services provided by the independent registered public accounting firm in accordance with these pre-approvals, and the fees
for the services performed to date. All of the services of Baker Tilly for 2023 and 2022 described above were pre-approved by our audit
committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Required Vote</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ratification of the appointment of Baker Tilly as our independent registered
public accounting firm for the year ending December 31, 2024 requires the affirmative &ldquo;FOR&rdquo; vote of a majority of the shares
present in person or represented by proxy at the annual meeting and entitled to vote on the proposal. You may vote &ldquo;FOR,&rdquo;
&ldquo;AGAINST,&rdquo; or &ldquo;ABSTAIN&rdquo; on this proposal. Abstentions have the same effect as a vote against the proposal. Broker
non-votes will not affect the outcome of voting on this proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Board Recommendation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our board of directors recommends a vote &ldquo;FOR&rdquo; the ratification
of the appointment of Baker Tilly as our independent registered public accounting firm for the year ending December 31, 2024.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL NUMBER 3<BR>
<BR>
TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING THE COMPANY&rsquo;S NAMED EXECUTIVE OFFICER COMPENSATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with Section 14A of the Exchange Act and the related
rules of the SEC, the Company is asking its stockholders to vote to approve, on an advisory (non-binding) basis, the compensation of our
named executive officers as disclosed in this proxy statement. This proposal, commonly known as a &ldquo;say-on-pay&rdquo; proposal, gives
our stockholders the opportunity to express their views on the compensation of our named executive officers. This vote is not intended
to address any specific item of compensation, but rather the overall compensation of our named executive officers and the principles,
policies and practices described in this proxy statement. Accordingly, the following advisory resolution is submitted for stockholder
vote at the annual meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">RESOLVED, that the stockholders of Immunic, Inc. (the &ldquo;Company&rdquo;)
approve, on an advisory basis, the compensation of the Company&rsquo;s named executive officers as disclosed in this proxy statement pursuant
to the compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables regarding named executive
officer compensation and the narrative disclosures that accompany the compensation tables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although the &ldquo;say-on-pay&rdquo; vote is non-binding, the board
of directors and the compensation committee will carefully review and consider the voting results when evaluating our named executive
officer compensation program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Required Vote</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Say on Pay Proposal requires the affirmative vote of a majority
of the shares present in person or represented by proxy at the annual meeting and entitled to vote thereon to be approved. You may vote
&ldquo;FOR,&rdquo; &ldquo;AGAINST,&rdquo; or &ldquo;ABSTAIN&rdquo; on this proposal. Abstentions will count towards the quorum requirement
for the annual meeting and will have the same effect as a vote against the proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board Recommendation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Our board of directors recommends a vote &ldquo;FOR&rdquo;
the approval of the non-binding advisory resolution approving the Company&rsquo;s Named Executive Officer compensation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">REPORT OF THE AUDIT COMMITTEE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The audit committee (which, as of the date below, is composed of the
undersigned directors) is a committee of the board of directors comprised solely of independent directors as required by the listing standards
of Nasdaq and rules and regulations of the SEC. The audit committee operates under a written charter approved by our board of directors,
which is available on Immunic&rsquo;s web site at http://ir.imux.com/documents-and-charters. The audit committee held four meetings during
fiscal year 2023. The meetings of the audit committee are designed to facilitate and encourage communication among the audit committee,
the Company, and the Company&rsquo;s independent auditor. The composition of the audit committee, the attributes of its members and the
responsibilities of the audit committee, as reflected in its charter, are intended to comply with applicable requirements for corporate
audit committees. The audit committee reviews and assesses the adequacy of its charter and its performance on an annual basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With respect to our financial reporting process, our management is
responsible for (i) establishing and maintaining internal controls and (ii) preparing our consolidated financial statements. Our independent
registered public accounting firm is responsible for performing an independent audit of our consolidated financial statements in accordance
with the auditing standards of the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;), and to issue a report
thereon. It is the responsibility of the audit committee to oversee these activities. Specifically, the audit committee is responsible
for the appointment, compensation, and general oversight of the external auditor, as well as fee negotiations with the external auditor.
It is not the responsibility of the audit committee to prepare Immunic&rsquo;s financial statements. These are the fundamental responsibilities
of management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the performance of its oversight function, the audit committee has:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reviewed and discussed the audited financial statements for fiscal year 2023 with the management of Immunic;&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>discussed with Baker Tilly the matters required to be discussed by Auditing Standard No. 16, Communications with Audit Committees,
as amended (AICPA, Professional Standards, Vol. 1, section 380), and as adopted by the PCAOB in Rule 3200T; and&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>received the written disclosures and the letter from Baker Tilly as required by applicable requirements of the PCAOB regarding Baker
Tilly&rsquo;s communications with the audit committee concerning independence, and has discussed with Baker Tilly its independence.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the audit committee&rsquo;s review of our audited financial
statements and the various discussions with management and Baker Tilly, the audit committee recommended to the board of directors that
our audited financial statements be included in our annual report on Form 10-K for the fiscal year ended December 31, 2023 for filing
with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This report of the audit committee shall not be deemed to be &ldquo;soliciting
material&rdquo; or to be &ldquo;filed&rdquo; with the SEC or subject to Regulation 14A promulgated by the SEC or Section 18 of the Exchange
Act, and shall not be deemed incorporated by reference into any prior or subsequent filing by Immunic under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), or the Exchange Act, except to the extent Immunic specifically requests that the information
be treated as &ldquo;soliciting material&rdquo; or specifically incorporates it by reference</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Barclay Phillips, Chair<BR>
Maria T&ouml;rns&eacute;n<BR>
Dr. J&ouml;rg Neermann</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 23, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">EXECUTIVE OFFICERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The names of our executive officers, their ages, their positions with
Immunic and other biographical information as of April 23, 2024, are set forth below. There are no family relationships among any of our
directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dr. Daniel Vitt</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">55</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer, President, Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Dr. Hella Kohlhof</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">51</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Scientific Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dr. Andreas Muehler</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">60</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Medical Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Inderpal Singh</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">58</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">General Counsel</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Patrick Walsh</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">41</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Business Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Glenn Whaley</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">56</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dr. Hella Kohlhof</B>. Dr. Kohlhof joined Immunic in 2017 as our
Chief Scientific Officer. She studied biology in Aachen, Gothenborg (Sweden) and Munich and received her Doctorate in Biology from the
Ludwig Maximilians University of Munich (Germany). During her Ph.D. and post-doctoral position at the Institute of Clinical Molecular
Biology and Tumor Genetics at the Helmholtz Centre in Munich, she worked on the normal and malignant B cell development influenced by
Notch and Epstein Barr Virus mediated signaling. In 2008, she joined 4SC AG as a research scientist and group leader and established the
research laboratory for translational pharmacology. She worked on 4SC&rsquo;s preclinical and clinical stage projects from the oncology
and immunology field, including IMU-838 and IMU-366. From 2011 onward, Dr. Kohlhof was responsible for the management and development
of 4SC&rsquo;s epigenetic clinical stage small molecule inhibitor 4SC-202. In early 2015, as Director of Development Projects, she took
over responsibility for the complete development portfolio of 4SC AG. She currently serves as managing director of Immunic Research GmbH,
a German subsidiary of the Company, and Constanze Investment GmbH, a German limited liability company, respectively. Dr. Kohlhof has a
strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational
pharmacology, clinical trial design and bio-marker development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dr. Andreas Muehler</B>. Dr. Muehler joined Immunic in August 2016
as our Chief Medical Officer. Dr. Muehler received his medical degree (MD) from Humboldt-University in Berlin, Germany, and an MBA degree
from Duke University. After a short period in clinical work, Dr. Muehler has worked within the pharmaceutical industry since 1992, mostly
in the U.S., with leadership positions in preclinical and clinical development, business development and licensing and marketing. Since
2003, Dr. Muehler developed and managed multiple medical companies in the U.S. Among them were 3TP LLC d/b/a CAD Sciences (White Plains,
NY), a medical software company developing an imaging solution for early detection of breast and prostate cancer, and Cellectar Biosciences,
Inc. (Madison, WI), a biotech company developing new cancer therapeutics and cancer imaging agents. Dr. Muehler was also President and
CEO of MicroMRI Inc. (Langhorne, PA), a medical device company developing solutions for improved osteoporosis diagnosis and therapy monitoring
based on bone micro-architecture. He has been on the board of directors of multiple small medical technology companies. After moving to
Munich in 2009, Dr. Muehler became managing director of the small healthcare private equity fund Palladius Healthcare GmbH (Munich, Germany),
which acquired distressed medical technology companies. Thereafter, Dr. Muehler worked as interim manager and independent senior medical
consultant with multiple assignments for clients in the pharmaceutical and medical device industries. Dr. Muehler presently serves as
managing director of Xanomed GmbH, a German limited liability company, and is sole owner of Xanomed Holding USA, a Florida sole proprietorship.<FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Inderpal
Singh</B>. Mr. Singh joined Immunic in June 2021 as our General Counsel. He joined from Sandoz International GmbH, where he served as
the Global Legal Head of Biopharma since January 2018. After earning his college degree in India, Mr. Singh qualified as an attorney with
specialization in Corporate and Commercial Law at Johannes-Gutenberg University in Mainz, Germany. Mr. Singh completed two executive MBA
programs at the University of Mannheim, Germany and INSEAD Business School in Fontainebleau, France. During his tenure at Sandoz and as
a member of various leadership teams, he was responsible for all legal activities, including development, regulatory, and medical matters,
as well as commercial operations, business development, alliance management and market access for biopharma. Before that, from 2015 through
2017, Mr. Singh served at Merck KGaA as Global Legal Head of Global Manufacturing and Supply and Regional Counsel of Middle East and Africa,
Commonwealth of Independent States and Turkey. From 2013 to 2015, he was Legal Director (Europe) at Biogen Idec International GmbH. Earlier
in his career, Mr. Singh spent 15 years in legal positions of increasing responsibility at Pfizer Deutschland GmbH and Pfizer Inc. (U.S.).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Patrick Walsh</B>. Mr. Walsh joined Immunic in October 2021 as our
Chief Business Officer. He joined from Akebia Therapeutics, Inc., where he served as Vice President of Business Development from July
2015 until October 2021 and completed an array of strategic transactions, including multiple partnerships, in-licenses, non-dilutive financings,
and a merger. Mr. Walsh holds both an M.S. in molecular, cellular and developmental biology and an MBA from the University of Michigan
and a B.A. in biology and economics from Colby College. Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which
time he worked on all aspects of business development. Earlier in his career, Mr. Walsh was a consultant to life science companies with
Capgemini SE and was on the healthcare investment banking team at Leerink Partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Glenn Whaley</B>. Mr. Whaley joined Immunic as Principal Accounting
Officer and Controller in December 2019. In April 2020, he was promoted to the position of Vice President Finance, Principal Financial
and Accounting Officer. In March 2022, he was promoted to the position of Chief Financial Officer. Mr. Whaley has more than 30 years of
experience in accounting and finance roles. Prior to joining us, Mr. Whaley was Vice President of Finance at Pernix Therapeutics, a branded
and generics pharmaceutical company, from March 2015 until May 2019. His responsibilities included Principal Financial and Accounting
Officer, from November 2018 until May 2019, Principal Accounting Officer and Controller from December 2017 until November 2018 and Vice
President of Financial Planning and Analysis from March 2015 until November 2017. Mr. Whaley was Vice President of Finance for Alvogen,
Inc, a global pharmaceutical company, from May 2011 until March 2015. His responsibilities included Vice President Finance of U.S. Operations
from August 2013 to March 2015 and Global Corporate Controller from May 2011 to August 2013. Prior to Alvogen, Mr. Whaley served as Corporate
Controller for ImClone Systems, a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology, from January
2007 to May 2011 and Senior Director of Financial Reporting from January 2005 to December 2006. Prior to ImClone Systems, Mr. Whaley served
in financial roles at increasing levels of responsibility in public accounting and the pharmaceutical and telecommunications industries.
Mr. Whaley holds a Bachelor of Science degree from Rutgers University Business School and is a Member of the New Jersey Society of Certified
Public Accountants and the American Institute of Certified Public Accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Biographical information for Dr. Daniel Vitt is set forth above in
the section titled &ldquo;<I>Board of Directors and Corporate Governance</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">EXECUTIVE COMPENSATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Processes and Procedures for Executive Compensation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee assists our board of directors in discharging
its responsibilities relating to oversight of the compensation of our chief executive officer and our other executive officers, including
reviewing and making recommendations to the board with respect to the compensation, plans, policies and programs for our chief executive
officer and our other executive officers and administering our equity compensation plans for our executive officers and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee annually reviews the compensation, plans,
policies and programs for our chief executive officer and our other executive officers. In connection therewith, our compensation committee
considers, among other things, each executive officer&rsquo;s performance in light of established individual and corporate goals and objectives
and the recommendations of our chief executive officer. In particular, our compensation committee considers the recommendations of our
chief executive officer when reviewing base salary and incentive performance compensation levels of our executive officers and when setting
specific individual and corporate performance targets under our annual executive incentive bonus plan for our executive officers. Our
chief executive officer has no input and is not present during voting or deliberations about his compensation. Our compensation committee
may delegate its authority to a subcommittee, but it may not delegate any power or authority required by agreement, law, regulation or
listing standard to be exercised by the compensation committee as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our nominating and governance committee has authority to review and
recommend to the board compensation programs for our outside directors, although this role has been predominantly undertaken by our compensation
committee, in consultation with members of our full board. Management generally does not have a role in the setting of director compensation.
Our nominating and governance committee may delegate its authority to a subcommittee, but it may not delegate any power or authority required
by agreement, law, regulation or listing standard to be exercised by the nominating and governance committee as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, our compensation committee has engaged Aon Hewitt,
an independent compensation consulting firm, to evaluate our levels and types of executive and director compensation and to recommend
changes as appropriate. Among other objectives, Aon Hewitt has assisted the compensation committee in identifying a peer group of companies
based on our current stage of development for the comparison of executive and director compensation, and has also provided to the compensation
committee comparative data on executive and director compensation practices in our industry and general advice on our executive and director
compensation programs. The compensation committee consults regularly with Aon Hewitt in connection with specific aspects of or questions
relating to our executive and director compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The compensation committee has the sole authority to approve the terms
of any engagement of Aon Hewitt. Although our board of directors and compensation committee consider the advice and recommendations of
our independent compensation consultants as to our executive and director compensation programs, our board of directors and compensation
committee ultimately make their own decisions about these matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The compensation committee has a policy that requires any compensation
consultant retained by the committee to be independent of the Company and management. The compensation committee reviewed the independence
of Aon Hewitt in light of this policy, SEC rules and Nasdaq listing standards regarding compensation consultants and concluded that Aon
Hewitt&rsquo;s work for the compensation committee does not raise any conflict of interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clawback Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recently adopted a written compensation recovery policy in accordance
with applicable Nasdaq rules, a copy of which was filed as an exhibit to our Annual Report on Form 10-K filed with the SEC on February
22, 2024. The policy, which is effective as of October 2, 2023, generally provides that we will seek to recover incentive-based compensation
received by any current or former executive officer, without regard to any fault or misconduct of such executive officer, in the event
of an accounting restatement of the Company&rsquo;s financial statements due to material noncompliance with any financial reporting requirement
under the securities laws during the three completed fiscal years immediately preceding the date we determine that an accounting restatement
is required. This policy supersedes the Compensation Recoupment Policy of the Company that was adopted and approved by the Board on July
2, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Say-on-Pay and Say-When-on-Pay</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hold our advisory vote on executive compensation (commonly known
as a &ldquo;say-on-pay&rdquo; vote) every three years, and hold our advisory vote on the frequency of say-on-pay votes (commonly known
as &ldquo;say-when-on-pay&rdquo; vote) every six years. We are holding an advisory say-on-pay vote at this year&rsquo;s annual meeting
of stockholders (see Proposal Number 3). The Compensation Committee annually reevaluates our compensation practices to determine how they
might be improved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Summary Compensation Table</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our named executive officers (&ldquo;NEOs&rdquo;) for the year ended
December 31, 2023 are Dr. <FONT STYLE="font-family: Times New Roman, Times, Serif">Daniel Vitt, our Chief Executive Officer and President;
Dr. Duane Nash, our Executive Chairman; Dr. </FONT>Andreas Muehler, our Chief Medical Officer; and Glenn Whaley, our Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><B>Name and Principal Position</B></TD>
    <TD STYLE="text-align: center"><B>Year</B></TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Salary</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>($)(1)</B></P>


</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option Awards</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>($)(2)</B></P>


</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stock Awards</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>($)</B></P></TD>
    <TD STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>Non-Equity Incentive Plan Compensation
                                   ($)</B></P></TD>
    <TD STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>All Other Compensation ($)(3)</B></P></TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>($)</B></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">Dr. Daniel Vitt</FONT></TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt">2023</FONT></TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-size: 10pt">585,042</FONT></TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-size: 10pt">341,880</FONT></TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-size: 10pt"><B>---</B></FONT></TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-size: 10pt">284,917</FONT></TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-size: 10pt"><B>---</B></FONT></TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-size: 10pt">1,211,839</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer, President</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">519,574</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1,828,768</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">208,829</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2,557,171</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Dr. Duane Nash<SUP>(4)</SUP></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2023</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">363,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">144,355</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">141,570</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">648,925</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I>Executive Chairman</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">347,403</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">635,187</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">86,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1,068,590</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Dr. Andreas Muehler</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2023</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">493,030</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">150,427</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">185,748</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">16,085</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">845,290</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Medical Officer</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">445,875</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">865,160</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">137,912</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">15,786</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1,464,733</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Glenn Whaley</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2023</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">415,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">125,356</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">161,850</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">702,206</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Financial Officer</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">401,700</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">953,800</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">120,510</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1,476,010</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD>An exchange rate of 1.076 Euro to USD based on the average exchange
rate for 2023 was used to convert payment amounts in euros for the table above for 2023. An exchange rate of 1.056 Euro to USD based
on the average exchange rate for 2022 was used to convert payment amounts in euros for the table above for 2022. Dr. Vitt received payment
of his salary in Euros. Dr. Muehler received payment in both USD and Euros.</TD>
</TR></TABLE>

<P></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD>The amounts in the &ldquo;Option Awards&rdquo; column reflect
the aggregate grant date fair value of stock options granted during the calendar year computed in accordance with the provisions of ASC
718. The assumptions that we used to calculate these amounts are discussed in Note 7 to our financial statements appearing at the end
of our Annual Report on Form 10-K for the year ended December 31, 2023. These amounts do not reflect the actual economic value that will
be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the
common stock underlying such stock options.</TD>
</TR></TABLE>

<P></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD>For Dr. Muehler, represents a pension allowance.&nbsp;&nbsp; </TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD>For 2023 and 2022, the amount in the &ldquo;Salary&rdquo; column
represents combined compensation for service as Executive Chairman and the cash retainer payable for service on the Company&rsquo;s board
of directors.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Pay Versus Performance Disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">In accordance with
SEC rules, set forth below is our analysis of the relationship between the compensation actually paid to our Chief Executive Officer and
other named executive officers (NEOs), and certain financial performance measures over the last three fiscal years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pay versus Performance Disclosure Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 13%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Summary Compensation Table Total for CEO ($)</B></FONT><B><SUP>1</SUP></B></TD>
    <TD STYLE="vertical-align: bottom; width: 13%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Compensation Actually Paid to CEO ($)</B></FONT><B><SUP>2</SUP></B></TD>
    <TD STYLE="vertical-align: bottom; width: 17%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Average <BR>
Summary Compensation Table Total for Non-CEO NEOs ($)</B></FONT><B><SUP>3</SUP></B></TD>
    <TD STYLE="vertical-align: top; width: 15%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Average <BR>
Compensation <BR>
Actually Paid <BR>
to <BR>
Non-CEO <BR>
NEOs ($)</B></FONT><B><SUP>4</SUP></B></TD>
    <TD STYLE="vertical-align: bottom; width: 22%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Value of Initial Fixed</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$100 Investment</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Based on: Company</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total<BR>
Shareholder<BR>
Return ($)</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 14%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Net Income (millions) ($)</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">(g)</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">2023</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">1,211,839</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">1,229,519 </FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">732,140</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">752,923</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">9.81</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">(93.6)</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">2,557,171</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">274,802</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">1,336,444</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">481,980</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">9.16</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">(120.4)</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">1,935,915</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">784,229</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">1,209,075</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">796,055</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">62.92</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">(92.9)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1 </SUP>The dollar amounts reported in this column are the amounts
of total compensation reported for Daniel Vitt, our Chief Executive Officer, for each corresponding year in the &ldquo;Total&rdquo; column
of the Summary Compensation Table in each applicable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2 </SUP>The dollar amounts reported in this column represent the
amount of &ldquo;Compensation Actually Paid&rdquo; to Daniel Vitt as computed in accordance with Item 402(v) of Regulation S-K. The dollar
amounts do not reflect the actual amount of compensation earned by or paid to Daniel Vitt during the applicable year. In accordance with
the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to total compensation, as reported on the Summary
Compensation Table, for Daniel Vitt for each year to determine the compensation actually paid:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; width: 60%"><FONT STYLE="font-size: 10pt"><B>Adjustments to Determine Compensation Actually Paid for CEO</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; width: 13%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 13%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 13%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Total Compensation (from Summary Compensation Table)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">$1,211,839</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$2,557,171</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$1,935,915</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Minus</U></I> amounts reported under the &ldquo;Stock Awards&rdquo; column in the Summary Compensation Table</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Minus</U></I> amounts reported under the &ldquo;Option Awards&rdquo; column in the Summary Compensation Table</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(341,880)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(1,828,768)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(1,379,575)</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Plus</U></I> fair value as of the end of the reported year of awards granted during the reported year that remain unvested as of year end</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">393,594</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">234,357</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">754,846</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Plus</U></I> increase (or <I><U>minus</U></I> decrease) in fair value from the end of the prior year to the end of the reported year of awards granted prior to the reported year that were outstanding and unvested as of the end of the reported year</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(18,927)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(624,700)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(394,128)</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Plus</U></I> increase (or <I><U>minus</U></I> decrease) in fair value from the end of the prior year to vesting date of awards granted prior to the reported year that vested during the reported year</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(15,107)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(63,258)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(132,829)</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Plus</U></I> fair value as of the vesting date of any awards granted and vesting during the reported year</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Minus</U></I> fair value as of the last day of the prior year of any awards for which the vesting conditions failed during the reported year</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation Actually Paid to CEO</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="text-decoration: underline double; font-size: 10pt">$1,229,519</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="text-decoration: underline double; font-size: 10pt">$274,802</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="text-decoration: underline double; font-size: 10pt">$784,229</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3 </SUP>The dollar amounts reported in this column represent the
average of the amounts reported for the company&rsquo;s named executive officers as a group (excluding Daniel Vitt) in the &ldquo;Total&rdquo;
column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers (excluding Daniel
Vitt) included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2023, Dr. Duane Nash, Dr.
Andreas Muehler and Glenn Whaley; (ii) for 2022, Dr. Duane Nash, Dr. Andreas Muehler and Glenn Whaley; and (iii) for 2021, Dr. Duane Nash,
Dr. Andreas Muehler and Glenn Whaley.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4 </SUP>The dollar amounts reported in this column represent the
average amount of &ldquo;compensation actually paid&rdquo; to the named executive officers as a group (excluding Daniel Vitt), as computed
in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by
or paid to the named executive officers as a group (excluding Daniel Vitt) during the applicable year. In accordance with the requirements
of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation for the named executive officers as
a group (excluding Daniel Vitt) for each year to determine the compensation actually paid, using the same methodology described above
in Note 2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; width: 60%"><FONT STYLE="font-size: 10pt"><B>Adjustments to Determine Compensation Actually Paid for Non-CEO NEOs</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; width: 13%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 13%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 13%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Total Compensation (from Summary Compensation Table)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">$732,140</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$1,336,444</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$1,209,075</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Minus</U></I> amounts reported under the &ldquo;Stock Awards&rdquo; column in the Summary Compensation Table</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Minus</U></I> amounts reported under the &ldquo;Option Awards&rdquo; column in the Summary Compensation Table</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(140,046)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(818,049)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(746,710)</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Plus</U></I> fair value as of the end of the reported year of awards granted during the reported year that remain unvested as of year end</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">110,496</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">88,651</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">304,478</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Plus</U></I> increase (or <I><U>minus</U></I> decrease) in fair value from the end of the prior year to the end of the reported year of awards granted prior to the reported year that were outstanding and unvested as of the end of the reported year</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(6,053)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(203,166)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(142,320)</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Plus</U></I> increase (or <I><U>minus</U></I> decrease) in fair value from the end of the prior year to vesting date of awards granted prior to the reported year that vested during the reported year</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(4,063)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">2,394</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">29,586</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Plus</U></I> fair value as of the vesting date of any awards granted and vesting during the reported year</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">60,449</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">75,704</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">141,946</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I><U>Minus</U></I> fair value as of the last day of the prior year of any awards for which the vesting conditions failed during the reported year</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation Actually Paid for Non-CEO NEOs</B></P></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="text-decoration: underline double; font-size: 10pt">$752,923</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="text-decoration: underline double; font-size: 10pt">$481,980</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="text-decoration: underline double; font-size: 10pt">$796,055</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following graph presents the Compensation Actually Paid to our
CEO and other Named Executive Officers versus our Company&rsquo;s 3-year cumulative Total Shareholder Return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 368px; width: 700px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red">&nbsp;</P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following graph presents the Compensation Actually Paid to our
CEO and other Named Executive Officers versus the Company&rsquo;s Net Income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 376px; width: 700px">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Non-Equity Incentive Plan Compensation and Bonus</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We offer our NEOs the opportunity to earn annual discretionary cash
bonuses, as determined by our board of directors or the compensation committee annually at their discretion. Actual bonus amounts for
our NEOs are determined by our compensation committee after consideration of Dr. Vitt&rsquo;s recommendations (except with respect to
his individual bonus). Our CEO makes recommendations to the compensation committee regarding annual bonus payouts for the executive officers
other than himself and does not participate in any discussions with the compensation committee regarding his own compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For 2023, annual bonuses were based on such factors as the board of
directors and the compensation committee deemed appropriate, including a variety of individual and Company priorities and objectives relating
to 2023, as well as each individual NEO&rsquo;s performance as it related to his area of responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2023, the board approved a 75.0% bonus payout for 2022 to
each of Dr. Vitt, Dr. Muehler, and Mr. Whaley. The bonuses were paid in January 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2024, the board approved a 97.5% bonus payout for 2023 to
each of Dr. Vitt, Dr. Muehler, and Mr. Whaley. The bonuses were paid in January 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Agreements With Our Named Executive Officers</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Dr. Daniel Vitt</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 4, 2019, Dr. Daniel Vitt and Immunic AG entered into an
addendum to the service agreement (the &ldquo;Vitt Service Agreement&rdquo;) dated September 29, 2016. This first addendum provided that
Dr. Vitt would continue to serve on the management board of Immunic AG until August 31, 2021and would receive an annual salary of EUR
360,000, to be paid in 12 monthly installments, and an annual bonus of 33% of his annual base salary upon achievement of certain targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2021 and effective September 1, 2021, Dr. Vitt and Immunic
AG entered into a second addendum to the Vitt Service Agreement, which provided an annual salary increase to EUR 414,000, and an annual
target bonus increase to 45%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 10, 2022, Dr. Vitt and Immunic AG entered into a third addendum
to the Vitt Service Agreement whereby Dr. Vitt will receive an annual salary of EUR 492,021, to be paid in 12 monthly installments, and
a targeted yearly bonus of up to EUR 246,011.50 upon achievement of certain targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 16, 2023, Dr. Vitt and Immunic AG entered into a fourth
addendum to the Vitt Service Agreement. Pursuant to the fourth addendum to the Vitt Service Agreement, Dr. Vitt will continue to serve
on the management team of Immunic AG until December 31, 2023. Dr. Vitt will receive an annual salary, effective January 1, 2023, of EUR
543,166, to be paid in 12 monthly installments, and a targeted yearly bonus of up to EUR 271,583 upon achievement of certain targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 18, 2023, Dr. Vitt and Immunic AG entered into a fifth
addendum to the Vitt Service Agreement, pursuant to which Dr. Vitt will continue to serve on the management team of Immunic AG until December
31, 2026. Dr. Vitt will receive an annual salary, effective January 1, 2024, of EUR 565,653, to be paid in 12 monthly installments, and
a targeted yearly bonus of up to EUR 311,573 upon achievement of certain targets. In connection with the fifth addendum, Dr. Vitt was
granted accelerated vesting of stock options upon termination of employment under specified circumstances and a one-year exercise period
following termination, subject to specified conditions including providing post-employment assistance with the transition of his duties
to other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Duane Nash</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 17, 2020, the Company entered into an employment agreement
with the with Dr. Nash (the &ldquo;Executive Chairman Agreement&rdquo;). The Executive Chairman Agreement establishes an &ldquo;at will&rdquo;
employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020.
Pursuant to the Executive Chairman Agreement, Dr. Nash is entitled to receive: (i) a monthly base salary of $25,417 (it being agreed that
such fee shall be inclusive of any fees associated with Mr. Nash&rsquo;s services as both a director of the Company and in the capacity
of Executive Chairman), (ii) employee benefits including, health insurance, dental insurance, basic life and accidental death and dismemberment
insurance, long and short term disability insurance and participation in the Company&rsquo;s 401(k) Plan, and (iii) reimbursements for
pre-approved reasonable business-related expenses incurred in good faith in the performance of the Mr. Nash&rsquo;s duties for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 15, 2020, the Company and Mr. Nash entered into an addendum
to the Executive Chairman Agreement, pursuant to which the term of the agreement was extended to April 15, 2021. The Company agreed to
make a one-time award to Mr. Nash of&nbsp;120,000&nbsp;stock options, which vest in six monthly installments starting on November 15,
2020.&nbsp;On April 15, 2021, the Company and Dr. Nash entered into a second addendum to the Executive Chairman Agreement, pursuant to
which the term of the agreement was extended to April 15, 2022. In connection therewith, the Company made a one-time award of 90,000 stock
options to Dr. Nash, which began to vest monthly over a period of 12 months commencing on May 15, 2021, and increased Dr. Nash&rsquo;s
monthly base salary to $27,960 from $25,417.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 15, 2022, the Company and Dr. Nash entered into a third addendum
to the Executive Chairman Agreement, pursuant to which the term of the agreement was extended to December 31, 2022. In connection therewith,
the Company made a one-time award of 75,000 stock options to Dr. Nash, which will vest monthly over a period of 12 months commencing on
April 10, 2022, and increased Dr. Nash&rsquo;s monthly base salary to $29,358 from $27,960.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 28, 2022, the Company and Dr. Duane Nash entered into Addendum
Number 4 to the Executive Chairman Agreement dated April 17, 2020, to extend the term of Dr. Nash&rsquo;s employment as Executive Chairman
of the Board of Directors of the Company to December 31, 2023. In connection with the addendum, the Company increased Dr. Nash&rsquo;s
monthly base salary to $30,250 from $29,358. On October 17, 2023, the Company and Dr. Duane Nash entered into Addendum Number 5 to the
Executive Chairman Agreement to extend the term of Dr. Nash&rsquo;s employment as Executive Chairman of the Board of Directors of the
Company to December 31, 2024. In connection with the addendum, the Company increased Dr. Nash&rsquo;s monthly base salary to $32,368 from
$30,250.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dr. Andreas Muehler</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Service Agreement with Immunic AG</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 4, 2019, Immunic AG entered into an addendum to the Service
Agreement (as amended, the &ldquo;Muehler Service Agreement&rdquo;), dated August 22, 2016, between Immunic AG and Dr. Andreas Muehler,
our Chief Medical Officer. The Muehler Service Agreement provided that Dr. Muehler would continue to serve on the management board of
Immunic AG until August 31, 2021, would receive an annual salary of EUR 154,000, to be paid in 12 monthly installments, and an annual
bonus of 30% of his annual base salary upon achievement of certain targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 10, 2021, Dr. Muehler and Immunic AG entered into a second
addendum to the Muehler Service Agreement, pursuant to which Dr. Muehler&rsquo;s annual salary was increased to EUR 177,100 and his annual
target bonus was increased to 35%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 10, 2022, Dr. Muehler and Immunic AG entered into a third
addendum to the Muehler Service Agreement. Pursuant to this third amendment, Dr. Muehler will continue to serve on the management team
of Immunic AG until December 31, 2023, and will receive an annual salary of EUR 204,155, to be paid in 12 monthly installments, and a
targeted yearly bonus of up to EUR 81,662 upon achievement of certain targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 16, 2023, Dr. Muehler and Immunic AG entered into a fourth
addendum to the Muehler Service Agreement, dated August 22, 2016, as amended September 4, 2019, June 10, 2021 and January 10, 2022, between
Immunic AG and Dr. Andreas Muehler, the Company&rsquo;s Chief Medical Officer. Pursuant to the Amended Muehler Agreement, Dr. Muehler
will continue to serve on the management team of Immunic AG until December 31, 2023. Dr. Muehler will receive an annual salary of EUR
223,768, to be paid in 12 monthly installments, and a targeted yearly bonus of up to EUR 89,507.20 upon achievement of certain targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 18, 2023, Dr. Muehler and Immunic AG entered into a fifth
addendum to the Muehler Service Agreement, pursuant to which Dr. Muehler will continue to serve on the management team of Immunic AG until
December 31, 2026. Dr. Muehler will receive an annual salary of EUR 231,825, to be paid in 12 monthly installments, and a targeted yearly
bonus of up to EUR 92,730 upon achievement of certain targets. In connection with the Muehler Service Agreement, Dr. Muehler was granted
accelerated vesting of stock options upon termination of employment under specified circumstances and a one-year exercise period following
termination, subject to specified conditions including providing post-employment assistance with the transition of his duties to other
employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employment Agreement with Immunic, Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 4, 2019, Dr. Muehler also entered into a separate employment
agreement (the &ldquo;Muehler Employment Agreement&rdquo;) with the Company. The Muehler Employment Agreement provided that Dr. Muehler
would continue to serve as Chief Medical Officer until August 31, 2021, and would dedicate approximately 40% of his time to the affairs
of the Company and approximately 60% of his time to the affairs of Immunic AG. The Muehler Employment Agreement provided for an annual
salary of $180,000 USD and an annual bonus of at least 18% of his annual base salary upon achievement of certain targets. Dr. Muehler
also received an inaugural equity award of an option to purchase 40,000 shares of Company common stock. Dr. Muehler is also eligible for
reimbursement for certain expenses, and customary insurance and benefits programs of the Company. Effective September 1, 2020, Dr. Muehler&rsquo;s
annual base salary was increased to $198,000. In June 2021 and effective September 1, 2021, Dr. Muehler&rsquo;s annual base salary under
the Muehler Employment Agreement was increased to $227,000 USD, and his yearly target bonus was increased to 35%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective January 10, 2022, Dr. Muehler&rsquo;s base salary that is
paid by the Company was increased from $227,000 to $230,287, and his targeted yearly bonus was changed to up to $92,114.80 upon achievement
of certain targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 19, 2023, Dr. Muehler also entered into a separate employment
agreement (&ldquo;Second Muehler Employment Agreement&rdquo;) with the Company. The Second Muehler Employment Agreement provides that
Dr. Muehler will continue to serve as Chief Medical Officer until December 31, 2026, and will dedicate approximately 50% of his time to
the affairs of the Company and approximately 50% of his time to the affairs of Immunic AG. The agreement provides for an annual salary
of $250,000 USD and an annual bonus of at least 40% of annual base salary upon achievement of certain targets. Dr. Muehler is also eligible
for reimbursement for certain expenses, and customary insurance and benefits programs of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If Dr. Muehler&rsquo;s employment is terminated by the Company without
Cause or by him for Good Reason (each as defined in the Muehler Employment Agreement), he is entitled to (i) twelve months&rsquo; base
salary, (ii) any accrued but unpaid annual bonus for the fiscal year ended prior to termination, and (iii) reimbursement of certain COBRA
premiums. Additionally, all of his outstanding equity awards will vest and become exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Glenn Whaley</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 21, 2019, the Company and Mr. Whaley entered into an offer
letter (the &ldquo;Offer Letter&rdquo;). Pursuant to the Offer Letter, Mr. Whaley initially served as Principal Accounting Officer and
Controller, and he was promoted in April 2020 to Vice President Finance, Principal Financial and Accounting Officer. The Offer Letter
provided for an annual base salary of $295,000 and an annual bonus of 30% of annual base salary upon achievement of certain targets. Effective
September 1, 2020, Mr. Whaley&rsquo;s annual base salary was increased to $320,000. On June 10, 2021, the Company and Mr. Whaley entered
into an employment agreement (the &ldquo;Whaley Employment Agreement&rdquo;) which provided for an annual salary of $390,000 and an annual
bonus of at least 35% of annual base salary upon achievement of certain targets. Effective January 1, 2022, Mr. Whaley&rsquo;s salary
was increased to $401,700 and a yearly target bonus was increased to 40%. Mr. Whaley is also eligible for reimbursement for certain expenses,
and customary insurance and benefits programs of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 10, 2022, Mr. Whaley was promoted to Chief Financial Officer.
In connection with the appointment, the Company made a one-time award to Mr. Whaley of an option to purchase 40,000 shares of the Company&rsquo;s
common stock, of which 25% of the shares vested on March 10, 2023, with the remainder vesting monthly thereafter over a total of 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Potential Payments Upon Termination or Change
in Control</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Vitt is entitled to severance of one year&rsquo;s salary and a
bonus upon (i) the conclusion of his term of service under the Vitt Service Agreement, as such term may be further amended or extended,
or (ii) the termination of his service before December 31, 2026, in each case provided that such non-extension or termination is not due
to serious cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon Dr. Nash&rsquo;s termination of employment for any reason, Dr.
Nash shall receive (a) a lump sum payment on the Date of Termination in an amount equal to the sum of the earned but unpaid Base Salary
through Date of Termination (Base Salary and Date of Termination as defined in the Executive Chairman Agreement); plus (b) any other benefits
or rights accrued or earned through his Date of Termination in accordance with the terms of the applicable fringe or employee benefit
plans and programs of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Muehler is entitled to severance of one year&rsquo;s salary and
a bonus upon (i) the conclusion of his term of service under the Amended Muehler Service and Employment Agreement, as such term may be
amended or extended, or (ii) the termination of his service before December 31, 2026, in each case provided that such non-extension or
termination is not due to serious cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If Mr. Whaley&rsquo;s employment is terminated by the Company without
Cause or by him for Good Reason (each as defined in the Whaley Employment Agreement), Mr. Whaley is entitled to (i) twelve months&rsquo;
base salary, (ii) any accrued but unpaid annual bonus for the fiscal year ended prior to termination, (iii) reimbursement of certain COBRA
premiums, and (iv) 50% of his outstanding equity awards will vest and become immediately exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The equity awards granted to our NEOs provide for accelerated vesting
in connection with a change in control in limited circumstances, as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">2019 Omnibus Equity Incentive Plan, as
Amended</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our 2019 Omnibus Equity Incentive Plan, as Amended on June 28, 2023
and March 4, 2024 (the &ldquo;Plan&rdquo;), provides that in the event of a Corporate Transaction, as defined in the Plan, (i) with respect
to unvested awards, unless such awards are assumed by the acquiring or succeeding corporation or replaced with equivalent awards, the
administrator will cancel such awards (unless the administrator accelerates their vesting), and (ii) with respect to vested awards, the
administrator may (a) allow grantees to exercise such awards within a reasonable period prior to the consummation of the Corporate Transaction
and cancel any outstanding awards that remain unexercised upon consummation of the Corporate Transaction, or (b) cancel any or all of
such outstanding awards in exchange for a payment equal to the amount that the grantee would have received (net of the exercise price)
if such vested awards were exercised immediately prior to the consummation of the Corporate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, pursuant to their stock option agreements, certain optionees,
including our named executive officers who have awards under the Plan, are eligible for full vesting acceleration of their outstanding
options in the event their service is terminated other than for cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Outstanding Equity Awards as of March
31, 2024</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth certain information concerning outstanding
equity for our named executive officers as of March 31, 2024. The Company is presenting this information as of March 31, 2024, rather
than as of fiscal year-end December 31, 2023, because of the repricing of certain stock options in March 2024 (as described in note 2
to the table) and material grants of stock options on January 17, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="12" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>OUTSTANDING OPTION AWARDS AS OF MARCH 31, 2024</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vesting</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commencement Date</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(1)</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Underlying Unexercised Options
Exercisable</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(#)</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Underlying Unexercised Options
Unexercisable</B>&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(#)</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>Option Exercise Price as of December
31, 2023</B>&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>($)</B>&nbsp;</P></TD>
    <TD STYLE="width: 11%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option Exercise Price as of March 31, 2024</B>&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>($) (2)</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option Expiration Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dr. Daniel Vitt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/17/2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">--- </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,160,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.21</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/17/2034</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer, President</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/2/2023</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">87,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">212,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.40</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/23/2033</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6/15/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,375</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,625</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.40</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6/15/2032</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/3/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">116,458</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">98,542</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.73</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/3/2032</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3/1/2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">86,250</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28,750</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15.72</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3/1/2031</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7/2/2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">73,336</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,664</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12.30</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">7/2/2030</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8/1/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">65,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13.29</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">8/1/2029</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dr. Duane Nash</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/17/2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">250,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.21</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/17/2034</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><I>Executive Chairman</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/2/2023</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">132,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.40</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/2/2033</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6/15/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.40</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6/15/2032</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3/10/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">75,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.88</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3/10/2032</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6/10/2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14.77</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6/10/2031</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4/15/2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">90,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15.44</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">4/15/2031</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10/22/2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">120,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17.00</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">10/22/2030</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7/2/2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">45,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12.30</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">7/2/2030</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7/22/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">29,959</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13.63</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">7/22/2029</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Glenn Whaley</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/17/2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">295,400</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.21</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/17/2034</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Financial Officer</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/2/2023</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32,083</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">77,917</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.40</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/2/2033</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6/15/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,375</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,625</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.40</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6/15/2032</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3/10/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.88</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3/10/2032</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/3/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">37,916</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32,084</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.73</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/3/2032</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3/1/2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15.72</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3/1/2031</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7/2/2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12.30</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">7/2/2030</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4/29/2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14,688</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">312</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.84</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">4/29/2030</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12/1/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7.37</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">12/1/2029</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dr. Andreas Muehler</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/17/2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">335,400</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.21</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/17/2034</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Medical Officer</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/2/2023</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">38,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">93,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.40</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/2/2033</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6/15/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,375</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,625</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.40</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6/15/2032</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1/3/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">54,166</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">45,834</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.73</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1/3/2032</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3/1/2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48,750</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">16,250</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15.72</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3/1/2031</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7/2/2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">40,336</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,664</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12.30</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">7/2/2030</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8/12/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13.34</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">8/12/2029</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8/1/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">---</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13.29</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">8/1/2029</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) All options vest 25% on the first anniversary of the vesting commencement
date and then in monthly installments over the following 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">(2) At a Special Meeting of Stockholders
held on March 4, 2024, our stockholders approved</FONT> t<FONT STYLE="font-size: 10pt">he repricing of outstanding stock options having
an exercise price above $3.00 per share to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by
the board of directors. Our board of directors then determined that the repricing date will be March 4, 2024 and that the exercise price
of options having an exercise price above $3.00 per share will be repriced to $1.72 per share, which is greater than $1.683 (110% of the
closing price of $1.53 on March 4, 2024). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Perquisites, Health, Welfare and Retirement
Benefits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our named
executive officers in the U.S. are eligible to participate in our employee benefit plans, including our medical, dental, vision, group
life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as all of our other employees.
</FONT>We provide a 401(k) savings plan to our employees, including our current named executive officers, as discussed in the section
below entitled &ldquo;401(k) Plan.&rdquo; Our NEOs in Germany receive health benefits through the German national healthcare system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We generally do not provide perquisites or personal benefits to our
named executive officers, except in limited circumstances and as noted in the Summary Compensation Table above. Our board of directors
may elect to adopt qualified or non-qualified benefit plans in the future if it determines that doing so is in our best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">401(k) Plan</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain a tax-qualified retirement plan that provides eligible
U.S. employees, including named executive officers, with an opportunity to save for retirement on a tax advantaged basis. All participants&rsquo;
interests in their deferrals are 100% vested when contributed. Pre-tax and after-tax contributions are allocated to each participant&rsquo;s
individual account and are then invested in selected investment alternatives according to the participant&rsquo;s directions. Currently,
we do not make matching contributions into the plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Internal
Revenue Code. As a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable
to the employees until distributed from the 401(k) plan, and all matching contributions, if any, are deductible by us when made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Equity Compensation Plans</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes information about our equity compensation
plans as of March 31, 2024. All outstanding option awards relate to our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Plan Category</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of securities to be issued upon exercise of Outstanding Options, Warrants and Rights (a)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Weighted-Average Exercise</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Price of Outstanding Options,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants and</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rights</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(b)</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Equity compensation plans approved by security holders:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; font-size: 10pt; text-align: left">2021 Employee Stock Purchase Plan (1):</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">1,000,011</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Amended 2019 Omnibus Equity Compensation Plan (2):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,318,323</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt; text-align: right">$1.68</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,131,506</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Assumed Vital Equity Compensation Plans:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">89,561</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Equity compensation plans not approved by security holders:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">10,318,323</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">10,221,078</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) At a Special Meeting of Stockholders held on March 4, 2024, our
stockholders approved an amendment to our Amended and Restated 2021 Employee Stock Purchase Plan to increase the number of shares of common
stock reserved for delivery under such plan by 1,000,000 shares to a total of 1,200,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) At a Special Meeting of Stockholders held on March 4, 2024, our
stockholders approved an amendment to our 2019 Omnibus Equity Incentive Plan, as Amended, to increase the number of shares of common stock
authorized for issuance by 9,100,000 shares to a total of 19,448,871 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Compensation Committee Report</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The compensation committee (which, as of the date below, is composed
of the undersigned directors) has reviewed and discussed the foregoing &ldquo;Executive Compensation&rdquo; section of this proxy statement
with management. Based on this review and discussion, the compensation committee recommended to our board of directors that such information
be included in this proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The report of the compensation committee shall not be deemed to be
&ldquo;soliciting material&rdquo; or to be &ldquo;filed&rdquo; with the SEC or subject to Regulation 14A promulgated by the SEC or Section
18 of the Exchange Act, and shall not be deemed incorporated by reference into any prior or subsequent filing by Immunic under the Securities
Act or the Exchange Act, except to the extent Immunic specifically requests that the information be treated as &ldquo;soliciting material&rdquo;
or specifically incorporates it by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tamar Howson, Chair<BR>
Maria T&ouml;rns&eacute;n<BR>
Dr. Richard Rudick</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 23, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">RELATED PERSON TRANSACTIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Related Person Transactions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not been a party to any transactions in which the amount involved
exceeded $120,000 and in which any of our executive officers, directors, promoters or beneficial holders of more than 5% of our capital
stock had or will have a direct or indirect material interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indemnification of Officers and Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered into indemnification agreements with each of our directors
and executive officers. The indemnification agreements, our amended and restated certificate of incorporation and our amended and restated
bylaws require us to indemnify our directors, executive officers and certain controlling persons to the fullest extent permitted by Delaware
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Related Person Transactions Policy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We adopted a written Related Person Transactions Policy that sets forth
our policies and procedures regarding the identification, review, consideration, approval and oversight of &ldquo;related person transactions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of our policy only, a &ldquo;related person transaction&rdquo;
is a past, present or future transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships)
in which we and any &ldquo;related person&rdquo; are participants, the amount involved exceeds $120,000 and a related person has a direct
or indirect material interest. Various transactions are not covered by this policy, including transactions involving compensation for
services provided to us as an employee, director, consultant or similar capacity by a related person, equity and debt financing transactions
with a related person that are approved by the board, and other transactions not otherwise required to be disclosed under Item 404 of
Regulation S-K. A &ldquo;related person&rdquo; is any executive officer, director or nominee to become director, a holder of more than
5% of our common stock, including any immediate family members of such persons. Any related person transaction may only be consummated
if approved or ratified by the affirmative vote of seventy-five percent (75%) of our disinterested directors then in office in accordance
with the policy guidelines set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the policy, where a transaction has been identified as a related
person transaction, management must present information regarding the proposed related person transaction to our audit committee for review
and recommendation for approval to our board of directors. In considering related person transactions, our audit committee and board of
directors take into account the relevant available facts and circumstances including, but not limited to whether the terms of such transaction
are no less favorable than terms generally available to an unaffiliated third-party under the same or similar circumstances and the extent
of the related person&rsquo;s interest in the transaction. In the event a director has an interest in the proposed transaction, the director
must recuse himself or herself from the deliberations and approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">SECURITY OWNERSHIP</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the beneficial ownership of our common
stock as of March 31, 2024 by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each person, or group of affiliated persons, who we know to beneficially own more than 5% of our common stock;&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each of our named executive officers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each of our directors; and&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>all of our executive officers and directors as a group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The percentage ownership information shown in the table is based on
an aggregate of 90,079,016 shares of our common stock outstanding as of March 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have determined beneficial ownership in accordance with the rules
of the Securities and Exchange Commission. These rules generally attribute beneficial ownership of securities to persons who possess sole
or shared voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable
pursuant to the exercise of stock options and warrants that are either immediately exercisable or exercisable on or before May 30, 2024
which is 60 days after March 31, 2024. These shares are deemed to be outstanding and beneficially owned by the person holding those options
and warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose
of computing the percentage ownership of any other person. The table does not include shares of common stock issuable pursuant to the
exercise of pre-funded warrants, which are immediately exercisable and remain exercisable until exercised in full for an exercise price
of $0.0001 per share of common stock. However, under the terms of the pre-funded warrants, a stockholder may not exercise the pre-funded
warrants to the extent such exercise would cause such stockholder, together with its affiliates and attribution parties, to beneficially
own a number of shares of common stock which would exceed 9.99% (or for stockholders who so elect, 5.99%) of our then outstanding shares
of common stock following such exercise (excluding for purposes of such determination shares of common stock issuable upon exercise of
such pre-funded warrants which have not been exercised). The amounts set forth in the table below give effect to such beneficial ownership
limitations. For each stockholder in the table below for which such beneficial ownership limitations apply, the number of shares of common
stock issuable pursuant to the exercise of pre-funded warrants held by such stockholder is set forth in the footnote for such stockholder.
Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all
shares shown as beneficially owned by them, subject to applicable community property laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise noted below, the address of each of the individuals
and entities named in the table below is c/o Immunic, Inc., 1200 Avenue of the Americas, Suite 200, New York, New York 10036. Beneficial
ownership representing less than 1% is denoted with an asterisk (*).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Number of Shares of Common Stock Beneficially Owned</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Percentage of Common Stock Beneficially Owned</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-style: italic">5% Stockholders:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">RTW Investments, LP<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">8,902,972</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">9.88</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">BVF Inc.<SUP>(2)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,902,972</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9.88</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Avidity Partners Management LP<SUP>(3)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,902,972</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9.88</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Soleus General Partners<SUP>(4)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,293,007</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8.09</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Janus Henderson Group plc<SUP>(5)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,993,007</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7.76</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Adage Capital Partners LP<SUP>(6)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,594,406</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.21</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Named Executive Officers and Directors:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Duane D. Nash, M.D., J.D.<SUP>(7)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">633,991</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Tamar Howson<SUP>(8)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">79,625</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Dr. Andreas Muehler<SUP>(9)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">562,499</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Dr. J&ouml;rg Neermann<SUP>(10)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">179,625</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Barclay Phillips<SUP>(11)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">79,625</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Maria T&ouml;rns&eacute;n <SUP>(12)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">36,888</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Dr. Daniel Vitt<SUP>(13)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">839,793</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Glenn Whaley<SUP>(14)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">219,882</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Dr. Richard Rudick<SUP>(15)</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">26,221</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt"><P STYLE="margin-top: 0; margin-bottom: 0">All directors and executive officers as a group and certain</P>
                                                                       <P STYLE="margin-top: 0; margin-bottom: 0">former named executive officers (9 people)</P></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,658,149</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3.0</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Less than 1%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Based on Schedule 13G/A filed on February 14, 2023 by RTW Investments, LP as the investment advisor to certain funds with respect
to shares directly held by such funds; and based on the purchase of common stock by funds for which RTW Investments, LP is the investment
manager, in the private placement transaction, which closed on January 8, 2024. The address of RTW Investments, LP is 40 10th Avenue,
7th Floor, New York, NY 10014. The amounts exclude an additional 1,026,762 shares of common stock underlying pre-funded warrants with a
9.99% beneficial ownership limitation. The amounts set forth in the table above give effect to such beneficial ownership limitations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Based on Schedule 13G filed on January 18, 2024 by BVF, Inc. The address of BVF, Inc. is 44 Montgomery St., 40th Floor, San Francisco,
California 94104. The amounts exclude an additional 8,580,151 shares of common stock underlying pre-funded warrants with a 9.99% beneficial
ownership limitation. The amounts set forth in the table above give effect to such beneficial ownership limitations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Based on Schedule 13G filed on January 16, 2024 by Avidity Partners Management LP, and based on the purchase of common stock by entities
affiliated with Avidity Partners Management LP in the private placement transaction, which closed on January 8, 2024. The address of Avidity
Partners Management LP is 2828 N. Harwood Street, Suite 1220, Dallas, Texas 75201. The amounts exclude an additional 1,586,651 shares
of common stock underlying pre-funded warrants with a 9.99% beneficial ownership limitation. The amounts set forth in the table above
give effect to such beneficial ownership limitation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Based on Schedule 13G filed on January 10, 2024 by entities affiliated with Soleus General Partners. The address of Soleus General Partners
is 104 Field Point Road, 2nd Floor, Greenwich, CT 06830.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD> Beneficial ownership of Janus Henderson Group plc is calculated based on the purchase of common stock in the private placement transaction,
which closed on January 8, 2024. The address of Janus Henderson Group plc is 201 Bishopsgate EC2M 3AE, United Kingdom.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(6)</TD><TD>Beneficial ownership of Adage Capital Partners LP is calculated based on the purchase of common stock in the private placement transaction,
which closed on January 8, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(7)</TD><TD>Consists of 22,032 shares of Common Stock and 611,959 options to purchase shares of Common Stock, which are exercisable within sixty
(60) days of March 31, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(8)</TD><TD>Consists of options to purchase shares of Common Stock, which are exercisable within sixty (60) days of March 31, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(9)</TD><TD>Consists of 14,406 shares of Common Stock held directly; 22,863 shares held in the Employee Stock Purchase Plan; 284,480 shares of
common stock held through Xanomed UG (haftungsbeschr&auml;nkt), an entity controlled by Dr. Muehler; and 240,750 options to purchase shares
of common stock, which are exercisable within sixty (60) days of March 31, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(10)</TD><TD>Consists of 100,000 shares of Common Stock and 79,625 options to purchase shares of Common Stock, which are exercisable within sixty
(60) days of March 31, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(11)</TD><TD>Consists of options to purchase shares of Common Stock, which are exercisable within sixty (60) days of March 31, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(12)</TD><TD>Consists of options to purchase shares of Common Stock, which are exercisable within sixty (60) days of March 31, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(13)</TD><TD>Consists of 14,000 shares of Common Stock held directly; 362,877 shares of Common Stock held through Listrax UG (haftungsbeschr&auml;nkt),
an entity controlled by Dr. Vitt; and 462,916 options to purchase shares of Common Stock, which are exercisable within sixty (60) days
of March 31, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(14)</TD><TD>Consists of 25,510 shares of Common Stock and 194,372 options to purchase shares of Common Stock, which are exercisable within sixty
(60) days of March 31, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(15)</TD><TD>Consists of 26,221 options to purchase shares of Common Stock, which are exercisable within sixty (60) days of March 31, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">OTHER MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 16(a) Beneficial Ownership Reporting
Compliance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 16(a) of the Exchange Act requires our executive officers and
directors, and persons who own more than 10% of a registered class of our equity securities, to file reports of ownership and changes
of ownership on Forms 3, 4 and 5 with the SEC. Such directors, executive officers and 10% stockholders are required by SEC regulations
to furnish us with copies of all Section 16(a) forms they file.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based solely on our review of the copies of such forms we have received
and written representations from certain reporting persons that they filed all required reports, we believe that all of our officers,
directors and greater than 10% stockholders complied with all Section 16(a) filing requirements applicable to them with respect to transactions
during 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Fiscal Year 2023 Annual Report</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our financial statements for our fiscal year ended December 31, 2023
are included in our 2023 annual report, which we will make available to stockholders at the same time as this proxy statement. This proxy
statement and our 2023 annual report are posted on our website at http://www.imux.com and at the website of SEC at www.sec.gov. You may
also obtain a copy of our 2023 annual report without charge by sending a written request to Immunic, Inc., Attention: Investor Relations,
1200 Avenue of the Americas, Suite 200, New York, New York 10036, Attention: Investor Relations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Company Website</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain a website at www.imux.com. Information contained on, or
that can be accessed through, our website is not intended to be incorporated by reference into this proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Availability of Bylaws</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of our bylaws may be obtained by accessing Immunic&rsquo;s filings
on the SEC&rsquo;s website at www.sec.gov. You may also contact our corporate secretary for a copy of the relevant bylaw provisions regarding
the requirements for making stockholder proposals and nominating director candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSALS OF STOCKHOLDERS
FOR 2025 ANNUAL MEETING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Stockholder Proposals for Inclusion in Proxy
Statement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stockholders may present proper proposals (other than nominations of
directors) for inclusion in our proxy statement and for consideration at the next annual meeting of stockholders by submitting their proposals
in writing to our corporate secretary in a timely manner. For a stockholder proposal to be considered for inclusion in our proxy statement
for our next annual meeting of stockholders, our corporate secretary must receive the written proposal with all relevant information at
our principal executive offices no later than the close of business on December 23, 2024; provided that in the event that the date of
the 2025 annual meeting is advanced more than 30 days prior to, or delayed by more than 30 days after, the anniversary of this year&rsquo;s
annual meeting, the relevant information must be received by the Company no later than the deadline set forth in a public announcement
to be made by the Company, which deadline will be a reasonable time after that public announcement and a reasonable time before the Company
begins to print and send its proxy materials for the 2025 annual meeting. In addition, stockholder proposals must comply with the requirements
of Rule 14a-8 under the Exchange Act regarding the inclusion of stockholder proposals in company-sponsored proxy materials. Proposals
should be addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immunic, Inc.<BR>
Attn: Corporate Secretary<BR>
1200 Avenue of the Americas, Suite 200<BR>
New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Nominations by a Stockholder Intending to Solicit Proxies
for the 2025 Annual Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to satisfying all applicable requirements under the Company&rsquo;s
bylaws, to comply with the SEC&rsquo;s universal proxy rules for our 2025 annual meeting, stockholders who intend to solicit proxies in
support of director nominees other than the Company&rsquo;s nominees must provide notice that sets forth all of the information required
by Rule 14a-19 under the Exchange Act no later than April 12, 2025; provided that in the event that the date of the 2025 annual meeting
is advanced more than 30 days prior to, or delayed by more than 30 days after, the anniversary of this year&rsquo;s annual meeting, then
such written notice must be received no later than the close of business on the later of the following two dates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>the 90th day prior to such annual meeting, or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>the 10th day following the day on which public announcement
of the date of such meeting is first made.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Stockholder Proposals and Director Nominations
Not for Inclusion in Proxy Statement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our bylaws also establish an advance notice procedure for stockholders
who wish to (i) present a proposal before an annual meeting of stockholders, but do not intend for the proposal to be included in our
proxy statement or (ii) nominate directors for election at an annual meeting of stockholders. In order to be properly brought before our
2025 annual meeting of stockholders, the stockholder must have given timely notice of such proposal or nomination, in proper written form.
To be timely for our 2025 annual meeting of stockholders, a stockholder&rsquo;s notice of a matter that the stockholder wishes to present,
or the person or persons the stockholder wishes to nominate as a director, must be delivered to the corporate secretary at Immunic&rsquo;s
principal executive offices not less than 90 days and not more than 120 days prior to the first anniversary of the date of the preceding
year&rsquo;s annual meeting of stockholders. As a result, any written notice given by a stockholder pursuant to these provisions of our
bylaws must be received by our corporate secretary at our principal executive offices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>not earlier than February 11, 2025, and&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>not later than March 13, 2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event that we hold our 2025 annual meeting of stockholders more
than 30 days before or more than 30 days after the one-year anniversary date of the 2024 annual meeting, then such written notice must
be received no later than the close of business on the later of the following two dates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the 90th day prior to such annual meeting, or&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the 10th day following the day on which public announcement of the date of such meeting is first made.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To be in proper written form, a stockholder&rsquo;s notice must include
the specified information concerning the proposal or nominee as described in our bylaws. Notices should be addressed to:<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immunic, Inc.<BR>
Attn: Corporate Secretary<BR>
1200 Avenue of the Americas, Suite 200<BR>
New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For information on how to access our bylaws, please see the section
entitled &ldquo;<I>Availability of Bylaws</I>,&rdquo; and for additional information regarding stockholder recommendations for director
candidates, please see the section entitled &ldquo;<I>Board of Directors and Corporate Governance-Requirements for Stockholder Recommendations
of a Candidate to our Board</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">*********</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We know of no other matters to be submitted at the 2024 annual meeting.
If any other matters properly come before the 2024 annual meeting, it is the intention of the persons named in the proxy to vote the shares
they represent as the board of directors may recommend. Discretionary authority with respect to such other matters is granted by a properly
submitted proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is important that your shares be represented at the 2024 annual
meeting, regardless of the number of shares that you hold. You are, therefore, urged to vote as promptly as possible to ensure your vote
is recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">THE BOARD OF DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York<BR>
April 23, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNUAL MEETING OF STOCKHOLDERS OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMUNIC, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">June 11, 2024</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GO GREEN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: left">e-Consent makes it easy to go paperless. With e-Consent, you can quickly access your proxy material, statements and other eligible documents
online, while reducing costs, clutter and paper waste. Enroll today via https://equiniti.com/us/ast-access to enjoy online access.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>NOTICE OF INTERNET AVAILABILITY OF PROXY
MATERIAL:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Notice of Meeting, proxy statement and proxy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">card are available at - http://www.astproxyportal.com/ast/22742/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt; font-weight: normal">Please
sign, date and mail<BR>
your proxy card in the<BR>
envelope provided as soon<BR>
as possible</FONT><FONT STYLE="font-size: 14pt">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt; font-weight: normal">&darr;</FONT>
<FONT STYLE="font-size: 10pt; font-weight: normal">Please detach along perforated line and mail in the envelope provided.</FONT> <FONT STYLE="font-size: 12pt; font-weight: normal">&darr;</FONT><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 10%">&nbsp;</TD>
  <TD STYLE="width: 40%"><IMG SRC="image_006.jpg" ALT=""> <FONT>20230300000000001000&#9;3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></TD>
  <TD STYLE="padding-left: 50pt; width: 40%">61124</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 10%">&nbsp;</TD>
  <TD STYLE="text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 7pt"><B>THE BOARD OF DIRECTORS RECOMMENDS
A VOTE "FOR" THE ELECTION OF DIRECTORS, &ldquo;FOR" PROPOSAL 2, AND "FOR" PROPOSAL 3.</B></FONT></P>
                                 <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 7pt"><B>PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED
ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE</B></FONT></P></TD>
  <TD STYLE="text-align: left; width: 10%; vertical-align: bottom">&nbsp;&#9746;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 3%; border-left: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">FOR</FONT></TD>
    <TD STYLE="width: 7%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">AGAINST</FONT></TD>
    <TD STYLE="width: 7%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">ABSTAIN</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">1.</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Election of Directors for a term expiring at the 2027 Annual Meeting of Shareholders</FONT></TD>
    <TD STYLE="border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">2.</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">Ratification of appointment of Baker Tilly US, LLP as our independent registered public accounting
    firm for fiscal year ending December 31, 2024</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9744;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9744;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">FOR</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">AGAINST&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">ABSTAIN</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>NOMINEES:</B></FONT></TD>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">3.</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Approval, by non-binding advisory vote, of the resolution approving named executive officer compensation.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9744;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>FOR ALL NOMINEES</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="image_003.jpg" ALT="" STYLE="height: 9px; width: 16px"></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Dr. Daniel Vitt</FONT></TD>
    <TD STYLE="border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4" ROWSPAN="5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">In their discretion, the proxies
are authorized to vote upon such other business as may properly come before the Annual Meeting. This proxy when properly executed will
be voted as directed herein by the undersigned stockholder. <B>If no direction is made, this proxy will be voted FOR the Nominees in
Proposal 1, &quot;FOR&quot; Proposal 2 and &quot;FOR&quot; Proposal 3&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>WITHHOLD AUTHORITY<BR>
    FOR ALL NOMINEES</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="image_003.jpg" ALT="" STYLE="height: 9px; width: 16px"></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Dr. Duane Nash&nbsp;</FONT></TD>
    <TD STYLE="border-left: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>FOR ALL EXCEPT</B><BR>
    (See instructions below)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="padding-left: 80; vertical-align: top; text-indent: -80"><FONT STYLE="font-size: 7pt"><B><U>INSTRUCTIONS</U></B>:
&nbsp;To withhold authority to vote for any individual nominee(s), mark &ldquo;FOR ALL EXCEPT&rdquo; and fill in the circle next to each nominee
you wish to withhold, as shown here: <IMG SRC="image_005.jpg" ALT=""></FONT></TD>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4"></TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="vertical-align: top"><FONT STYLE="font-size: 7pt">To change the address on your account, please check the
    box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the
    account may not be submitted via this method.</FONT></TD>
    <TD STYLE="border-left: black 1pt solid; text-align: left; vertical-align: middle">&#9744;&nbsp;</TD>
    <TD COLSPAN="4" STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-size: 7pt">MARK "X" HERE IF YOU PLAN TO ATTEND
    THE MEETING.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-left: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="2" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; vertical-align: bottom; width: 13%"><FONT STYLE="font-size: 7pt">Signature of Shareholder</FONT></TD>
  <TD STYLE="border: Black 1pt solid; width: 15%">&nbsp;</TD>
  <TD STYLE="text-align: center; vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 7pt">Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></TD>
  <TD STYLE="border: Black 1pt solid; width: 10%">&nbsp;</TD>
  <TD STYLE="text-align: left; vertical-align: bottom; width: 13%"><FONT STYLE="font-size: 7pt">Signature of Shareholder</FONT></TD>
  <TD STYLE="border: Black 1pt solid; width: 15%">&nbsp;</TD>
  <TD STYLE="text-align: center; vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 7pt">Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></TD>
  <TD STYLE="border: Black 1pt solid; width: 10%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 1%; vertical-align: bottom"><IMG SRC="image_006.jpg" ALT="" STYLE="width: 13px; height: 14px"></TD>
  <TD STYLE="width: 3%"><FONT STYLE="font-size: 7pt"><B>Note:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
  <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as
executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full
corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized
person.</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><IMG SRC="image_006.jpg" ALT="" STYLE="width: 13px; height: 14px"></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F 4L# 2(  A$! Q$!_\0
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M %%%% !16)?>)8-/U"2UE@D8(!ET([C/0X]JV(I!+$D@! =0P!ZC- #Z***
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MR&UZAHK'$0'^\5/'U- 'O%%>1^$?BE>2ZA!8:\8I(IV"+=JH0HQ/&X#C';(
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M?_0EKHOA;X?M['PU'JK1J;V^RQD(Y2,$A5!].-WX^PKG?C-_R$](_P"N,O\
MZ$M=_P"!O^1'T?\ Z]EH L^)],@UCPW?V<Z!@T+%"1]QP,JP]P<5X3X'TB'7
M?%MA:7"!K;)EF4_Q*HSCZ$X!]LU]#7O_ !XW'_7)OY&O#/A1_P CK;_]>TG\
MA0![PB+&@10%4#  & !7BOQ;TR"S\16MY#&J&\A)EVC 9U.-WUP0/PKVRO(_
MC/\ \?FB_P#7.?\ FE 'H'@VX>Z\&Z/-(27-I&I).2<#&?QQ7CGQ4_Y':_\
M^N,?_H KUWP'_P B-H__ %[C^9KR+XIC_BM[_P#ZXQ_^@"@#W^JFJ?\ ()O?
M^N#_ /H)JRCK(@9"&5AD$=Q6?XANDLO#FIW,GW8[61L9QD[3@?4GB@#R'X/?
M\C?/_P!@Z3_T9%7H7Q._Y)[J?^]!_P"CDKS[X/C'C"<>FGR?^C(J]!^)W_)/
M=3_WH/\ T<E 'G_PJT"VU76KF_NXUECL%0QQN,@R-G#>^ I_$@]J]NKR[X,?
M\>>L?]=8_P"1KU&@#P'XFZ1;:5XOE2U14BNH%N3&HP%9BRG'U*Y_&O;M#N7O
M= TVZD)+SVL4C9.>2@)_G7D'Q@_Y'*W_ .P?'_Z,EKUGPO\ \BEHW_7A!_Z+
M% 'BOQ _Y*5J7_76#_T5'7OTDBQ1M(YPJ@LQ] *\!^('_)2M2_ZZP?\ HJ.O
M>+Z%KBPN(%.&DB9!GU(Q0!\]6:7'CCQQ&)F96U"X+N<\QQ@$X'T1<#Z"OH2P
MT^TTNSCL[*!(+>,86-!@#_$^YY->"?#>[CL?'&G&?Y!+N@^;C:S*0!]2<#\:
M^A* ,O6O#VE^(;=(=3M$G6-@R'D,O/(##D XP1WK1BB2"%(HD5(T4*J(,!0.
M@ '04^B@#BOBK_R(MQ_UVB_]"%>$5[O\5?\ D1;C_KM%_P"A"O*-)\.M)MGO
ME*IU6'H6_P![T'MUH =X6,=M=/>7)\N(QF.-V!P6R"<'Z UV45S!./W4T;_[
MK@UCZE;A]-=$4#RP&50, 8_^MFN9P* /0Z*X2*]NX/\ 57,J^P<X_*KL7B#4
M(_O.D@_VD_PQ0!OZU-]GT6\DS@^45!]"WRC^=>;D@#)X KHM:UY[W3?LSPJC
M.X)*L<$#GI]<5M_#?P:=9O%UG48LZ?;M^Z1AQ/(/YJIZ]B>.Q% '3?#3P:=.
M@77-0CQ>3)_H\3=88S_$?1F_0<=R*]'HHH *\V^,G_(!TW_K[_\ 9&KTFJU[
MIUEJ,:QWMI!<HAW*LT8< ],C- '#_!__ )%&Z_Z_G_\ 1<=-^,?_ "*=C_V$
M$_\ 14E=W9V%IIT)BLK6&VC9MQ2&,(">F<#OP/RI+W3[/48EBO;6"YC5MX2:
M,. V",X/?!/YT <3\(/^10N/^OY__0$KOZKV=A::?"8;*UAMHBVXI#&$!/K@
M?058H ^>/^:J_P#<P_\ MS7T/6=_8&C_ &K[5_95E]I\SS?.\A=^_.=V<9SG
MG-:- 'G_ ,8/^11MO^OY/_0'IGP<_P"13OO^P@__ **CKN[RPM-0A$-[:P7,
M0;<$FC#@'IG![\FDLM/L].B:*RM8+:-FWE(8P@+8 S@=\ ?E0!Y1\9O^0GI'
M_7&7_P!"6O0/ W_(CZ/_ ->RUIWFDZ=J+(U]86MTR A3-$KE0>N,BK%O;PVL
M"001)%"@PD<:A54>@ Z4 -O?^/&X_P"N3?R->&?"C_D=;?\ Z]I/Y"O>64.I
M5@"I&"#WJA:Z'I-C.)K/3+.WE (#Q0*K >F0* -"O(_C/_Q^:+_USG_FE>N5
M3O-)T[42AOK&VNC&"$,\2OMSUQD<=!0!D^ _^1&T?_KW'\S7!_%OP]<?;8=>
M@B+V[1"&Y*C/EL"=K'V(.,].!ZUZS;V\-I D%O$D4*#"QQJ%51[ =*>Z*ZE6
M *D$$$9!% 'BWASXJ76D:5#87M@+Q8%"12K+L;:.@;@YP.,__KINK^+-8^(+
M_P!DV%G]DL5'G7&&+_*O.YVP  ,<#N<<UZ3<> O"US,99-&MPQZ^7N0?DI K
M8L])L-/M6M;.RM[>!OO1QQA0WU'>@#QOX/G/C&X/_4/D_P#1D5>A?$[_ ))[
MJ?\ O0?^CDK?M-%TO3YC-9:=:6TI4H7AA5#MX.,@=.!^56;JTM[VW:WNH(IX
M&QNCE0,K8.1D'W - 'FGP8_X\M8_ZZQ_R:O4:JV6F6.FJZV-E;VP<Y<0Q!-Q
M]\=:M4 >(?&#_D<K?_L'Q_\ HR6O6?"__(I:-_UX0?\ HL58N]%TO4)A->Z=
M:7,H4('FA5R%Y.,D=,D_G5N&&.")(HD5(T4*B(,!0.  /2@#P+X@?\E+U+_K
MK!_Z*CKZ K.N-!TB[N6N;G2[*:=B"TLD"LQP,#)(ST _*M&@#Q+XB>"KK3-3
MGUK3HG>PG<RR>6#NMY"<D\<[2>0>W3CBK&C?%Z]M+-(-3L1>N@P)TEV,W^\,
M$$^XQ]*]EK O?!/AO4)3+<:/:F0G):-3&2??:1F@#S#7_BKJNIQ+!ID7]FIN
M!:17WR,1V!P !GVY_.O3-#U?6KS1+2XO]$>*Z=,R+YBISGKM/(R,'!Z9JUIO
MA70M(D62PTJVBD7I)LW./^!')_6MB@#BO$YUG4#]G&F2"S1@PVJ)&8CD$XSC
M':N2='B8K(K(W<,,']:]BIDD22KMD177T89H \>(!!!&01@BN1FB,$\D1ZHQ
M%>_3^'-(N/OV,2GUCRG_ *#BO/\ Q5X0LH-5W0231K+&&Y(89Y']!WH \^HK
M;E\,W"Y,4\3CT8%3_6H8/#6K75Y%:PVP:21L*VX%1[G'04 1>&O#4_BS7Q:K
MN2RM\&YF'\*^@_VCR!]">U>_6EI!8VD5K;1+%!$@2.-1PH':J'ASP_:^&]'C
MT^V^;'SRRD8:60]6/^'8 "M:@ HHHH *":*IZAIEKJD217<9=$;< '*\XQV/
MO0!<S17&+H&G'Q;)8&%OLPLQ*$\QOO;@,YSGI74:?IUMID#0VD92-FWD%BW.
M ._T% %K-+6#;G_BM;[GC[)'_.I?%1_XIF^P?X!W_P!H4 ;(.:3-0V?_ !XV
M_P#US7^5<VFEV>J>*M:%Y&7$7D;,.5QE.>A]A0!U6:6LNRT'3=/N1<6L)27:
M5R9&;@^Q-1>*R1X9O2#@[5_]"% &SFBN7D\.:5%I0N=TMK((0YG6=AM..O7U
MK3\-W-Q>>'[2>Z),S*06(Y8!B ?Q !H U:*HZQJ"Z7I5Q>'DHOR#U8\*/SQ6
M%H"7&C:K_9UW(S_;81<*6.<2@?.OOZ_@* .KI,TM<HFE6FJ^+-96\C:01>24
M =EQE!GH?:@#JZ,XKE[2-=+\5IIUE/(UM+ 7E@=RXB(Z$9Z9X_/Z5H^*"1X:
MOB.NP?S% &OFBN>M_"VC26T3M;L69%)/G/UQ]:VK2VAL[5+>!2L2#"@DG]30
M!-FE)Q6#;'_BM;_G_EUC_G2^,B1X4O2#C_5_^AK0!NTF:1E#H5;H1@UQ_B3P
M_ING:,T]K"R2"1%SYK'@GW- '8YI<UEVGAW3+&Z6YMH&25<X)D8]1CH357Q9
M_P @RW_Z^XOYT ;U(3BEKE;6V/BJZN+J\D?^S(I#'!;JQ"R8ZNV.O^?Q .H5
MU<94AAZ@YIU8:^%K&WNH;BQ,MG)&P+&%SAQZ$'-:]PSI;R/$NZ14)5?4XX%
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M.2VB=]/4LR D^8_7'UK=MX8[:WC@B7;'&@1%] !@"L?_ (1+2?[D_P#W_?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &: PP# 2(  A$! Q$!_\0
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M*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\
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M_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\
M^?"U_P"_*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ
M?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/
M_P"?"U_[\K_A5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E
M_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q
M=/\ ^?"U_P"_*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *
M7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C
M^Q=/_P"?"U_[\K_A5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5V
MB@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\
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M110 4444 %>>?$;XN'PAKVG>&=#T*X\6>+]0A:Y@TJWF2!(X%.#--,_$:9R
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MJ.C>*;RQT^X!8M;0^3&-BY/3#O\ ]]&MGX%LK?";X@@$$KKVN X/0^:Y_J*
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M_B2\^*WPS^&OPSNSOU>?5SIWB&(G)6VTUP9MW^_B'Z[J /KBBOE&*RE^)WQ
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M_ /X]: ;&\T?3M(>ZBL=(OKE;A["-[5'\D.KNNT$D@!B!N]<T ?7=%?-NO\
MA:V^#/[.VN^-= %S+XUO-#A^U:Y+,SW$K2>6"^"VU0F[*@#"A0!6/;_#C7-+
MNO">I>#?AEK7A_7K2_MI+[7KG6K*1K^U)Q<"X(N6:7>I+<@D$#;B@#VWP#X]
MU#Q5XX^(&C7<-M':^'[^"UM7A5@[J\"2$N2Q!.6/0#BN]KYJ\+_"/P]\3OC%
M\8/^$GAN-5T^#5+5(],:YDCMMYM(\RLJ$;GQP"?N\XY.:YBQ\7:S%^SUH_A^
M'5]0MA=^-/\ A$_[368M<PV1NF7_ %AY!" (#V&* /KRN"\ ^/=0\5>./B!H
MUW#;1VOA^_@M;5X58.ZO DA+DL03ECT XKROQU\,/#GP'\0> O$'@6TDT._O
M-?M='O+:&ZE==0MIBP=9%=SN9?OACSD9)[C(\4>*-2\&Z7^TIJVD220ZC#>V
MBQ3Q'#0E[6%#(#V*ABV?:@#VSXS>/-0^'?A:QU+38;:>>?5K*Q9;I691'-,L
M;$;6!W $XYQGL:[ROE+XM? CPI\/_ 7A75=!^V6]^NMZ4+JZCO9&74BTZ9>=
M2Q5SD[P<9!Z''%:GC@W7CSX^>)]&U;P5J'CS1-!T^S%II,5[;0VT;S*[/</'
M--&)&.-BGG;M/3@D ^F:*^0O&/AWQ7X=^ /B32M4LK[PW8KXIL6\/PWEY#=S
MV5J]S 50,CN,1ONVAF)Q@=*^DO 'PP\/?#.TNH=!LW@>\99+RXFGDFENI "/
M,D9R<N<DD]\T 5_C!\0V^%7P[U7Q0FF_VN]CY06R\_R/,+RI&!OVMC&_/0]*
MY33_ (V>(=)\7Z'HGCCP*WA:#7)?LNGZE::K'?PO<8+"*0!$*$@<'!R?Q(B_
M:[W_ /#/OB?RMOF;K3;OZ9^UPXS[5QU]%XLOOCA\/]-^*<VD/IBO->Z#_P (
M];R);S7\<?2Y,K,RLJ%F0*<$X^E 'TI7->./'NG^ 8-'EU"&YF75-3M])A^S
M*K%99FVHS;F&%!ZD9/L:^=H[.;XH?$#XAW'B'X=:IX_BT[6)-)L574K6&#3X
M8T3'EQR3H5D<G>9 ,\C!X(K*\;_#&ZO?A;\,4^(>C//XBM_%5KH_FW]RD]PV
MGR7+[8Y'B<JV8]H/)/'7- 'V'17@_P 4?"^C^!=2^"^CZ)90Z7I5OXK40VT6
M0BEH9R<9/4LQ_$UL>)?^3IO!/_8NZC_Z-AH ]@HKYN_9T^%NAZ_/KOBK5XYM
M2U2P\4ZD-,\V9Q'8!;EB?+0$#+,26)!)X'05S_P\^#'ASQ]X#\>ZOXA2\U.Z
MMM<UD:>K7<B1Z>5F=M\**P"N7^8L02< =!B@#ZQHKSW]GWQ!>^*?@GX,U349
MY+J^N-.C\Z>5BSR,HVEF)ZDXR3ZFO0J "BBB@ HHHH **** "BBB@ HHHH *
M\_\ B!_R&8?^O=?_ $)J] KS_P"('_(9A_Z]U_\ 0FH [/1?^0-8?]>\?_H(
MJ[5+1?\ D#6'_7O'_P"@BKM !1110 4444 %%%% !1110 4444 %</\ $;X/
MZ'\2KC3[Z[FU#2-;T[<+/6M&N3;7D ;[RA\$%3_=8$<GUKN** //=#^">DZ?
M9:M;:QK&O>,5U.V:SN/^$BU%KA?);&46-0L:=!\RJ&XZUAZ1^S/X?T^XTY+[
M7_%'B'2--E6:RT/6-4,UC;LA!CP@52X3 "AV8 #%>O44 <U:^ ]/L_B%?^,4
MFN3J=YI\6FR1,R^2(XW9U(&W=NRYR=V.G%-\+_#W3O"5UXFN+.:ZD?Q!?OJ%
MT)W4A)&14(3"C"X4=<G.>:Z>B@#YX^)'P/L[/P[\)?!5A9:IK'A[3=>_TF7Y
MFEBA,4Y\QY(E79AF&'&W!QSFO1/!/P3TKP;XED\0SZQKGB?6_(-K!>^(+T7+
MVL).6CBPJA02!DD%CZ\G/H=% 'D]]^SGI+:QJ5[HWBCQ9X4@U*X:[O-/T'5/
M(MI9F.7D"E&*,W<H5_05U0^&.DIXI\-:ZDMXESX?L9M/M(C,'1HY @)D+ LS
M 1C!W>N<UUU% '%WGPGT34/%GB'7[E[N:?7=*71[NW\T+%Y W?=V@.K'<>=W
MTQ65X3^!6E>&?$MGKEUKWB+Q/>6$;Q:>NOZA]ICL0XVL8E"K\Q7Y=S;FQWKT
MFB@#QC4OV6/#FH:+J.@KX@\3V7A>\>64:!::@L=G [DL2@\O=M#$N$9F3=SM
M-=;XY^#^E>.M-T&"74-4TB]T.02:?JFE7"Q74)V;& 8JRX9>"-O-=U10!Q\7
MPQT]?$OAC7IM0U*[U'P_82Z?!)<S*YG60('>8[<LYV Y! R3Q7)ZC^S3H-QJ
M>J3Z=X@\4>'=.U29KB_T71M4\BRN)&/[QBFTLN_HVQER.*]<HH XJ\^$?AZX
MM?!UK;13:99>%+M+O3K6S8!-RQM&%?<&++AR3R"3R3UJ[J7P]T[5/B#HWC"6
M:Z74]+M)[.&)'40LDI!8L-NXD;1C##Z&NHHH *YGP)X!L/A_9ZG#93W5Y+J6
MH3:G=W5XRM++-*06)*JHP  H&. !7344 <1J'P@\/ZMXJ\0:W>)-<?V_IB:7
MJ6GNR_9KB-"=KD;=V\!BNX-T[9YK+\%_ NR\%ZQI]Y'XL\6:M;:<K+9:9J>J
M>9:0 J4&$55+[5)"[RV.U>ET4 <!I/P;TW0?B%?>*]-UC6[$W\YNKO1H;M1I
M]Q.8]AE>/9N+$8/WL9 ..*Q-4_9I\-:EK6M72ZKX@L=+UJ8W&I>'[+43%I]U
M*PP[O&%W9;C< P#8&01Q7K5% 'F=Q\ = D\)^$M%M]0U;3KCPLH72M9LYT2^
MA&W:PW;"C!UX92F".U6/!OP1TCP7KFMZS'JVM:MJFM6B6E]=:K=B=Y I<AQ\
MHVG#XPN$ 5<*.<^B44 >=Z?\#M"TW0/ VD17>HM;>#[I;NP9Y(R\KA'4"4[,
M$8D/W0O05Q_Q7^'7_"POV@_AM(=)NC9Z%#/J5]J1A86SJ'0P6^_&UG\U=^W.
M0N3CFO=** "N:_X0'3_^%C'QIYUS_:ATL:3Y.Y?(\D2F7=C;NW;CUW8QV[UT
MM% &+XR\'Z5X^\,:AX?UJV^U:9?1^7-'DJ>H(((Z$$ @]B!7"Z?^SWIL'B+P
M_KFH^*?%/B#4-"F\VQ;5;])$C'ELA0HL:J<A@2V-Y*K\V.#ZI10!Q47PC\/^
M;XU-TD^H6_BYU;4K6Y<>7@0B+:FT!E&T YR2#R"*XU?V5_#DUM8V^H>(O%6L
MPZ;/#/IL>HZF)EL/*D5U6)=FW!"A"6#-MR PS7L]% !7GWAKX(>'/"GQ.UWQ
MU9&\.KZPA66&213;Q%MAD:-0H*LYC4L23G':O0:* /,_%'P%TK7O%%]XATWQ
M!XD\(ZIJ"JM_)X>OQ MWM7:K2(R.NX#@, #^9K2E^#^CS6GA&![W5)?^$:O_
M .TK::XNS-+<3%7#&9Y S/GS&)P1SC&!Q7=44 <AX^^&MKX^?3[@ZQK7A_4;
M#S!;ZAH=Y]GE57V[T((9&4[%X93C QBLNV^!/A6/X=ZIX-N8KO4M.U61I[^Z
MOKEI;NYG8@^>\IY,@*K@]MHXKT.B@#R71_V;]$T[Q!X?UV]\1>)_$.L:'-YM
MG>:SJ(N&5?+9#$1L"[3NR2 &)5<L<8J76OV=="U[5KJ:[USQ(VBWEV;VZ\-C
M4V_LV>4OO;=&06VLWS% X7/:O5:* $ "@ # '05S?BWP'I_C+4O#=[>S7,4N
M@Z@-2MEMV4*\@1DP^5.5PYX&#G'-=+10!Y[XZ^">D^-?$EOXBAU;6O"_B"*'
M[,^I^'[P6\L\.21%(&5E=03D97/ YXK0\&_";P]X*\/ZEI-M%<7ZZJ6?4[S4
MKAKBYOF9=C-+(W))7C P!V S7944 >7:%^SWH&D>"=7\(WFJZYX@\.ZA ELE
MAJ]X)4LXT)*+!M12F"003D_(O/%,T_\ 9[TV#Q%X?US4?%/BGQ!J&A3>;8MJ
MM^DB1CRV0H46-5.0P);&\E5^;'!]4HH YKPSX#T_PKXB\3:S:37,EUX@N8[J
MZ29E*(R1+& @"@@84=2>:I>/_AA9>/YK"Z;5]:T#4[$.MOJ.AWQMIE1RI=",
M%'4E%X93TKLJ* .&\#_!_1O ZZO-%=ZGK&KZNH2^UG6+K[1>3* 0J[L!5503
MA54#VID?P;T6+X/GX;BZO_[#^PFP^T&1/M/EDDYW;-N[G^[CVKO** /._$'P
M2TK6KW1-1L]7UGP]K.DV/]FQ:II$\<<\MM@?NI=\;(ZY ;[O!Y&*J:3^SWX=
MT?PCXP\.Q7^L3VGBK<VH7%U=B:XW-$(W=9'4G<<;CNW<D]!@#T^B@#'F\)Z;
M>>$3X:O(/MVDO9_8)89SDRQ;-A#$8Y([C'MBN#\-?L^V'AF_TYX_&'C&]TO3
MW5[71;S6"UG'M(**5"AW5<#"LQ' XKU2B@#FO#/@/3_"OB+Q-K-I-<R77B"Y
MCNKI)F4HC)$L8" *"!A1U)YKGK7X"^%8_ .K>#[N.ZU+1]2OIM0E^U2@2I-)
M)YFY'15V[6^[W]2:]&HH \Q\+_ '2=!U[3]8U/Q!XD\87NF\Z>?$>H_:$M&(
M*ET1552^#C<P8^_%;,7PC\/^;XU-TD^H6_BYU;4K6Y<>7@0B+:FT!E&T YR2
M#R"*[6B@#QA?V5_#DUM8V^H>(O%6LPZ;/#/IL>HZF)EL/*D5U6)=FW!"A"6#
M-MR PS73^.O@OI/C;Q%;^(8M6UKPSX@A@^R'4] O/L\LL&XL(Y RLKJ"2>5Z
M_05Z!10!YS<? [2+[P*WAB]UC7=1ADOH=0FU&^OO/O)I8I$==SNI 7]VHVJH
M '3'6O1J** .;^(G@/3_ (F>$+[PYJDUS!8WAC:22T95D&R19!@LK#J@SQTS
M4'Q ^&^F?$6PTNWOY[JSFTN_AU*SO+)D6:&:,Y4@LK#!Y!&.0:ZNB@#S/Q1\
M!=*U[Q1?>(=-\0>)/".J:@JK?R>'K\0+=[5VJTB,CKN X#  _F:OZ]\&=#\1
M?#ZV\)7=WJIM[:9+J#4S>L]_'<*Y<3B9]Q,FXDY((YQC%=[10!Y[KWP5TKQ1
MX!L_#&L:OK>HO9W O+;7)KP?VE!<!RRRI*% #+N('RX P,56\)_ 31/"GC2U
M\6_VOKNL^(8;66SDOM6O1.\\;E2 WR@ +M^4)M W-D$G->ET4 <UX#\!Z?\
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MNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\
MXN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO
M^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_X
MN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - V
MZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;
MK_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ
M_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\
MT#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?
M/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\
M] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT
M52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?
M/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"
M[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO
M_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[
M15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[Z
MB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ
M+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^
MHO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K
M_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#
M;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ
M_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^W
MS_\ 0-NO^^HO_BZL6\K31[GA> YQMD*D_7@D4 2TC,%4LQ 4#))Z"EKAOBYH
MNNZYX?LXM%2>ZACO$DU'3K.^:QN+VU"L&BBG4J4;<4;[R!MI4LH8T =I;7,-
MY;Q7%O*D\$J"2.6-@RNI&0P(X(([U+7BJ?8[CX%^([3P]J?B70!H*7L3V=W=
M WMI)%&S"V,Q+MY:[D96CD)VA ),9%=;>+8:A\+M'O\ Q#K>H:9IUO8P7=Y=
M6NH2VCR_NAP\T9$G+$'"L"Q !R"00#O:*^?_  O8Z]XBU+PGX6\1ZMKMC9/I
M>I:LL::C/:W[H+I$M4GF1ED+1PRC<I;EB-^XKSZ=\'M9OO$'PR\/7VI3O=WT
MEL!+<2 !IBI*[S@#E@ >@ZT =E1110 4444 %>?_ ! _Y#,/_7NO_H35Z!7G
M_P 0/^0S#_U[K_Z$U '9Z+_R!K#_ *]X_P#T$5=JEHO_ "!K#_KWC_\ 015V
M@ HHHH **** .$U;X.Z+KGBZ36;Q[N6SF4/<Z.+RX6RN;A63;-+ )/*<A8P,
M,A!ZG) Q=UKX5Z!X@\30:_>_VL=4MSF&2#6[V".+@ A(HYE10P4;@%PV.<UU
MU% '/Z#X2CT77O$.L/<&YO-8FC9VV[!'%'&$CC SSCYR6ZDN>P %>;X9^')O
M#%CX?^PR0Z98R"6T%O=S136[@D[XYD<2(WS,,A@<,1T)%=110!RTWPS\.3>&
M;30?L$D6GVDOVBW:"ZFBN(ILL3*MPKB42,7?<^_<V]LD[CFO8_#'2]+UK0+J
MS'D6.B0W*VME\S$S3D>9.\C,6=B-^=V23(S$DX([&B@#C](^$GA/1)+LVVE;
MX[JWDLV@NKB6XACMW.7ABBD=DAC8XRD853M7CY1B?0_AGX<\/66HVMO827,6
MHQ"WNSJ5U-?/-"%*K$7G=V\L!FPF=HW-@<G/4T4 <]X3\ Z+X)-RVE07 FN0
MB2W%Y>SW<S(@(1/,F=V"+EL(#M&YL#DUT-%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<S\0/ \'CS0_L;7
M=UIEY$WF6FHV,\L,]M(5*EE:-T;E688S@YY!KIJ* .0G^%/ANX\+2>'?L][%
MI<TKSSK;ZI=137+N"',TR2B27<"<[V;.!GH,07WP;\+ZEX=TW0[F'4YM/TVY
M6\M VM7OFPRJ"$99O.\S"@_*-V%[ 5VU% '&W?PC\.7VGVUI<#5IOLSR/#=/
MKE\;M!( '07'G>;L8*N8]^T[0<9 KJ=-TVUT?3[:PL;>.TLK6)88+>%0J1HH
MPJJ!T   JS10 4444 %%%% !7G_Q _Y#,/\ U[K_ .A-7H%>?_$#_D,P_P#7
MNO\ Z$U '9Z+_P @:P_Z]X__ $$5=JEHO_(&L/\ KWC_ /015V@ HHHH ***
M* "BJ=YJUI87EA:3S".XOI&BMX\$F1E1G8<#C"JQY]*N4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 454U;6+#0=/EOM3O;?3K*+'
MF7-W*L4:9(499B ,D@?4BN=_X6[X%_Z'3P[_ .#6#_XNM(TYS5XQ;(E.,=).
MQUM%<E_PMWP+_P!#IX=_\&L'_P 71_PMWP+_ -#IX=_\&L'_ ,75>QJ_RO[B
M?:T_YE]YUM%<[I/Q&\)Z]J$5CIGB?1M1O9<^7;6FH12R/@%CA58DX )^@-=%
M6<HR@[25BXR4M8NX4445)04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7G_ ,0/^0S#_P!>Z_\ H35Z!7G_ ,0/^0S#_P!>Z_\ H34 =GHO_(&L
M/^O>/_T$5=JEHO\ R!K#_KWC_P#015V@ KD]6^+G@70=1GT_4_&GA[3K^!ML
MMK=ZK!%+&<9PRLX(.".M=97"_%[1-:UCP]8RZ)86^MSZ=?Q7\NBW4X@345C#
M%8?,(*J0YC<;AMW1C..H -?P[\2/"/C"^>ST'Q3HNMWB1F5K?3M0AN)%0$ L
M51B0,D#/N*Z.O,O"5KXDUSXI7OB2^\+MX0TI=.^PLEU=P37>I2;HWCDD6!G1
M%BQ,JY=F/FG@ D5Z;0!X+\1_#]AX>\3:]XYU32=$\:Z/!<VC2RRS>7JNAO&8
MALMFPP(R5E\L/"V7;E]X%=/XFT6TM?CQX&U*-)#>7=OJ*R22S.X"K#$ J*Q(
MC7N54 $Y)R3FNHO/A;X7U#QU!XNNM%L;C78(?*CN9+6)F4AE*R;BN[>NT -G
M@9 ZU+JGPQ\':YK)U?4?">AZAJQ96-_=:;#).2H 4^8REL@ 8YXP* ,WXDZA
MX*N-)F@\4)9ZS%931G^QG N'FGD5A#']FR?,=^2BLIY&X?=R/-_^$)DTG0?A
M=X4\26L9T:^UN[DN]'D(EMHPT5S/;63]5=(SM 7E28EQP *]3N_A5X6U:XU.
M?6=%LO$,FH72W<O]L6T=R$98Q&BH&4A5500!_M,>K&KD/P[\*6_AV70(O#&C
M1Z%,_F2:6FGQ"U=L@[C%MVDY4')'8>E 'B&GZ;9:C#X4\-74,=SX*D\9ZI9Q
MV,@WVLL44=PT$!4DJT2RHVU#\N8E&. *[CX7ZE!HO@W6]-T^XAB$>JZK;Z%:
M>8/GCBD?$<*ECE48,H5>%"XP *]!NO"&A7WA]=!N=$TZXT-46-=,EM(VM@JD
M%5$1&W (&!CC JO#X'TBUUC2+^"V6W72;62TL+.%%2WME?:&9$ PK;4"@CHI
M('4Y /F/5+>#PM\-?#>M>%2UIKFK>#+^]UC4+,D7-U^ZA=[F9@=SR+([8=@2
MI<@$=*ZOQ?IME\/;;X@6O@:&/1K%?!D5Y*FDC8L<I>55G 4\2F)7._&X^6#D
MXKWC2?!V@:#>ZA>:9H>FZ==Z@V^\N+2TCBDN6R3F1E +G+,><]3ZTOA_PAH7
MA*SFM-#T33M&M9G,DL&GVD<".Q !9E0 $X &3Z4 >>_#_P /:+X0^*VHZ7X7
ML[;3M&?P_:7-Q:V("P^<995CE*@XWNBG+$98(,DXKUFLGP[X2T/P?:RVV@Z+
MI^B6TK^;)#IUK';H[X W$( "< #/M6M0 C;MIV@%L< G S5/SM1_Y];7_P "
M6_\ C=7:* *7G:C_ ,^MK_X$M_\ &Z/.U'_GUM?_  );_P"-U=HH I>=J/\
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M[4?^?6U_\"6_^-T>=J/_ #ZVO_@2W_QNKM% %+SM1_Y];7_P);_XW1YVH_\
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MUI]>Z:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV/->CA<=1Q=U!VDMT]&OD7&:EL;=%4O*U'_GZM?_  &;_P".4>5J/_/U:_\
M@,W_ ,<KT2R[15+RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\ X#-_\<H NT52\K4?
M^?JU_P# 9O\ XY1Y6H_\_5K_ . S?_'* +M%4O*U'_GZM?\ P&;_ ..4>5J/
M_/U:_P#@,W_QR@"[15+RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\ X#-_\<H NT52
M\K4?^?JU_P# 9O\ XY1Y6H_\_5K_ . S?_'* +M%4O*U'_GZM?\ P&;_ ..4
M>5J/_/U:_P#@,W_QR@"[15+RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\ X#-_\<H
MNT52\K4?^?JU_P# 9O\ XY1Y6H_\_5K_ . S?_'* +M%4O*U'_GZM?\ P&;_
M ..4>5J/_/U:_P#@,W_QR@"[15+RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\ X#-_
M\<H NT52\K4?^?JU_P# 9O\ XY1Y6H_\_5K_ . S?_'* +M%4O*U'_GZM?\
MP&;_ ..4>5J/_/U:_P#@,W_QR@"[15+RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\
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M">M?LI_\E\\+_P#;U_Z2S5^AE?GG^RG_ ,E\\+_]O7_I+-7Z&5\!Q!_O4?\
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M)@_YZ77_ (%R_P#Q57:*[SY8I?V3!_STNO\ P+E_^*H_LF#_ )Z77_@7+_\
M%5=HH I?V3!_STNO_ N7_P"*H_LF#_GI=?\ @7+_ /%5=HH I?V3!_STNO\
MP+E_^*H_LF#_ )Z77_@7+_\ %5=HH I?V3!_STNO_ N7_P"*H_LF#_GI=?\
M@7+_ /%5=HH I?V3!_STNO\ P+E_^*H_LF#_ )Z77_@7+_\ %5=HH I?V3!_
MSTNO_ N7_P"*H_LF#_GI=?\ @7+_ /%5=HH I?V3!_STNO\ P+E_^*H_LF#_
M )Z77_@7+_\ %5=HH I?V3!_STNO_ N7_P"*H_LF#_GI=?\ @7+_ /%5=HH
MI?V3!_STNO\ P+E_^*H_LF#_ )Z77_@7+_\ %5=HH I?V3!_STNO_ N7_P"*
MH_LF#_GI=?\ @7+_ /%5=HH I?V3!_STNO\ P+E_^*H_LF#_ )Z77_@7+_\
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M*_X4 7:*I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^% %VBJ7]BZ?_SX6O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:/[:T_\ Y_[7_O\ +_C0!=HJE_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (T
M7:*I?VUI_P#S_P!K_P!_E_QH_MK3_P#G_M?^_P O^- %VBJ7]M:?_P _]K_W
M^7_&C^VM/_Y_[7_O\O\ C0!=HJE_;6G_ //_ &O_ '^7_&C^VM/_ .?^U_[_
M "_XT 7:*I?VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"- %VBJ7]M:?\ \_\
M:_\ ?Y?\:/[:T_\ Y_[7_O\ +_C0!=HJE_;6G_\ /_:_]_E_QH_MK3_^?^U_
M[_+_ (T 7:*I?VUI_P#S_P!K_P!_E_QH_MK3_P#G_M?^_P O^- %VBJ7]M:?
M_P _]K_W^7_&C^VM/_Y_[7_O\O\ C0!\L_MY_P#,C?\ ;]_[;U\F5]6_MU7U
MO>?\(1Y$\4^W[=N\MPV,_9^N*^4J_3,G_P!QI_/\V?!YG_O<_E^2"BBBO9/+
M*M]_!^/]*J5;OOX/Q_I52OPOB7_D:UO^W?\ TE']6<$?\D_AO^W_ /TN0444
M5\R?<GT=^PC_ ,E=U?\ [ <W_I1;U]VU\&_L,W4-I\6M6>>:.%#HDP#2,%&?
M/M^.:^Y?[:T__G_M?^_R_P"-?28#^"?C/%7_ ",GZ(NUY)\4O@V=6F;7O#?^
MAZS&WFO#&VP3,.=RG^%_T/UYKT[^VM/_ .?^U_[_ "_XT?VUI_\ S_VO_?Y?
M\:VQ6%I8RG[.JO\ ->:/CI14E9GF7PM^,@UB9="\1_Z'K4;>4DL@V"9AQM8?
MPO[=_KQ7K5>6?%+X>:)XXA:^L;^SL]<0?++YRA9\=%?GKZ-_3I@_#7XR3Z5=
MCP[XN<Q2Q-Y45_(P..P60]QZ/^?K7DT<55P,UAL:[I_#/OY/LS-2<7RR/<:*
MI?VWIQY%_:D?]=E_QH_MK3_^?^U_[_+_ (U]";%VBJ7]M:?_ ,_]K_W^7_&C
M^VM/_P"?^U_[_+_C0!=HJE_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\ O\O^
M- %VOG']N[_DD6D?]AR'_P!)[BOH'^VM/_Y_[7_O\O\ C7SM^W-J%K=_"724
M@N89G&MPDK'(&./(N.>#7+BOX,CW,C_Y&5'U/AJBBBOE#]Y"O7_V2?\ DX/P
MI_V]_P#I)-7D%>N?LGS1V_Q_\+22R+%&OVK+.0 /]$F[FMJ'\6'JOS/-S3_<
M*_\ @E^3/T?HJE_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\ O\O^-?7G\^%V
MBJ7]M:?_ ,_]K_W^7_&C^VM/_P"?^U_[_+_C0!=HJE_;6G_\_P#:_P#?Y?\
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M& #S7X93:A8ZE\-[]M=U359?%6BSWFJ+>7LD\+S>7%,LD<;$I" 9&4+'M7#
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M"QFOM?YE*BBBOQ,_K4*]<_9/D:+X_P#A9EC:9A]J^1,9/^B3>I _6O(Z]?\
MV2?^3@_"G_;W_P"DDU;4/XL/5?F>;FG^X5_\$OR9^A_V^?\ Z!MU_P!]1?\
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MG10!C>$_"]KX/T9=/M99[G,DD\UU=.&FN)I'+R2.0 -S,2<  #H   !LT44
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M5*OM94N7EE>W->UG>WF?8_\ PT)X0_Y[7?\ X#FC_AH3PA_SVN__  '-;O\
MPJ?PA_T +3_OD_XT?\*G\(?] "T_[Y/^-?1\F:_SP^YGX[^\\CF_^&C/"G]S
M4#_VP7_XJD_X:,\*?\\]0_[\+_\ %5U@^&?A0 #_ (1[3_\ OPM+_P *U\*?
M]"]IW_@.O^%'L\T_Y^0^YA:IW.,?]I3PNK$"SU5Q_>6&/!_.2D_X:5\,?\^.
MK?\ ?F+_ ..5W2?#_P +QJ%'AS2B!_>LHR?S*TO_  @/AC_H7-)_\ 8O_B:/
M8YI_S]C_ . A:IW//Y/VE_#X;]WINI,OJRQ@_P#H9IG_  TQH7_0+U'\H_\
MXJO2(_!GA^%=L>A:;&O7"V<8'\J?_P (CH7_ $!=/_\  6/_  H]AF?_ #^C
M_P" A:?<^?OC-\8-.^)7PZU;PW8V5U:S7ODXGN-NU-DR2= 3G(0C\:^9?^%8
MW7_/[#_WR:^R_P!IS1=/TGX%^)Y[&PM;.=?LN)+>%8V'^E1#J!Z$_G7P/_:%
MU_S\S?\ ?PU]?D^"SRI0DZ.,C%7V]FGT7F?,YG*G&LE5CS.W>W5G7+\,+C/S
M7T8'LA/]:?\ \*OE_P"@@G_?H_XUQK7MPXPT\K#W<FF?:)?^>K_]]&O=_LWB
M![YBE_W"C_F>3[7#?\^_Q9U]Y\+Y1:RG^T8QM7/S1D#CGDYXKS>M.\FD:W<-
M(Q''!)]:S*_/\_P^-P^+C''5_:R<59\JC97EI9']!>'=I9;5E#2/.]//EC=W
M\]-.EO,****^;/U0Z_X._P#)7? __8<L?_2A*_4RORS^#O\ R5WP/_V'+'_T
MH2OU,KWLM^"1^5\8_P >EZ/\PHHHKUS\^"BBB@ HHHH **** "BBB@ HHHH
M**** "O/_B!_R&8?^O=?_0FKT"O/_B!_R&8?^O=?_0FH [/1?^0-8?\ 7O'_
M .@BKM4M%_Y UA_U[Q_^@BKM !1110 4444 %%%% !1110 4444 4]8U:TT'
M2[K4;^86]E:QF6:4@G:H&2< 9/X5<KS/XL>"7\9:UH#Q0Z#K[Z>D\LGA?Q$?
M]&NT;8OGC"2;7C/ <QN,2,OR[LU+\.?&D5UX*\*'0/!NJC2)X_L^VWN+5XM-
M$<AB96:2=6=%*MM,:OE0,#HM 'H]%%% !12-NVG: 6QP"<#-4_.U'_GUM?\
MP);_ .-T 7:*I>=J/_/K:_\ @2W_ ,;H\[4?^?6U_P# EO\ XW0!=HJEYVH_
M\^MK_P"!+?\ QNCSM1_Y];7_ ,"6_P#C= %VBJ7G:C_SZVO_ ($M_P#&Z/.U
M'_GUM?\ P);_ .-T 7:*I>=J/_/K:_\ @2W_ ,;H\[4?^?6U_P# EO\ XW0!
M=HJEYVH_\^MK_P"!+?\ QNCSM1_Y];7_ ,"6_P#C= %VBJ7G:C_SZVO_ ($M
M_P#&Z/.U'_GUM?\ P);_ .-T 7:*I>=J/_/K:_\ @2W_ ,;H\[4?^?6U_P#
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M\<H_X8#U'_H<K7_P ;_XY7A?4J_\OXH^K_UDRK_G]_Y++_(YS]A'_DKNK_\
M8#F_]*+>ONVOGSX$?LQZC\$_%UYKG]N6NL_:+%[+[/Y+0;=TD;[MV6S_ *O&
M,=^O%>[>=J/_ #ZVO_@2W_QNO<PE.5*ERS5F?F6?XNCC<:ZV'E>-ET:_.Q=H
MJEYVH_\ /K:_^!+?_&Z/.U'_ )];7_P);_XW78?.%VBJ7G:C_P ^MK_X$M_\
M;H\[4?\ GUM?_ EO_C= %VBJ7G:C_P ^MK_X$M_\;H\[4?\ GUM?_ EO_C=
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M?_&Z/.U'_GUM?_ EO_C=?1GXZ7:*I>=J/_/K:_\ @2W_ ,;H\[4?^?6U_P#
MEO\ XW0!=HJEYVH_\^MK_P"!+?\ QNCSM1_Y];7_ ,"6_P#C= %VBJ7G:C_S
MZVO_ ($M_P#&Z/.U'_GUM?\ P);_ .-T >9?M6?\D#\4?]NO_I5#7YYU^EGQ
M6\#ZC\3O .J>&O,M=-^W>5_I6]I=FR5)/N[5SG9CJ.M?//\ PPCJ/_0WVO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<%5BLK_2M$EC^S+NS(662[D+N^3^\W@@L6.3S6]\._"NI>#=#72KR[TFXM8
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M##'(01A2^3N4C(920#OJ*XW4_BAI.@ZMK-IJ4R1II[VL2I:1W%S=2R3JQ5!
MD)+$A20(S(<!B0N*3X:^/A\0/^$DGBV?8]/U1K&W/DR0R;5AB<B5'^99 [NI
M4A2-N" 0: .SHK&NO&GA^RN)(+C7=,@GC.UXY;R-64^A!/%1?\)]X8_Z&/2?
M_ Z+_P"*K#V]):.:^]"NC>HK!_X3[PQ_T,>D_P#@=%_\51_PGWAC_H8])_\
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MEX*TG[9<6L_BNWUB37;W[+?W-C#=3R+(C1K<P@31JL<BJKA2<1*"I!->S44
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M<N&0JG*C#=:]JHH \U\(_"NZ\)S111WD-U:P^&X-%61@4=Y4>1BY0 A4.\8
M)QT[5IVWA77M'^#=IX;TRYLXO$-OH\>GQW4C/Y"3"(1F0$+N(')' S@=*[>B
M@#P;7/V:]1;2M-T[2_&%Y=6D>DW&@2QZM!;!8K.2+ ,8@@0NRRQPMB1B" _(
M)R>SUSP[XR\:?#G7]&U>'0M-U*YM!!:+974T\)D R7D=HD*JQP-H1BH!.YLX
M'HU% 'F>N>&?&EUKBZWI]OH,5]J&C_V7?075[.\5HPD9DEB9809QB1\HPBSA
M?F'-</:_ OQH(] LKS4[6\M=,N-)FCF&M7L<<,5K]G,D"V2((9,M%(ZS29;Y
MP"HP"OT)10!Y3X@^%.K:MXZO-:AN+);6;5](OU1W<.([59!(" N-QWC;S@\Y
M(K/\&^&Y3\?/%9CFC?0-'Q>6]NJ8\G4+V-#.,],A(M_3_EZ;KGCV:B@#S_Q1
M\*K?QEX\75M3EN?[*&E&P,%EJ=U:/(YE+$.(70.A4XPQ(]JY+Q-\'/$NK>*(
MFMKFU70;75-/O+%/[6N[>.TM;=X6-JMA&OV=N8W996)/S 8& 1[;10!Y'XC^
M%OB"3XB7?B_29=-FN8KVSN[2RO)Y8DF6.UGMY4D=4;RSB?<K!7Y7! S75?#?
MPSK/A_\ X2*ZUU[%KW5]3.H>7I[.T<2F"&/R\N 6*F,C=@;N&PN=H[*B@#RN
MZ_9Q\,75U+-]KU2/S'+[$FC(&3G RA/YFHO^&:O#'_/]JW_?Z+_XW7K-%>4\
MJP+U]DC/V<>QY-_PS5X8_P"?[5O^_P!%_P#&Z/\ AFKPQ_S_ &K?]_HO_C=>
MLT4O[)P/_/I![.'8\OO/@586?A#4-+T6^G@OY+FVO[>[OL2K'<6\HEAW*H7*
M;EPPZD$\]*L:_H/C?QQX4U73M5M?#^CW!2&2S6SO9[M);B.5909':&(QH2@7
M 5S\Q.>,'TBBO1I4H48*G35DBTDE9'D%]\-_%OB:;Q1?:J=%LKK5AI:P6MG<
MS3) MK<M(X>1HE+DAL@A%Y.TCY=S:'CKX8:KXGL?B5#:W%G&WB72H;&S,SN!
M'(D<JDR84X7,@Z9/!XKT^BM1GC_CKX:^+M47QE8:&^BG3_$]M"LMUJ$\R2VL
MB0^4RK&D9#JP5,,74J68[7P 4\6?"_Q5>^*M:U;2;ZW%EJ$]DTNGIJESILES
M%#;RQLC7,"&2+$CQN-F=P0J< U[#10!XWX:^%?B?PGH_@T6[Z7J%_HVK:A=W
M,=Q?7 22&Z:<Y69HY)&=1*OWP=Q!RW>K>H_"C6FT#Q";&YL(]?;Q(WB'1II7
M?RHG^0!92%R-RB1&V@\.<9KUFB@#QG6/@?=P:7X-;3'6]O\ 0[*:TN(?[9N]
M(%TTQC>6;[1:@R!C)&6*E2K;SG! -=[X'\*_\(SX.73%L8]-GD::66&/4I]0
M7S9'9F8W$RK)(6+;B6 Y)KJ:* ."\,^$]=\(_"'0_#MO%I.IZK86,-I/;WDD
M@M+E54+(F\(64$9PQC;W7FN,M_@+<WFCVUA?Z=H-KI+>(XM6D\-6Y>?3K6W6
M(H\40>-0Q=CYA7RXURQX[M[A10!R/PZ\'W/@6TU32%:W_L%+UYM(AA)W6]NX
M#M"P(  60R!0"0$*CC&*ZZBB@ HHHH *\_\ B!_R&8?^O=?_ $)J] KS_P"(
M'_(9A_Z]U_\ 0FH [/1?^0-8?]>\?_H(J[7DJZO?1*$2]N$11A565@ /0<TO
M]M:C_P _]U_W^;_&@#UFBO)O[:U'_G_NO^_S?XT?VUJ/_/\ W7_?YO\ &@#U
MFBO)O[:U'_G_ +K_ +_-_C1_;6H_\_\ =?\ ?YO\: /6:*\F_MK4?^?^Z_[_
M #?XT?VUJ/\ S_W7_?YO\: /6:*\F_MK4?\ G_NO^_S?XT?VUJ/_ #_W7_?Y
MO\: /6:*\F_MK4?^?^Z_[_-_C1_;6H_\_P#=?]_F_P : /6:*\F_MK4?^?\
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MY_[K_O\ -_C1_;6H_P#/_=?]_F_QH ]9HKR;^VM1_P"?^Z_[_-_C1_;6H_\
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MO\: /6:*\F_MK4?^?^Z_[_-_C1_;6H_\_P#=?]_F_P : /6:*\F_MK4?^?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &C PP# 2(  A$! Q$!_\0
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M*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\
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M_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\
M^?"U_P"_*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ
M?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/
M_P"?"U_[\K_A5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E
M_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q
M=/\ ^?"U_P"_*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *
M7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C
M^Q=/_P"?"U_[\K_A5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5V
MB@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\
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M(-7EM-.6Y\8:@EI?JD<@2)#'*Q,0WY!S&/O%NIKW&ODOPG_R2S]F?_L-1?\
MHBXK1E\7/\ ?^%Q^&[=6C;"ZYX<A_OM>$0[$'HMP1P/4T ?4=>5>./BYXDT7
MXF1>#/#/@R'Q->'21JTDT^L+9!$,S1;<&)\G(!Z]_:ND^#W@9?AM\,?#GAS
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M^,(KB+5[62:%?MEQ'/,;<2-Y.]XV96;R]H)R3QSS7H= !1110 4444 %%%%
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MIOB#Q)X1U34%5;^3P]?B!;O:NU6D1D==P' 8 '\S6E+\']'FM/",#WNJ2_\
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MT/B[X>Z=XTUCPSJ5[-=13^'[[^T+5;=U"O)L*8?*DE<,>A!]ZZBB@#S+Q-\
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M'_Z"*NU2T7_D#6'_ %[Q_P#H(J[0 4444 %%%% $,UW!;S012S1QRSL4B1V
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MU%_\70!=HJE]OG_Z!MU_WU%_\71]OG_Z!MU_WU%_\70!=HJE]OG_ .@;=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14
M,UW!;S012S1QRSL4B1V :1@I8A1W. 3QV!-34 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7G_Q _Y#,/\ U[K_ .A-7H%>?_$#_D,P_P#7NO\ Z$U
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MU%_\75VB@"E]OG_Z!MU_WU%_\71]OG_Z!MU_WU%_\75VB@"E]OG_ .@;=?\
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M,P_]>Z_^A-7H%>?_ ! _Y#,/_7NO_H34 =GHO_(&L/\ KWC_ /015VJ6B_\
M(&L/^O>/_P!!%7: "O./B9)H?BC2=2TO6K/Q18C3[J(6VJ:+I]V]Q'.T199[
M5[=';Y0S*6V[025;.<'T>N&^*]CJ>JV/A^QLKC5+6PNM8@CU.71W>.X%MAS@
M21_/&ID$0=E((0MR!DT 8/PQTW1)/&5]JW]I^--?U^6U,2WOBK2;JSBMX,IN
MCA#6T$*;BJ,0HW,5SS@UZO7A7P7TO6=-\=-!=Q>,/]$TV>VU*37K^[GL6N!<
M@0R6QFD99"\89BRY"J$'RLS@^ZT %%%% !1110 4444 %%%% !1110 4444
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M7XDA/SZ;X@V0_*55E83H[P$,&& ),G!XKU+KR* (IKN"WF@BEFCCEG8I$CL
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MHO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\
M0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_O
MJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_
M - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__
M $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\
M] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M
M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[1
M5+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[
M?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+
MH NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_OJ+_X
MNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\
MXN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO
M^^HO_BZ/M\__ $#;K_OJ+_XN@"[7Y,U^K/V^?_H&W7_?47_Q=?E-7V?#O_+W
M_MW]3Y?._P#EW\_T"BBBOLCY<*]:_93_ .2^>%_^WK_TEFKR6O5_V69&B^/'
MAAEC:9A]J^1,9/\ HLWJ0/UKCQO^ZU?\+_(ZL+_O%/U7YGZ'T52^WS_] VZ_
M[ZB_^+H^WS_] VZ_[ZB_^+K\F/T8NT52^WS_ /0-NO\ OJ+_ .+H^WS_ /0-
MNO\ OJ+_ .+H NT52^WS_P#0-NO^^HO_ (NC[?/_ - VZ_[ZB_\ BZ +M%4O
MM\__ $#;K_OJ+_XNC[?/_P! VZ_[ZB_^+H NT52^WS_] VZ_[ZB_^+H%]/G_
M )!UR/\ @47_ ,70!=HHHH AFNX+>:"*6:..6=BD2.P#2,%+$*.YP">.P)J:
MO#OB)IMQHGCB[\3>*HM>G\/6L]M/I>L:%J;QQZ.H"I()[0.H=68N6<),2DC*
MP55%:-[X\L_"_B[XF^*-6<?9/#\%CIENC2!!EXQ-@,QVKYDEQ&I8D ;!DX&:
M /8**^5-'^(MQ>?\)3H\'Q!BUJ^U/6='@DNM,U03"VAN7C6Y%IACY: N8E9<
M;25/WZ]I^&8GTOQ-XU\/B^OK[3=-N[=K-M0NI+J6(2VZN\?FR$NP#98;F8C?
MC.   #T*BO ?#FI:I*?#/BY]:U274M6\576F75DU[*UF+427$2PK;DF-"@A1
MMX4.2K$L=Q!/#FI:I*?#/BY]:U274M6\576F75DU[*UF+427$2PK;DF-"@A1
MMX4.2K$L=Q! /?J*\!\.:EJDI\,^+GUK5)=2U;Q5=:9=637LK68M1)<1+"MN
M28T*"%&WA0Y*L2QW$'L?'$$WBKXI:'X7GU+4M.T@Z1>:DZ:7?2V4L\RR0QIF
M6)E?:@D8[0<$LI(.!0!Z;17@/A74M4^),G@+1M9UK5(;:7P]=ZC<2Z?>RV4]
MY/'-% CM)"4; 5V?:, EP2#@5SV@ZYKGCSPUKE[J7B/5[2[\.^%;>\LI+&]D
MM?,N#]I)NI5CVB;/V>,;75DP&^7YC0!]/T5YG;7\P^('@;5&41S:]HDUO>)M
M +,BQ31D_P"Z6F'_ &T->F4 %%%% !1110 5Y_\ $#_D,P_]>Z_^A-7H%>?_
M ! _Y#,/_7NO_H34 =GHO_(&L/\ KWC_ /015VJ6B_\ (&L/^O>/_P!!%7:
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M^LU?DS7V?#O_ "]_[=_4^7SO_EW\_P! HHHK[(^7"O6OV4_^2^>%_P#MZ_\
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M_4^7SO\ Y=_/] HHHK[(^7"O6OV4_P#DOGA?_MZ_])9J\EKUK]E/_DOGA?\
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M+$G+,VXD$GL3UM !7G_Q _Y#,/\ U[K_ .A-7H%>?_$#_D,P_P#7NO\ Z$U
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M8,T<"2.RP(2%)2,*ORKQ\HQU% ",Q520I8@9VCJ?:J?V^?\ Z!MU_P!]1?\
MQ=7:* *7V^?_ *!MU_WU%_\ %T?;Y_\ H&W7_?47_P 75VB@"E]OG_Z!MU_W
MU%_\71]OG_Z!MU_WU%_\75VB@"E]OG_Z!MU_WU%_\71]OG_Z!MU_WU%_\77Q
M#^TM\1O%F@_&SQ'8Z9XGUG3K*+[-Y=M::A-%&F;:)CA58 9))^I->8_\+=\=
M?]#IXB_\&L__ ,77T]'(JE:G&HIK5)_>>!4S>%.<H.#T=C]+/M\__0-NO^^H
MO_BZ/M\__0-NO^^HO_BZ_-/_ (6[XZ_Z'3Q%_P"#6?\ ^+H_X6[XZ_Z'3Q%_
MX-9__BZU_P!7JO\ S\1G_;5/^1GZ6?;Y_P#H&W7_ 'U%_P#%URUY\9?"&G7D
M]I=Z_I-K=02-%+!-JUFCQNIPRLIFR""""#TQ7Y^?\+=\=?\ 0Z>(O_!K/_\
M%UPNHWD^H:A=75U/)<W4\K2RS3.7>1V)+,S'DDDDDFOG\XPE3*:<)MJ7,['V
MG#%"EQ#6J4FW#D2?3N?IO_PO+P1_T,VB_P#@XLO_ (]1_P +R\$?]#-HO_@X
MLO\ X]7Y@45\K_:4_P"4_0_]3J'_ #]?W(_3_P#X7EX(_P"AFT7_ ,'%E_\
M'J/^%Y>"/^AFT7_P<67_ ,>K\P**/[2G_*'^IU#_ )^O[D?K=]OG_P"@;=?]
M]1?_ !='V^?_ *!MU_WU%_\ %U=HKWC\K*7V^?\ Z!MU_P!]1?\ Q='V^?\
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M1]OG_P"@;=?]]1?_ !=7:* *7V^?_H&W7_?47_Q='V^?_H&W7_?47_Q=7:*
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MG:"54$Y.2?1JRO#NC7>AV;P7FNZAX@E:0N+G48[=)%& -@$$4:XX)Y4GD\]
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M?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\
MBZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN
M@"[15+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\
MXNC[?/\ ] VZ_P"^HO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+
M_P"+H NT52^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XN@"[15+[?/_T#;K_O
MJ+_XNC[?/_T#;K_OJ+_XN@"[15+[?/\ ] VZ_P"^HO\ XNC[?/\ ] VZ_P"^
MHO\ XN@"[15+[?/_ - VZ_[ZB_\ BZ/M\_\ T#;K_OJ+_P"+H NT52^WS_\
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M9?[O1]7^1^R>&G^]XC_"OS&4445^4'] A1110!^O=%%%?:G\U!1110 4444
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M.%!+(0A7:/O%@,\UW5>??&P>';CPG:V?B/3-6UR&\OX(;72M%GEBN+JXR60
MQR1C"A6D.]PH\O<>5% &1\,[.^\ ^-+SPA=:'X6LK:\M6U2UO/"FG'3TD"&*
M-UGMRS[6W2#:P<[@O0$$5ZQ7CGACX:Z3JFO75Q<>$_'OARYF@59=2O\ Q?.W
MG!"=D1,&I2.<;W(!&T9;D$\^Q ;0!0 M<O\ $O3-=UCP7J-IX;N!;:M)Y>PF
M=K<R('4R1K*H)B9T#*' RI8$8(R.HK(\5>&;7Q=H=QIEWO5)-KQRQ2O%)#(I
M#)(KQLK*RL 058'CK0!XWIWQ"T#X5^$]=L+9=2\+ZM]NA@32_%^I":*SN+E"
MRRBY:613"=LLK8E/*.,!FP<+PQXX>\^&&IZ7IOC>;7)W\7PZ1+K$6HB>Z2TG
MNDCWJX8^7O7>$9< ;LIT%>Y^!O >G^!=-,-L]Q>W\ZQF]U.^N)+BYO)%0+O>
M21F;'!PN<+D@ 5)-\/\ 0)]%U329-/#6&IW+WEU'YKY:9V#F16W;D8, P*D;
M2 5P10!XW<3:A;_$1/A\FN:ROAV;74!F;4YS=B+^SGN#;+=%O. ,B!L[RVW*
M@A>*]*^#]W=R:#JUE=7ES?KIFL7EA;W-Y*TLK0QRD(&=OF<J#MW-DG;DDGFK
MG_"I_#']B-I?V*Y,37?V\W1U"Y-[]HQM$WVKS/.W[?DW;\[/E^[Q23_#'2_L
MOAJPL\V>D:+??VB+0;G:XF <JSRLQ8GS',C,26=A\Q.3D \EM==U>UTG1_'"
MZOJESJ^H>([ZQGT]KV5K,VZO<QI MMDQH4$$9WJH<E6)8[B#<\%:EJF@Q^!-
M936M4UFY\1^'KK4=2BO;V6>"6=88IU>.-B5A 9V0+%M&& P<#'JMG\,O#=CX
ME;78;"1;_P V2X56NIFMXYI 1)+';ES$DC MEU0,=S9/S-D\,_#/PYX0U&2^
MTJPDAG,;01B6ZFFCMXF8,T4"2.RP(2%)2,*IVKQ\HP >:_#*;4+'4OAO?MKN
MJ:K+XJT6>\U1;R]DGA>;RXIEDCC8E(0#(RA8]JX8 @X&/<ZY?PS\,_#G@_4G
MOM*L9(+@QM!'YMW-,EM$S!FC@21V6!"0I*1A5^5>/E&.HH 1F"*6.< 9X!)_
M*J?]K0?\\[K_ ,!)?_B:NT4 4O[6@_YYW7_@)+_\31_:T'_/.Z_\!)?_ (FK
MM% %+^UH/^>=U_X"2_\ Q-']K0?\\[K_ ,!)?_B:NT4 ?GA^U-,L_P >/$[J
M&"G[+]]"I_X]8>Q ->45ZU^U9_R7SQ1_VZ_^DL->2U^LX+_=:7^%?D?G.*_W
MBIZO\PHHHKL.4*S9O]:_^\:TJS9O]:_^\:_/.,O]WH^K_(_9/#3_ 'O$?X5^
M8RKNFZU?Z2VZSNY8.<[5;Y3]1T-4J*_)I14E9JY^^U*<*L7"I%-/H]3N],^*
MUW$HCU"UCNTZ%X_D;\1T/Z5H^9X,\5?>"Z=<M_VQ/_Q)KS.BN*6#IWYJ=XOR
M/FZG#N$YO:81RHR[P=E]VWY'Z*Z#^TC8R2"#7=+GT^93M:2W_>*#[J<,/UKT
M/1OB'X>\0\:;J(O7QDQQ12%Q]5VY'Y5:U[P?HGBB,KJFF6]X<8\QTPX^CCYA
M^!KS/7OV;M/E<SZ'J<^GS [ECG_>(#[,,,/UKZ7_ (4\-VJK_P !E_D?AGOQ
M\SUC^UH/^>=U_P" DO\ \31_:T'_ #SNO_ 27_XFO#?,^*OPYX(?7+"/_MZ7
M _*0#\A6WX?_ &D--G80:YIT^FS [6DA_>(#WR.&'TYJX9O0OR5TZ<O[RM^.
MP_:+9Z'J_P#:T'_/.Z_\!)?_ (FC^UH/^>=U_P" DO\ \3570?%VB^)HPVEZ
ME;WAQDI&_P X^JGD?B*UZ]F$XU%S0=UY&F^Q2_M:#_GG=?\ @)+_ /$T?VM!
M_P \[K_P$E_^)J[15C*7]K0?\\[K_P !)?\ XFC^UH/^>=U_X"2__$U=HH I
M?VM!_P \[K_P$E_^)H_M:#_GG=?^ DO_ ,35VB@"E_:T'_/.Z_\  27_ .)H
M_M:#_GG=?^ DO_Q-7:* *7]K0?\ /.Z_\!)?_B:^2/V^+M+K_A!=BRKM^WY\
MR)T_Y]^FX#-?8E?(/_!0+_F0_P#M_P#_ &VKBQO\"7R_,^EX;_Y&M'_M[_TE
MGR%1117RY^X!1110!^B?[)^H10? #PLC).6'VK[EO(P_X^YNX4BO6_[6@_YY
MW7_@)+_\37EO[)/_ ";YX4_[>_\ TKFKU^OKJ'\*'HOR/Y]S3_?Z_P#CE^;*
M7]K0?\\[K_P$E_\ B:/[6@_YYW7_ ("2_P#Q-7:*W/,*7]K0?\\[K_P$E_\
MB:/[6@_YYW7_ ("2_P#Q-7:* *7]K0?\\[K_ ,!)?_B:/[6@_P">=U_X"2__
M !--U;7M.T&W\[4;ZWL8NS3R!<_3/7\*\V\1?M&:!INZ/3(+C5Y1T8#RHOS8
M9_\ ':XL1C,/A5^^FE^?W;DN2CNSTO\ M:#_ )YW7_@)+_\ $U1U3QEH^APB
M74;LV,9Z-<0NF?IE>:\<_P"$L^)_Q$XTJQ;2+%^DL:>4-I[^8_)_X!5[2?V<
MY[^?[7XFUV6ZG;ETMB68_61^3_WS7F_VE6Q&F#HMKO+W5_P3/G<OA1K^(?VC
M/#^FADTN"XU:7LV/)B_-AN_\=KXR_LGPOX=YNYQ>3K_ S;SGTVKP/QK[_P##
MOPU\->%]K6&E0"9>D\P\R3/J&;./PQ7Y@5]+DV58[,?:+$XITXZ7C3TOO]IZ
MGA9I4=+D<HIO7Y;'<WGQ&2WC\G3+!8HQ]TR  #_@*_XUS6H^)=2U3(N+N0H?
M^6:':OY#K^-9=%?>X'A[+,O?/1HKF_F?O2^]W_"Q\W4Q-6II*6@5%=?\>[?A
M_.I:BNO^/=OP_G7?FG^X8C_!+_TEGJ9#_P C;"?]?(?^E(SZ***_G@_L@***
M* /HG]AFX2U^+6K,XD(.B3#]W&SG_7V_90:^Y?[6@_YYW7_@)+_\37P_^PC_
M ,E=U?\ [ <W_I1;U]VU])@/X)^,\5?\C)^B*7]K0?\ /.Z_\!)?_B:/[6@_
MYYW7_@)+_P#$U=HKT3Y I?VM!_SSNO\ P$E_^)H&K0$XV7/_ ("R_P#Q-7:*
M "BBB@#P[XB:;<:)XXN_$WBJ+7I_#UK/;3Z7K&A:F\<>CJ J2">T#J'5F+EG
M"3$I(RL%5174^'FF\1_$[XA/]JEM7L(+/2+6:$*7@#0F=Y$#AEW%IEZJ0?+7
M((%7=6^#NBZYXNDUF\>[ELYE#W.CB\N%LKFX5DVS2P"3RG(6,##(0>IR0,7H
M?!+P^,O$>HB;;IFNV,$-Q'#-)%.D\8=-Z.A!7=&ZC<I# Q@CKD 'EBZQJ]E\
M/-8T]=<U(O<>-O[$.I373/<Q6TEW'&P20G*$J652N-I;Y<8%.US4M4\-P^*/
M"]CK6J)I_P#PD.D:=#>W%[+/=6L%V8O.1+B0F3/+;6+$KYHP1A0/1M-^"_A3
M2]-U2PBM=0FL]3;S+J&\UB\N0TFX/YJ^;,VR7< WF+AP0#G(%7[?X9^'+?PW
M?:%]@DFL+Z7S[IKFZFFN)I?EQ*T[N92Z[$VONW+L7:1M& #&^&8GTOQ-XU\/
MB^OK[3=-N[=K-M0NI+J6(2VZN\?FR$NP#98;F8C?C.  .#\.:EJDI\,^+GUK
M5)=2U;Q5=:9=637LK68M1)<1+"MN28T*"%&WA0Y*L2QW$'T?_A4ND0?V/#9M
M-#9V6J#5[A9YI;F>]N%0K&TL\KM(VT[3R3D1JOW1BKUG\,_#FG^)CKT%A(NH
M>;)<*K74S6\<T@(DECMR_E)(P+9=4#'<V3\S9 /'K77=7M=)T?QPNKZI<ZOJ
M'B.^L9]/:]E:S-NKW,:0+;9,:%!!&=ZJ')5B6.X@Z_PRFU"QU+X;W[:[JFJR
M^*M%GO-46\O9)X7F\N*99(XV)2$ R,H6/:N& (.!CTJS^&7ANQ\2MKL-A(M_
MYLEPJM=3-;QS2 B26.W+F))&!;+J@8[FR?F;+-!^&.@>$[J>\T6T:TO6A>"!
MYKF:XCM$9MQ2&)W*PQ[@I*1A%.U?[HP <]XX@F\5?%+0_"\^I:EIVD'2+S4G
M32[Z6REGF62&-,RQ,K[4$C':#@EE)!P*\MT'7-<\>>&M<O=2\1ZO:7?AWPK;
MWEE)8WLEKYEP?M)-U*L>T39^SQC:ZLF WR_,:]DM/@SX>7PIHFBW:W4[:7&Z
MQWUK>3V=PS2<S'S(75@LC$LR [>G'RC%K5OA%X2UI;)+C2?+AM+5+%+>TN9K
M:&2V4Y6"6.)U6:(<XCD#+\S<?,<@'F7B#4M4\87'BJ[N-:U31Y=!\*V>IV,.
MG7LMJJ74L<\CS2*A F&8D4)(&3"M\OS&NR\#W\W_  L2Y+J(QK?A^QU:>,*!
MBX4M$['W*>4/^V8KH_$_PS\.>,;V.ZU6PDFE6(6[B&ZF@2XA#;A%.D;JLT>2
M?DD#+\S<?,<FC^%KRV^(&O\ B&[FA:&YM;6PL8(LYCACWN[-D##-)*W R-J+
MSDD  ZFBBB@ HHHH *\_^('_ "&8?^O=?_0FKT"O/_B!_P AF'_KW7_T)J .
MST7_ ) UA_U[Q_\ H(J[5+1?^0-8?]>\?_H(J[0 5Y+^TG?6VG^#]$>_U]?#
M&F'7+3[5JL;(MS;H"Q#6Y8'Y]P4$@-A#(2" :]:KSWXV^*[[PKX6L_L&M6OA
MA]0OX[&37[Z%98=.5U<^:RNRJ>55!N.W+C- $?P[\0:)JFMS1:=\6?\ A.IQ
M S'3OM>F2[%W+^]Q:P(_&0,D[?FZ9Q7HU>7^#==U;2?BA?\ A&[\6Q^,K;[
M;_?-#;QWNF,#$HBF\A40K()"Z916PI^\,&O4* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _//]JS_ )+YXH_[=?\ TEAKR6O6OVK/^2^>*/\
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M3M!M_.U&^M[&+LT\@7/TSU_"O$/^$L^)_P 1.-*L6TBQ?I+&GE#:>_F/R?\
M@%7M)_9SGOY_M?B;79;J=N72V)9C]9'Y/_?-<?\ :5;$:8.BVN\O=7_!/)YW
M+X4;'B+]HS0--W1Z9!<:O*.C >5%^;#/_CM<S_PEGQ/^(G&E6+:18OTEC3RA
MM/?S'Y/_  "O5_#OPU\->%]K6&E0"9>D\P\R3/J&;./PQ73T?4\;B/\ >:W*
MNT-/QW#EE+XF>'Z3^SG/?S_:_$VNRW4[<NEL2S'ZR/R?^^:])\._#7PUX7VM
M8:5 )EZ3S#S),^H9LX_#%=/17;A\MPN&=X05^[U?WLN,(QV04445Z185^3-?
MK-7Y,U]GP[_R]_[=_4^7SO\ Y=_/] HHHK[(^7"HKK_CW;\/YU+45U_Q[M^'
M\Z\S-/\ <,1_@E_Z2SW<A_Y&V$_Z^0_]*1GT445_/!_9 4444 ?1W["/_)7=
M7_[ <W_I1;U]VU\)?L(_\E=U?_L!S?\ I1;U]VU])@/X)^,\5?\ (R?H@HHH
MKT3Y **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M/_B!_P AF'_KW7_T)J] KS_X@?\ (9A_Z]U_]":@#L]%_P"0-8?]>\?_ *"*
MNU2T7_D#6'_7O'_Z"*NT %>?Z3JQ\6?$#QWX:UDVUUI=G#:0PZ-<11NLT,D1
M:29P1EE9F,>#\O[KIDFO0*Y+QM\*?"OQ$NM.NM>TE;F^TZ02VE]!/+;74##)
M&R:)E<#)SC=C.#C(% '.>';'3?!/QB/AKPWIVF:7H]WHC:A=V&FV4%N()TG5
M(Y&\M Q\Q7D'S$C]SQWKU"N7\!_#'PO\,K*XM?#6D0Z:ES(9;B7<\LT[$DYD
ME<L[\L<;F.,G%=10 445R_Q+TS7=8\%ZC:>&[@6VK2>7L)G:W,B!U,D:RJ"8
MF= RAP,J6!&",@ Z*UNX+V'S;>:.>+<R;XF#+N5BK#([@@@^A!%35Y%\/['0
MWT'Q-X<B?Q1X1-G-'=:AI^J:J7FM$D42%HKH2R$1R[7+,DN0?,/R-7-KJ6L6
MOPZO38ZOJT.@ZYXHM+'2+Z\NY9;V/3II88G=9I29 ';SO+9B6"R(0?NX /H&
MBOGJXFU"W^(B?#Y-<UE?#LVNH#,VISF[$7]G/<&V6Z+>< 9$#9WEMN5!"\5Z
M5\'[N[DT'5K*ZO+F_73-8O+"WN;R5I96ACE(0,[?,Y4';N;).W))/- '=T5\
MZVNNZO:Z3H_CA=7U2YU?4/$=]8SZ>U[*UF;=7N8T@6VR8T*"",[U4.2K$L=Q
M!N>"M2U308_ FLIK6J:S<^(_#UUJ.I17M[+/!+.L,4ZO'&Q*P@,[(%BVC# 8
M.!@ ]^HKPSX93:A8ZE\-[]M=U359?%6BSWFJ+>7LD\+S>7%,LD<;$I" 9&4+
M'M7# $' Q[G0 44C,$4L<X SP"3^54_[6@_YYW7_ ("2_P#Q- %VBJ7]K0?\
M\[K_ ,!)?_B:/[6@_P">=U_X"2__ !- %VBJ7]K0?\\[K_P$E_\ B:/[6@_Y
MYW7_ ("2_P#Q- 'P!^U9_P E\\4?]NO_ *2PUY+7J_[4TRS_ !X\3NH8*?LO
MWT*G_CUA[$ UY17ZS@O]UI?X5^1^<XK_ 'BIZO\ ,****[#E"LV;_6O_ +QK
M2K-F_P!:_P#O&OSSC+_=Z/J_R/V3PT_WO$?X5^8RBBBOR@_H$**** /U[HJE
M_:T'_/.Z_P# 27_XFC^UH/\ GG=?^ DO_P 37VI_-1=HJE_:T'_/.Z_\!)?_
M (FC^UH/^>=U_P" DO\ \30!=HJE_:T'_/.Z_P# 27_XFC^UH/\ GG=?^ DO
M_P 30!=HJE_:T'_/.Z_\!)?_ (FC^UH/^>=U_P" DO\ \30!=KG_ !%X!\/^
M*E8ZEI=O/*W_ "V5=DO_ 'VN#^M:?]K0?\\[K_P$E_\ B:/[6@_YYW7_ ("2
M_P#Q-9U*<*L>6HDUYB:3W/F']H3X=Z/\*/#=KK5M+<W=I=7JV;6DP5BNZ.1]
MP;C('EXP1WZ\5X)]@\*^(_\ 42K93M_"I\LY]-IX/X5],?ML7T=U\*]*5%F!
M&M1']Y Z#_43]V KXGKV\MX;HSP_UC!U9T*EWK%Z/UB]'^!\EF%;V5=TW%.-
MCK]2^&]];Y:TECNT_NGY&_7C]:YF\TVZTZ39<V\D!_VU(!^A[U9T[Q%J.E8%
MM=R*@_Y9L=R_D:Z:S^) FC\K4[))HSPS1=_^ GK^=>I[3B/+?XD(8F"ZKW)_
M=\/R1YML-5V;@_O1P]5;[^#\?Z5Z5_9OA;Q'_P >TPL[AOX5.PY]-IX/X50N
M/A3<37*@7\8MQG+[#O\ ^^<X_6O&SKB;!8C+ZN&K1E2JZ>[.+3TDKVW3/J^%
M>3+\XH8JM)>SCS7:UWA)+SW9YS5FQTVZU*3R[6WEN'](T)Q]?2O0O[%\(>%^
M;VX%]<+_  ,V\Y]-J\#_ (%5:^^*<=M'Y.D:<D,:_=:4  ?\ 7_&OR;ZU.I_
M!@WYO1'[[_;6)Q>F78:4E_-+W8_CJRCI?PLU.[PUW)'8I_=SO?\ (<?K6O\
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M9?[O1]7^1^R>&G^]XC_"OS&4445^4'] A1110!^O=%%%?:G\U!1110 4444
M%%%% !1110!\\_MP?\DGTG_L-P_^B)Z^'Z^X/VX/^23Z3_V&X?\ T1/7P_7Z
M-D?^YKU9\1FW^\OT04445[YXP4E]JEXMNEN+N<0'.8O,;;^6<4M5;[^#\?Z5
M\MQ/&,LJJN2O;E_]*1]QP2E+/\.GM[W_ *1(J4445^'']6A1110!^CG[)/\
MR;YX4_[>_P#TKFKU^O(/V2?^3?/"G_;W_P"E<U>OU]=0_A0]%^1_/N:?[_7_
M ,<OS84445N>8%%%% !1110 4444 %?DS7ZS5^3-?9\._P#+W_MW]3Y?._\
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M9?[O1]7^1^R>&G^]XC_"OS&4445^4'] A1110!^O=%%%?:G\U!1110 4444
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M.RL+5-D4,8X4=?J23DDGDDDG)- %^BBB@!&8(I8YP!G@$G\JI_VM!_SSNO\
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MT4 4O[6@_P">=U_X"2__ !-']K0?\\[K_P !)?\ XFKM% %+^UH/^>=U_P"
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MA)XFUWX@6UO>^"]6OO".DSPW5JVGW-@5OKD89991+<(Z1Q-RJ!2690Q.%"D
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M7V[:^WQPGU5O!^K1:,^F+I0U%KBR\O<L[OYNT7!D\L@C'R;N>5%>H4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !61XDUZ;P_9Q26^C:CKMQ-)Y:6FF
MI'O/!)8M*Z1HH /+.,G &20#KUR'Q.U;Q3I?AY!X1T236-3N)EA9XY(%-G&0
M=TX2:2-9&7LFX9)&3@&@"BOQCTJ;PSI>JVVFZG=WFI7LFFVVBQQQB\:ZC9Q+
M$0T@C4IY4A9B^W"9#'(RJ_%E+O0X=1TWPMX@U:7?<1W-C;0P)-9O"VR596EF
M2/<&X 1V+=5W $UR\?A/4=+T7P1J&C^%M6C?PWJ$\MQI-_<V9OKQ)H9$EG#I
M.83(9)?,.Z1<_/T.T&A>:;XZTGPN^GV'AG4"?$FIWM_JLVF7=E]JTR"5\K#&
M)9HT:9DP"X9E0[B-_!(!Z!=?$V&3PYI.M:+H.L^)K34K3[=$-,BB4I#M5MSF
M:2-0WS ; Q<\X4X)'0^&_$%EXK\/Z=K6G2-+8:A;I<P.RE24=0PR#T.#TKSC
MQA)XFM_!N@>'_"W@O5M/TJX@-K>BTN; 7FF6R*%6*-7N!&9'7@.'8(.<$X%>
MA>$;>*S\,Z9;0:1-H%O;P+!%IEP8B]NB#:J$QNZ= .C&@#7HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *1FVJ2<X SP,FEILC%(V8*7(&0JXR?;F@#C=
M#^*%OJOB%='OM#U?P]<S6<E_:OJT<*)<P(RJ[+LE=D*[T)24(P#=.#BAH/QJ
MTS7VC9-%URVMKNREU'3+B6U1UU.",C<T"QNS@D,C!9%1B'! ZXP?"%GXD\5>
M(M4U+Q=X/U;1M2OK.;3[:9KBQEL]-M3SL4QW#2.\A"LS[ "548 7)I>&-!\7
MZ;#X4:Y\*3"X\%Z)/:(HO;8+JUR8XXD%NP<E(V$;,6E\LC<ORGG !WFA?$R'
M5[C6[.ZT'6-&U72;9+N;3;R.&6>6%P^QHO(ED5\F-UVAMV1@@9&;?A#QU%XK
MO=4L)=)U#0M5TTQ&XL-2\DR!)%+1R!H9)$*MAA][(*G('&>/^'B>)(;?Q%J^
MM>$-5B\6:A;B:9[FZLHX)-@(BL[=H;B1D1=S8=P,EF8D$X%CX2>&=3T7Q%XF
MO7T?4-!T6^6V,-KKE]'?7\MPBLLDKSK+,Q0KY2JKRMC8V%4'D ]/HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\_^('_ "&8?^O=?_0FKT"O/_B!_P AF'_KW7_T)J .ST7_ ) UA_U[Q_\
MH(J[5+1?^0-8?]>\?_H(J[0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI6IWW@?0M,U/P:7M[F?6+AEUGP_<:QY$SWC&*(VT,BK&[JY*W#-M4*0&P^:
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M-<N(JRHP4HJY[F3X&EF%>5*M/D25[Z=TNOJ?9/\ PN+P#_T/'AO_ ,&UO_\
M%T?\+B\ _P#0\>&__!M;_P#Q=?G'_P *=\??]"/XD_\ !3<?_$4?\*=\??\
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M&L/^O>/_ -!%7:I:+_R!K#_KWC_]!%7: "BBB@ HHHH **** "BBB@ HHHH
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M^_\ R$G^%%% !_PF&K_\_?\ Y"3_  H_X3#5_P#G[_\ (2?X444 '_"8:O\
M\_?_ )"3_"C_ (3#5_\ G[_\A)_A110 ?\)AJ_\ S]_^0D_PH_X3#5_^?O\
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MX3#5_P#G[_\ (2?X444 '_"8:O\ \_?_ )"3_"C_ (3#5_\ G[_\A)_A110
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M_"8:O_S]_P#D)/\ "C_A,-7_ .?O_P A)_A110 ?\)AJ_P#S]_\ D)/\*/\
MA,-7_P"?O_R$G^%%% !_PF&K_P#/W_Y"3_"C_A,-7_Y^_P#R$G^%%% !_P )
MAJ__ #]_^0D_PH_X3#5_^?O_ ,A)_A110 ?\)AJ__/W_ .0D_P */^$PU?\
MY^__ "$G^%%% !_PF&K_ //W_P"0D_PH_P"$PU?_ )^__(2?X444 '_"8:O_
A ,_?_D)/\*HWVH7&K2B:ZD\V15V!MH''7' ]S110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  ) ! # 2(  A$! Q$!_\0
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7%BC_ (-"_P#DU;QG_P!?EM_Z+- '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  )  X# 2(  A$! Q$!_\0
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:%%O#<R /=1M$9F<L7\LQ1#*^9AOV=HH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  .  T# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
